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Abstract 
In  order  to  successfully  invade  a  new  species,  lentiviruses  must  overcome 
restriction factors, dominant blocks to replication, and be able to make use of 
available  host  factors  such  as  entry  receptors  for  replication.  Human 
immunodeficiency virus (HIV 1) infection is blocked at a post entry stage by 
rhesus macaque TRIM5α, an effect that is enhanced by host factor cyclophilin A 
(CypA),  but  largely  evades  restriction  by  the  human  TRIM5α  variant.  HIV 1 
replication  is  also  inhibited  by  simian  APOBEC3G  but  is  able  to  evade 
restriction by human APOBEC3G by inducing its degradation through expression 
of accessory protein Vif. Viral entry and tissue tropism are determined by an 
interaction of the viral Env glycoprotein with a cell surface receptor and a 
seven transmembrane domain co receptor. The feline immunodeficiency virus 
(FIV) infects diverse felid species including the African lion, where infection 
has likely been endemic since at least the late Pleistocene, and the domestic 
cat, a more recent host. For domestic cat strains of FIV (FIV Fca), entry is 
mediated by host proteins CD134 and CXCR4, but the identity of receptors in 
non domestic strains of FIV is unknown.  
This thesis demonstrates that two strains of FIV isolated from lions (FIV Ple 
subtypes B and E) differ in their receptor tropism and that subtype E shares 
entry receptors with FIV Fca. The findings suggest  that alternative receptor 
usage is a strategy employed by FIV in this species and has implications for the 
disputed pathology and tissue tropism of infection in African lions. Next, we 
tested the hypothesis that species which have harboured lentiviral infection for 
a  long  time  are  better  able  to  prevent  viral  replication  than  recent  hosts. 
Whilst  we  found  that  TRIM5α  is  non functional  in  all  felid  species  tested, 
evidence  of  potent  APOBEC3  activity  was  found  and,  in  lion  cells,  potently 
restricts production of infectious FIV. Moreover, lion primary T cells prevent  
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replication of diverse FIV strains and restrict primate lentiviruses at post entry 
stages, suggesting that co evolution with lentiviruses has driven the selection 
of broad ranging restriction factors. Structural and biophysical analyses suggest 
that whilst FIV’s interaction with CypA appears to be conserved in affinity with 
HIV 1, the interaction does not appear to be crucial for replication and, in the 
absence of restriction by TRIM5α, the role of the capsid CypA interaction is 
discussed. Overall the study explains the permissivity of domestic cat cells to 
retroviral infection and identifies FIV infection of lions as an example of host 
adaptation driven by current lentiviral infection. 
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Chapter 1.  Introduction 
1.1 Preface 
Investigating the mechanisms by which viruses appropriate host cell machinery 
to replicate themselves is crucial to our understanding of infections and their 
associated  pathologies.  In  conjunction  with  studies  of  host  immunity,  such 
research can reveal the co evolutionary battles between host and parasite and 
expose  the  interactions  important  for  viral  infection  and  suggest  potential 
strategies  of  viral  disruption.  Lentiviruses  are  widespread  mammalian 
pathogens  and  include  the  human  and  feline  immunodeficiency  viruses  (HIV 
and  FIV)  which  cause  AIDS  in  their  respective  hosts.  Humans  and  cat 
lentiviruses  are  proposed  to  have  invaded  their  hosts  after  comparatively 
recent cross species transmission events: within the past 150 years for humans 
and since the domestication event that gave rise to domestic cats. However, 
replication of these viruses is blocked in the cells of other species by a suite of 
proteins termed  ‘restriction  factors.’ Evolution  of  such  restriction  factors  is 
proposed  to  have  been  driven  by  previous  or  ongoing  encounters  with 
pathogens. In this thesis, a comparison is made between infections in domestic 
cats and African lions, where FIV is thought to have been endemic for hundreds 
of thousands, if not millions of years. The study investigates the characteristics 
of  FIV  strains  circulating  in  these  species  and  asks  what  changes  long term 
lentiviral  infection  has  brought  about  in  host  and  pathogen  with  particular 
reference to restriction factors. Chapter 1. Introduction 
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1.2 Retroviruses 
Viruses are obligate intracellular parasites, reliant on host cell machinery to 
carry out the instructions encoded within their genomes. They must use the 
available  host  factors  in  a  precise  and  controlled  order  to  carry  out  each 
sequential  stage  of  the  viral  lifecycle.  Several  replication  strategies  are 
available  to  viruses  with  respect  to  the  nature  of  their  genomes  and  the 
manner of their replication, all of which must ultimately allow the expression 
of viral proteins through messenger RNA (Baltimore  1971). The  Retroviridae 
virus family is characterised by a replication strategy of positive sense RNA 
genome that is reverse transcribed by viral enzyme reverse transcriptase (RT) 
into a double stranded DNA copy which is inserted into the host genomic DNA 
from  which  mRNA  transcripts  and  novel  genomic  RNA  transcripts  can  be 
derived. Members of the family are broadly categorised into simple or complex 
retroviruses, with simple viruses generally bearing three open reading frames 
(ORFs), gag (which encodes the major structural proteins), pol (encoding RT 
and other proteins necessary for replication) and env (encoding the envelope 
glycoprotein  responsible  for  entry  into  cells).  The  simple  retroviruses  are 
subdivided into genera Alpha-, Beta- and Gammaretrovirus, whist the complex 
viruses  are  divided  into  the  Spuma-  and  Lentivirus  genera  both  of  which 
possess a number of smaller ‘accessory’ genes (Figure 1 1). Chapter 1. Introduction 
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Figure  1-1  Genomic  organisation  of  simple  and  complex  retroviruses.  Murine 
leukaemia virus (MLV) is a simple retrovirus belonging to the Gammaretrovirus genus 
and  possesses  three  open  reading  frames,  as  well  as  5’  and  3’  long  terminal  repeats 
(LTRs).  Human  immunodeficiency  virus  type  I  (HIV-1)  belongs  to  the  complex 
Lentivirus genus and has an additional suite of accessory genes. Some of these genes are 
shared by the feline immunodeficiency virus (FIV), which has an open reading frame 
termed orfA which encodes a protein which bears similarities to HIV-1 Vpr (Gemeniano 
et al. 2003). The gag-pol open reading frames are produced as polyproteins which are 
cleaved by viral protease into mature peptides matrix, MA; capsid, CA; nucleocapsid, 
NC; protease, PR; reverse transcriptase, RT; dUTPase, DU; and integrase, IN.  
The  first  demonstration  of  the  infectious  property  of  lentiviruses  was  the 
transmission of equine anaemia in serum filtrate, now known to bear equine 
infectious anaemia virus (EIAV; Vallee and Carre 1904). In Icelandic sheep, the 
maedi  visna  disease  was  introduced  in  the  mid twentieth  century  and  the 
spread  of  the  disease  was  shown  to  be  caused  by  a  transmissible  virus 
(Sigurdsson, 1953), later demonstrated to be the prototypic  lentivirus, maedi 
visna virus (MVV; Haase and Varmus 1973). The viruses were given the prefix 
lenti-  (lentus  meaning  slow  in  Latin)  due  to  the  long  incubation  period  for 
pathological  manifestations  to  occur.  Symptoms  of  MVV  infection  include 
pulmonary infection and neurologic disease (meadi, laboured breathing, visna, Chapter 1. Introduction 
 
21 
 
wasting  in  Icelandic) but arise at  least  two  years  after infection.  This  slow 
progression  of  disease  is  a  common  feature  of  the  lentiviruses  but  tissue 
tropism and the associated pathology is diverse (Narayan and Clements 1989). 
The field rose to prominence as a research subject with the discovery of human 
immunodeficiency virus type I (HIV 1) which infects and depletes CD4+ T cells, 
compromising  cellular  immunity  and  causing  acquired  immunodeficiency 
syndrome (AIDS) (Barre Sinoussi et al. 1983; Gallo et al. 1984). The Lentivirus 
genus is known to infect diverse mammalian orders including cattle (bovine 
immunodeficiency  virus;  BIV),  goats  (caprine  arthritic  encephalitis  virus; 
CAEV),  horses  (EIAV)  and  primates  (simian  and  human  immunodeficiency 
viruses; SIV and HIV). However, the discovery of feline immunodeficiency virus 
(FIV;  Pedersen  et  al.  1987b)  was  followed  by  the  finding  that,  uniquely 
amongst  non primate  lentiviruses,  it  causes  an  AIDS like  syndrome 
characterised by recurrent gingivitis stomatitis, cachexia, neuropathology and 
an increased incidence of tumour development (Torten et al. 1991; Ackley et 
al. 1990; Yamamoto et al. 1989; Sparger et al. 1989; Pedersen et al. 1987a; 
Hosie et al. 1989; Pedersen 1993; Callanan et al. 1992; Callanan et al. 1996). 
FIV infects an estimated 10% of domestic cats in the UK and species specific 
strains of FIV have now been identified in at least 15 non domestic felid and 
hyenid  species  (Brown  et  al.  1994;  Troyer  et  al.  2004;  Barr  et  al.  1995; 
Carpenter et al. 1996; Hofmann Lehmann et al. 1996; Troyer et al. 2005). As 
well  as  being  a  major  veterinary  pathogen,  FIV  has  attracted  considerable 
attention as a model for investigating common principles of AIDS progression 
and in the development of vaccines for the prevention of lentiviral infection. 
On  the  25
th  anniversary  of  the  description  of  AIDS,  a  co discoverer  of  HIV 
declared “we can safely say that we know as much about HIV as we do of any 
pathogen and about AIDS as we do any human disease” (Gallo 2006). Despite 
this, the virus is now responsible for a global pandemic infecting 40.3 million 
people,  with  at  least  two thirds  of  cases  occurring  in  the  developing  world Chapter 1. Introduction 
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(World Health Organisation 2005). It is therefore of necessity and substantial 
value  to  investigate  the  mechanisms  by  which  lentiviruses  replicate  and 
interact with their hosts.   
The lentiviral lifecycle is superficially simple: particles invade the cell, reverse 
transcribe and integrate their genomes, translate their proteins and bud from 
the cell surface. However, the lifecycle is dependent on a vastly complex array 
of interactions with host proteins. For instance, in July 2009, the HIV 1 Human 
Protein Interaction Database lists 1,737 entries for Env alone (Fu et al. 2009), a 
number that will no doubt grow substantially. What's more, the information to 
carry out these functions is encoded by a genome of only 9,000 10,000 base 
pairs (bp), resulting in gene products that must carry out multiple functions. 
For the most part, host virus interactions promote the viral lifecycle, but it is 
becoming  increasingly  clear  that  an  additional  suite  of  host  factors  that 
evolved  specifically  to  interfere  with  retroviral  replication  must  also  be 
overcome  for  successful  replication.  These  agents  are  known  as  ‘restriction 
factors’  and  are  considered  as  part  of  the  innate  immune  system  or  as 
members  of  a  separate  ‘intrinsic  immune  system’  (Bieniasz  2004).  This 
separate classification is justified by their constitutive expression in a wide 
range of host cells and their absence of requirement for pathogen stimulation 
or  intercellular  communication.  To  date,  the  main  restriction  factors  of 
retroviral replication fall into three classes, the post entry restriction factors 
(including  murine  Fv1  and  mammalian  TRIM5α),  hypermutation inducing 
restriction factors (the APOBEC3 family of proteins) and inhibitors of budding 
(tetherin). A variety of counter measures have been devised on the part of the 
virus, including host specific escape mutants and the generation of entire new 
genes that disrupt the activities of the restriction factors.  Chapter 1. Introduction 
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1.3 Cross species transmission of lentiviruses in the primates and 
felids 
In  order  to  successfully  infect  a  new  species,  a  lentivirus  requires  a 
transmission event (zoonosis) and subsequent acquisition of adaptations that 
facilitate replication and transmission in the new host. There are currently 36 
primate species known to be infected with lentiviruses, confined to Africa and 
Asia  (Santiago  et  al.  2005).  The  causes  of  AIDS,  HIV 1  and  HIV 2,  were 
introduced to humans as multiple cross species transmissions from nonhuman 
primates.  The  chimpanzee  (Pan  troglodytes)  simian  immunodeficiency  virus 
(SIVcpz) crossed into humans on at least three separate occasions during the 
19
th and 20
th centuries, giving rise to HIV 1 groups M (major), O (outlier) and N 
(non M, non O) (Keele et al. 2006; Gao et al. 1999). HIV 2, originating from 
SIVsm  of  sooty  mangabeys  (Cercocebus  atys),  is  thought  to  have  been 
transmitted  to  humans  on  at  least  eight  occasions,  giving  groups  A  to  H 
(Damond et al. 2004). However, six of the groups have only been identified as 
individual infections, with only groups A and B showing evidence of human 
human transmission (Damond et al. 2004) and even these groups remain largely 
confined  to  West  Africa.  Additionally,  a  virus  has  been  identified  in  a 
Cameroonian  woman  that  resembles  SIV  strains  circulating  in  gorilla 
populations (Plantier et al. 2009). Thus it seems likely that lentiviruses have 
crossed from apes and monkeys into humans on numerous occasions, no doubt 
many  or  most  of  these  unnoticed.  Only  one  transmission  event,  from 
chimpanzees to humans around 1904 and giving rise to HIV 1 group M, has given 
rise  to  the  global  pandemic  (Keele  et  al.  2006;  Worobey  et  al.  2008).  The 
comparative rarity of successful zoonosis events in the primates implies that 
species specific  blocks  to  replication  (be  they  dominant  host  blocks  or  the 
inability to use host factors in the new host) must be overcome for successful 
transmission. Chapter 1. Introduction 
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Of  the  37  known  species  of  felids,  21  species  have  been  shown  to  harbour 
antibodies reactive to FIV and many of these species harbour viral sequences 
consistent with species specific strains (VandeWoude and Apetrei 2006; Troyer 
et al. 2008). Unlike the primate lentiviruses, prevalence of FIV is worldwide, 
with infections occurring in both old and new world species. However, not all 
branches of felids are infected which suggests that virus colonised these hosts 
after the modern felid species radiation in the late Miocene ~10.8 million years 
ago
1  (mya;  Johnson  et  al.  2006).  The  co occurrence  of  diverse  primate, 
ungulate and feline lentiviruses in Africa, and the paucity of FIV in Asia (only 
one endemic Asian species has tested FIV seropositive, the Mongolian species 
Pallas cat (Barr et al. 1995)), has lead to the hypothesis that FIV originated in 
Africa  and  was  subsequently  disseminated  worldwide  (Troyer  et  al.  2008; 
Pecon Slattery et al. 2008b). Unlike most felid taxa, all six species belonging to 
the Panthera genus are infected with FIV, and in lions, six highly divergent 
viral  subtypes  (A  to  F)  are  circulating  (Pecon Slattery  et  al.  2008b).  These 
observations are consistent with an ancient infection in this species. The range 
of modern lions is confined to the African continent and a relic population in 
the Gir forest of India. However, fossil evidence points to a much larger former 
distribution, including Asia and North America. The virus is proposed to have 
colonised the Panthera lineage before spreading to America through movement 
of species across the Bering Straits. Two opportunities for this dissemination 
have arisen: during periods of low sea level dated to 4.5 mya that allowed the 
movement of ocelot lineage members that subsequently diverged into cheetahs 
and pumas, and a more recent event in the late Pliocene/early Pleistocene 
(3.6  –  2.5  mya)  that  permitted  the  movement  of  lions  into  North  America 
(Troyer et al. 2008; Johnson et al. 2006). The low sequence diversity of FIV in 
cheetahs points to a relatively recent introduction of FIV, probably since the 
extirpation  of  North  American  cheetah  subspecies  10,000  years  ago  (Pecon 
                                         
1 N.B. A phylogeny of the Feliformia is presented in Appendix 4. Chapter 1. Introduction 
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Slattery et al. 2008b; Menotti Raymond and O'Brien 1993), making it unlikely 
that the ocelot lineage was infected with lentivirus at the time of migration to 
North  America.  It  is  therefore  possible  that  lions,  where  infection  is  more 
ancient, were vehicle for FIV dissemination into the new world during their 
migration in the late Pliocene/early Pleistocene. Analysis of mitochondrial and 
genomic  DNA  markers  in  African  lions  suggests  episodes  of  population 
fragmentation occurred during the Pleistocene (1.8 mya   10,000 years before 
present;  Antunes  et  al.  2008).  Geographical  concordance  between  FIV Ple 
subtypes and hypothesised historical sub population ranges is consistent with 
an invasion of FIV Ple that pre dates the expansion of modern lion populations 
estimated  between  324,000–169,000  years  before  present  (Antunes  et  al. 
2008).  Diversity  of  FIV  in  the  North  American  species  puma  (also  known  as 
cougar or mountain lion; Puma concolor with FIV strain FIV Pco) is also high 
with  substantial divergence  between the  two  clades  A and  B  (Troyer et al. 
2005), pointing to this species as an early host for new world colonisation for 
FIV. In contrast, the closest relative of the domestic cat, Felis sylevstris, the 
wildcat (Driscoll et al. 2007), is free from FIV infection, suggesting that the 
zoonosis into domestic cats took place after their domestication, estimated at 
10,000 years ago from archaeological evidence (Vigne et al. 2004). Thus in a 
similar manner to the primates, lentiviral infection is still spreading through 
the taxa, and comparisons between the transmissions of feline and primate 
lentiviruses  have  yielded  some  interesting  insights  into  the  relationship 
between host and pathogen. In the primates, cross species transmissions tend 
to occur primarily between closely related species, so that the phylogenies of 
host and virus closely resemble each other (VandeWoude and Apetrei 2006). In 
contrast, zoonoses in the felids frequently take place between more distantly 
related  species,  resulting  in  discordant  host  and  virus  phylogenies 
(VandeWoude  and  Apetrei  2006).  Such  transmission  has  given  rise  to  a 
phylogeographic distribution in the felids, where viral strains are more likely to Chapter 1. Introduction 
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resemble those endemic within the same geographical area than those present 
in closely related host species. 
1.4 Lentiviral entry 
1.4.1 Receptors for HIV 1 entry 
The  Env receptor  interaction  is  a  critical  determinant  for  cell  tropism  and 
pathogenesis for lentiviral infection. For HIV 1, an interaction with surface 
expressed  CD4  allows  targeting  of  helper  T cells  and  cells  of  the 
macrophage/monocyte  lineage  whilst  further  subpopulation  specificity  is 
provided by the differential affinities for chemokine co receptors, CXCR4 and 
CCR5. CD4 is a member of the immunoglobulin superfamily that is expressed on 
the surface of T helper cells as a transmembrane glycoprotein. Its in vivo role 
is to act, along with the variable T cell receptor (TCR), as a ligand for major 
histocompatability  complex  (MHC)  class  II,  whilst  cytotoxic  T cells,  which 
express CD8, interact with MHC class I. MHC class II is expressed on the surface 
of antigen presenting cells and displays protease digested oligopeptides in its 
peptide binding groove. In the event that antigen presented by MHC class II 
molecules is recognised by TCR of a given T helper cell, activation of that T 
cell will typically result leading to an antigen specific clonal expansion. CD4 
aids in this process by amplifying the intracellular signal generated by TCR by 
recruitment  of  membrane anchored  tyrosine  phosphatase  Ick,  initiating  a 
downstream signalling pathway and resulting in the activation of transcription 
factors  such  as  NFκB  and  NFAT  which  stimulate  transcription  of  T cell 
activation genes such as interleukin 2 (Janeway et al. 2001; reviewed in Delon 
and  Germain  2000).  The  chemokine  receptors  (CCRs)  are  G protein  coupled 
receptors  that  belong  to  the  7 transmembrane  domain  super family  (7TM). 
CCRs  are  responsible  for  the  binding  of  soluble  ligands  (chemokines)  which 
effect intracellular responses in the target cell (for review see Rot and von Chapter 1. Introduction 
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Andrian  2004).  Many  chemokines  act  as  chemo attractants  for  specific  cell 
types, and upon binding initiate intracellular signalling that typically results in 
a directional kinetic response. Members of the chemokine receptor family bind 
the various chemokines with differential specificity and chemokines are often 
promiscuous in their ligand specificity, resulting in various responses such as 
proliferation, adhesion, differentiation or barrier migration depending on the 
nature and context of the interaction (Rot and von Andrian 2004). 
1.4.2 Molecular mechanism of HIV 1 entry 
The  majority  of  research  into  the  mechanisms  of  lentiviral  entry  has  been 
performed  in  the  primate  lentiviruses  (HIV 1/SIVmac),  but  it  is  increasingly 
becoming clear that attributes of HIV attachment and fusion hold true for FIV 
entry. Moreover, gp120 and gp41 bear structural homology to viruses as distant 
as  influenza  A  haemagglutanin  HA1  and  HA2  glycoproteins,  suggesting  a 
convergent or conserved mechanism for viral penetration (Weissenhorn et al. 
1997). The HIV particle supports several envelope ‘spikes’ protruding from the 
surface, each consisting of an exposed trimer of gp120 subunits (SU) anchored 
to  the  membrane  through  a  non covalent  interaction  with  trimeric  gp41 
transmembrane  glycoprotein  (TM),  in  such  a  manner  that  gp41  is  generally 
sequestered  by  gp120  (Weiss  et  al.  1990;  Kowalski  et  al.  1987).  gp120  is  a 
large,  multiply glycosylated  protein,  comprising  several  conserved  domains 
(C1 C5), interspersed with variable domains (V1 V5) bounded by intramolecular 
disulphide bonds, creating loop structures (Starcich et al. 1986; Leonard et al. 
1990).  Being  exposed  to  the  adaptive  immune  system,  antibodies  are 
generated to gp120, particularly to V2 and V3 (Moore et al. 1994), some of 
which are capable of neutralising infection (Karlsson Hedestam et al. 2008). A 
considerable degree of sequence variation is tolerated in the variable loops, 
allowing  the  expansion  of  mutants  that  escape  antibody  neutralisation  but Chapter 1. Introduction 
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preserve fusogenic activity (Karlsson Hedestam et al. 2008). Although regions 
within V2 and V3 do play a part in receptor attachment (Wyatt et al. 1995; 
Trkola et al. 1996), a major function of the variable loops appears to be to 
provide  a  largely  irrelevant  antibody  binding  surface,  whilst  protecting 
conserved domains critical for entry mechanisms.  
Entry to cells expressing co receptor alone can be promoted using soluble CD4 
(Moore et al. 1990). Antibodies directed to co receptor do not normally inhibit 
infection, but after incubation with soluble CD4, entry is rendered antibody 
sensitive, suggesting that the initial attachment step of Env to CD4 promotes a 
conformational  change  that  primes  the  virus  for  co receptor  attachment 
(Salzwedel et al. 2000). This conformation change, elucidated by differential 
sensitivity of V3 to proteases, exposes motifs within the V3 loop which are able 
to interact with cognate chemokine receptors (Sattentau and Moore 1991). In 
turn,  the  Env chemokine  receptor  interaction  allows  gp41  to  insert  its 
hydrophobic N terminus termed the ‘fusion peptide’ into the cell membrane 
with the simultaneous dissociation of gp120 (Sodroski 1999). Trimers of gp41 
are  then  thought  to  bring  about  the  fusion  of  the  two  membranes  by 
conformational rearrangement from a prehairpin state to a final six α helical 
hairpin  structure  (Gallo  et  al.  2001;  Weissenhorn  et  al.  1997).  Once  the 
membranes are fused, the viral contents are deposited within the cytoplasm 
and the intracellular stages of the lifecycle begin.  
1.4.3 Variable tropism of HIV 1  
HIV 1 strains have long been known to preferentially target either macrophages 
(MΦ tropic) or T lymphocytes (T tropic) (Collman et al. 1989). For the most 
part, this specificity can be explained by the preferential use of CCR5 or CXCR4 
(R5 and X4 HIV 1 strains), since CXCR4 is widely expressed in helper T cells, 
whereas CCR5 is found in the monocyte lineage. Further T cell subpopulation Chapter 1. Introduction 
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tropism  can  also  be  explained  by  CCR  use:  the  memory  (CD45RA+)  T cell 
population expresses CCR5 and accordingly is targeted by R5 isolates. Likewise, 
infection of other cell types is dependent on alternative chemokine tropism: 
invasion of the central nervous system is associated with use of D6, expressed 
widely on astrocytes (Neil et al. 2005) and CCR3 using Envs have been isolated 
from neural tissue and macrophages (Aasa Chapman et al. 2006; Peters et al. 
2004). However, not all specificity can be explained by CCR expression given 
that  some  macrophage tropic  strains use  CXCR4  (Simmons  et  al.  1998),  and 
some R5 using strains can only poorly infect macrophages (Peters et al. 2006). 
This apparent anomaly can be explained by the ability to use low levels of CD4 
and CCR efficiently, perhaps marked by an increased affinity for the receptors 
(Gray et al. 2005; Peters et al. 2006). Thus for HIV 1, cell tropism is a function 
of  both  co receptor  identity  and  the  nature  of  the  CD4  interaction,  with 
variations  in  the  ability  to  bind  its  two  cell surface  receptors  providing 
substantial subpopulation tropism.  
Studies of HIV infection in humans have shown that tropism usually, but not 
always,  progresses  from  R5  to  X4  or  dual tropic  R5X4  over  the  course  of 
infection, a change that is accompanied by mutations in the V3 loop and an 
increase in cytotoxicity (Page et al. 1992; Chavda et al. 1994; Fenyo et al. 
1988; Connor et al. 1997). Individuals with a CCR5 mutation that prevents R5 
infection  (CCR5  32)  are  largely  resistant  to  infection  with  HIV,  despite 
expressing normal CXCR4 (Dean et al. 1996; Liu et al. 1996). These data imply 
that  replication  of  X4  variants  is  somehow  restricted  and  early  stages  of 
infection are performed by R5 strains. The use of R5 by early variants appears 
to  be  a  conserved  mechanism  in  primates,  with  SIV  strains  from  sooty 
mangabeys and rhesus macaques as well as HIV 1 and HIV 2 all employing the 
same strategy (Chen et al. 1998). The precise nature of the CXCR4 restriction is 
poorly defined, but is proposed to be a series of barriers to viral transmission Chapter 1. Introduction 
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at the mucosal surface and sub mucosa that preferentially select R5 variants 
over X4, known as the gatekeeper hypothesis (Margolis and Shattock 2006). The 
expansion of X4 or R5X4 viruses in the later stages of infection is proposed to 
require  a  certain  level  of  immune  depletion,  as  a  conserved  gp120 
neutralisation epitope is protected in R5 HIV 1 variants but not in X4 and R5X4 
variants (Lusso et al. 2005). Thus changes in tropism are a major aspect of AIDS 
pathology and represent a mechanism of ensuring primate lentivirus survival 
through successful transmission and subsequent invasion of tissues. 
1.4.4 Receptors for FIV Fca entry  
Although highly divergent at the primary protein sequence level, FIV Env is 
thought  to  share  a  similar  domain  architecture  to  HIV 1,  with  comparable 
variable loops defined by disulphide bridges (Pancino et al. 1993). In contrast 
to HIV 1, FIV uses CD134, a member of the tumour necrosis factor receptor 
family, as a primary receptor for entry (Shimojima et al. 2004). CD134, also 
referred to as OX40, is widely expressed on activated rat and human CD4+ T 
cells (Mallett et al. 1990), where its activation is required for activated T cell 
survival and expansion (Song et al. 2005b; Gramaglia et al. 1998; Pippig et al. 
1999; for a review of CD134 function see Croft et al. 2009). CD134 is also found 
at low levels on CD8+ T cells, macrophages and activated B cells in humans 
(Baum et al. 1994). In domestic cats, CD134 is present on mitogen stimulated 
T cells in vitro (Shimojima et al. 2004; de Parseval et al. 2004) as well as CD4+ 
T cells in vivo (Joshi et al. 2005) but absent from CD8+ T cells (de Parseval et 
al. 2004). Accordingly, FIV replicates predominantly in activated CD4+ T cells 
but  during  late  stages  of  infection,  an  expansion  of  tropism  to  B cells, 
macrophages and CD8+ T cells is observed (Willett and Hosie 2008; de Parseval 
et al. 2004). FIV Env is able to use feline but not human CD134 for entry, a fact 
that has been exploited for the mapping of receptor domain usage by FIV Env. Chapter 1. Introduction
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require additional CRD2 interactions are able to use chimeric hCD134/fCRD1 (Willett et 
al. 2006b; de Parseval et al. 2005). 
For FIV strains such as GL8 and CPG41 (‘early’ or acute stage isolates), entry is 
contingent on expression  of both  CD134  and  CXCR4.  However, other  strains 
circulate  with  a  reduced  requirement  for  the  CRD2  domain  (Willett  et  al. 
2006b; de Parseval et al. 2005). These strains, such as PPR and B2542 (‘late’ or 
chronic  stage  isolates),  are  more  sensitive  to  inhibition  by  soluble  CD134L 
(Willett et al. 2006b) and are able to infect cells expressing a chimeric CD134 
that bears the CRD1 domain of feline CD134 in a human CD134 background 
(hCD134/fCRD1) (de Parseval et al. 2005). The finding recapitulates in vitro 
experiments  where  it  was  shown  that  long  term  passage  of  FIV  in  CD134 
negative  CrFK  cells  induces  the  generation  of  replication competent  viruses 
with mutations in the ES(E/D) motif of the V3 loop of Env (Shimojima et al. 
1998). For both in vivo and in vitro isolates, the mutations at this loop involve 
a charge switch to lysine at one of the glutamates which allows the virus to use 
CXCR4  directly,  with  reduced  requirement  for  CD134  (Willett  et  al.  1997a; 
Willett et al. 1997b; Willett et al. 2007). 
A model of FIV progression is emerging that links the molecular mechanisms of 
virus plasma  membrane  fusion  to  the  broadening of  target cell  tropism  and 
development of feline AIDS (Willett and Hosie 2008). In the early stages of 
infection,  viral  entry  is  characterised  by  a  more  complex  Env receptor 
interaction  involving  CD134  CRD1  and  CRD2.  As  with  HIV 1,  the  two step 
primary receptor attachment followed by a conformational change allows the 
sequestration  of  the  relatively  invariant  CXCR4 binding  domain  from  the 
humoral  immune  response  until  it  is  required  for  mediation  of  entry.  In 
contrast, during the chronic stages of infection, immunity is compromised and 
correspondingly,  viruses  have  a  reduced  need  for  protecting  the  CXCR4 Chapter 1. Introduction 
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interacting domain and isolates become less reliant on CD134. Accompanying 
the reduced CD134 requirement is a broadening of cell tropism and invasion of 
new tissue types, reminiscent of the switch from R5 to X4 in HIV 1. Although 
still dependent on CD134 and CXCR4, late stage FIV infection requires a low 
complexity and possibly low affinity interaction with CD134, similar to HIV 1 
isolates that are able to alter their tropism by altering the nature of the CD4 
interaction (Peters et al. 2006; Gray et al. 2005). Substantiation of this model 
will  come  from  longitudinal  studies  following  the  progression  and  relative 
prevalence  of  viral  mutants  within  individual  cats,  coupled  with  an 
understanding of the molecular basis of infection.  
1.4.5 Receptor tropism of non domestic cat FIV 
Very little is known about the receptor usage of non domestic cat lentiviruses. 
However, domestic cat mitogen stimulated peripheral blood mononuclear cells 
(PBMCs) may be infected with FIV isolates from lion (FIV Ple for Panthera leo) 
and puma (FIV Pco for Puma concolor) (VandeWoude et al. 1997b) but CD134 
and CXCR4 are not down regulated during infection as would be expected if 
entry was mediated by these receptors (Willett et al. 2006a). Furthermore, 
infection  by  FIV Ple  and  FIV Pco  cannot  be  inhibited  by  CXCR4  inhibitor 
AMD3100 or by SDF α, a CXCR4 binding chemokine and a CD134 negative cell 
line 3201 supports the replication of both viruses but not domestic cat strains 
of FIV (FIV Fca) (Smirnova et al. 2005). Taken together, these data suggest that 
FIV Ple  and  FIV Pco  do  not  require  CD134  and  CXCR4  as  receptor  and  co 
receptor,  using  in  preference  an  unknown  cell  surface  receptor.  Multiple 
strains of FIV Pco as well as FIV Ple B 458 have been used to successfully infect 
domestic cats (VandeWoude et al. 2003; VandeWoude et al. 1997a; Terwee et 
al. 2005). The in vivo manifestations of these strains are distinct from FIV Fca 
infection, characterised by reduced pathogenicity and altered tissue tropism, Chapter 1. Introduction 
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with  strains  such  as  FIV Pco 1695  showing  a  greater  propensity  to  infect 
intestinal  tract  mucosa  (Terwee  et  al.  2005).  Infected  domestic  cats  were 
either able to mount a robust humoral and cellular immune response to PBMC 
replicating  virus  (VandeWoude  et  al.  2003),  or  were  able  to  prevent  PBMC 
infection and clear pro viral load three months post infection (Terwee et al. 
2005). It has been suggested that the lengthy period that FIV Ple and FIV Pco 
are  proposed  to  have  co evolved  with  their  hosts  has  reduced  their 
pathogenicity  through  host adaptation  [burk]  (Carpenter  and  O'Brien  1995). 
However, it is possible that differential Env receptor tropism is at least in part 
responsible for the altered pathology and, until the identification of the FIV 
Ple/Pco  receptor/receptors,  the  relevance  of  this  will  remain  unknown. 
Recently, phylogenetic analysis of wild FIV Ple isolates in Africa revealed that 
env of FIV Ple subtype E is more closely related to the envs of FIV Fca than to 
other FIV Ple subtypes or FIV Pco (Pecon Slattery et al. 2008a). The E subtype 
appears to be the result of a recombination event with other viruses, as trees 
drawn  using  the  gag-pol  open  reading  frame  indicate  a  monophylogenetic 
relationship with other strains of FIV Ple. Chapter 3 presents a study of the 
comparative receptor requirements of FIV Ple isolates and finds that FIV strains 
with alternate receptor tropism are circulating in wild lion populations, raising 
important  questions  about  the  evolution  and  pathogenicity  of  FIV  in  this 
species. 
1.5 Post entry restriction 
In order to replicate, lentiviruses are dependent on the presence of compatible 
host factors, use of which they have specifically evolved to incorporate into 
their lifecycles. As has been described, infectivity of lentiviruses is conditional 
on  the  presence  of  cognate  entry  receptors  and  their  absence  precludes 
replication. Thus non functional receptors, such as human CD134 for FIV, are Chapter 1. Introduction 
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thought  to  provide  a  substantial  barrier  to  cross species  transmission.  The 
restriction  factors  provide  another  barrier  to  replication  that  must  also  be 
overcome for successful infection and cross species transmission. This study is 
primarily concerned with hypermutation inducing enzyme APOBEC3 and post 
entry restriction factor TRIM5α and its modulator cyclophilin A.  
1.5.1 Murine Fv1 system 
The first system of retroviral restriction to be described was the murine Friend 
Virus susceptibility (Fv) system (Lilly 1967). Allelic variants of the Fv1 gene 
display  strain specific  restriction  to  the  simple  retrovirus  murine  leukaemia 
virus (MLV). Cells of genotype Fv1
n/n, present in the NIH strain of mice, are 
able to restrict strain MLV B but permit infection by MLV N while cells bearing 
Fv1
b/b, present in BALB/c mice, display the opposite phenotype. The alleles are 
co dominant so that Fv1
n/b heterozygotes are restrictive to both strains (Pincus 
et al. 1971). Fv1 encodes an endogenous retroviral gag gene (Best et al. 1996), 
prompting speculation that Fv1 is able to multimerise with MLV capsid proteins 
and  prevent  early  stages  of  infection.  However,  Fv1  is  almost  entirely 
unrelated to the MLV capsid gene (Best et al. 1996) and its mode of function 
remains unknown. Retroviral restriction was thought to be confined to mice 
until it was shown that non murine cells of diverse species, including those of 
human origin, exhibit a phenotype akin to cells bearing Fv1
b/b: they specifically 
restrict MLV N (Towers et al. 2000; Hofmann et al. 1999). This property was 
historically termed Ref1 in humans and Lv1 in primates, both now known to be 
functions  of  the  a splice  variant  of host  protein  TRIM5.  Curiously,  the  viral 
determinant of N versus B tropism in the Fv1 system has been shown to map to 
capsid residue 110, precisely the same residue that confers MLV N resistance to 
TRIM5a restriction in human cells (Towers et al. 2000).  Chapter 1. Introduction 
 
36 
 
1.5.2 TRIM5α restriction 
TRIM5α provides a potent, pre reverse transcription block to replication. The 
gene  was  identified  by  cDNA  screen  as  the  factor  responsible  for  the  Lv1 
restriction phenotype in rhesus macaque cells (Stremlau et al. 2004). TRIM5 
belongs to the TRIM (tripartite motif) family of proteins (Reymond et al. 2001), 
which is found in species extending from the nematode Caenorhabditis elegans 
to  primates.  A  large expansion  of  TRIM  genes  has  occurred,  resulting  in  68 
genes  in  the  human  genome  including  the  cluster  of  closely  related 
TRIM6/34/5/22 on human chromosome 11 which is found as a syntenic region 
in many mammalian genomes (Reymond et al. 2001; Sardiello et al. 2008). Of 
note, the cluster is absent from the chicken genome, suggesting a mammalian 
origin and its absence from the possum genome indicates that the genes arose 
sometime after the marsupial/eutherian (placental) mammal split dated to 90 
180 mya (Sawyer et al. 2007). In some lineages, TRIM5 itself is the subject of 
multiple  duplications,  with  eight  predicted  tandem  copies  in  the  bovine 
genome and seven in the murine genome (termed TRIM12 and TRIM30 in the 
mouse) (Sawyer et al. 2007; Tareen et al. 2009). It is presumed that the gene 
duplications  are  maintained  as  they  may  provide  restriction  factors  able  to 
simultaneously combat specific pathogens, although the pathogens that have 
driven the evolution of each paralogue have in most cases not been identified. 
In  contrast,  several  taxa  possess  non functional  pseudogenes  of  TRIM5. 
Humans,  for  example  have  a  non functional  inverted  duplication  of  TRIM5 
named TRIMP1 (Reymond et al. 2001) and the canine TRIM5 has been disrupted 
by  the  insertion  of  the  transcript  of  an  apparently  unrelated  gene  PNRC1 
(Sawyer et al. 2007). Interestingly, in taxa such as the canids which lack TRIM5, 
positive selection of the TRIM5 locus seems to have been compensated for by 
an increase in selection of TRIM22, perhaps suggestive of an overlap in antiviral 
function of these two genes (Sawyer et al. 2007). Chapter 1. Introduction 
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The tripartite  motif  (TRIM)  gene  family  is characterised by  the presence  of 
three  domains:  a  RING  (really  interesting  new  gene)  domain  capable  of  E3 
ubiquitin  ligation,  one  or  more  B Box  domains  and  a  coiled coil  domain 
responsible  for  formation  of  multimers  (Reymond  et  al.  2001).  Several 
members of the gene family (60% of those in humans), including the longest 
(alpha) isoform of TRIM5 possess an additional C terminal B30.2 domain (also 
known as a PRY SPRY domain). In some primate species, a retrotransposition 
event has resulted in the B30.2 domain being replaced by a cyclophilin domain, 
resulting in a TRIM5 CypA fusion, termed TRIMCyp (Newman et al. 2008; Wilson 
et al. 2008; Virgen et al. 2008; Sayah et al. 2004). Subcellular localisation of 
TRIM  proteins  is  found  to  be  diverse  with  localisation  typically  nuclear, 
cytoplasmic or both (Reymond et al. 2001). For TRIM5α, localisation is in the 
cytoplasm, where it is able to form discrete puncta termed cytoplasmic bodies 
when  over expressed.  However  formation  of  cytoplasmic  bodies  is  not  a 
prerequisite for restriction activity of TRIM5α (Perez Caballero et al. 2005b), 
and the biological role of these structures is unknown. Amongst the primate 
TRIM5α orthologues, an ability to inhibit the replication of a broad range of 
exogenous  and  endogenous  retroviruses  has  been  documented,  including 
members of the lenti-, beta , gamma  and spuma- retroviruses. (Saenz et al. 
2005; Song et al. 2005a; Keckesova et al. 2004; Kaiser et al. 2007; Diehl et al. 
2008;  Yap  et al.  2008).  The  precise  mechanism  of the  restriction  ability  of 
TRIM5α remains the subject of enquiry, but roles for the individual domains 
have  been  described,  allowing  hypotheses  for  the  overall  mechanism  of 
restriction to be advanced. 
1.5.3 Virus interaction maps to TRIM5 B30.2 or CypA domain 
The B30.2 domain is a conserved protein domain found uniquely in vertebrates 
that possess adaptive immune systems (Rhodes et al. 2005). The domain is a Chapter 1. Introduction 
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composite of two more ancient domains: the PRY domain, which contributes 
the  N terminal  50 60  amino  acids,  and  the  SPRY  domain,  first  identified  in 
fungus Dictyostelium, which contributes the C terminal ~140 amino acids. The 
resulting B30.2 (also referred to as PRY SPRY domain) is present in more than 
150 human proteins in eleven gene families in the human genome including the 
BTN immunoglobulin receptors and DEAD box domain proteins (Rhodes et al. 
2005; Woo et al. 2006).  
The TRIM5α B30.2 domain is thought to engage the incoming viral core in the 
cytoplasm by recognition of specific features in the capsid N terminal domain 
(Owens et al. 2004; Stremlau et al. 2004). An alignment of mammalian TRIM5 
B30.2 domains reveals the presence of three areas of variability termed v1 to 
v3 (Song et al. 2005a). Structures have been solved of the B30.2 domain of 
TRIM21 (a close relative of the TRIM5/6/32/22 family which is known to bind 
IgG and is involved in Sjorgen’s syndrome (Keeble et al. 2008)) and of a related 
Drosophila protein, GUSTAVUS (Woo et al. 2006), which show the SPRY forming 
a β sandwich pocket formed by the conserved β strands, referred to as β1 to 
β13.  Protruding  from  this  core  structure  are  the  variable  loops,  forming  a 
surface  capable  of  protein protein  interaction.  For  TRIM21,  and  potentially 
TRIM5, a separate pocket derived from the PRY subdomain is formed and with 
an exposed surface analogous to TRIM5α v1 (James et al. 2007). Part of this 
region is lacking in Macaca nemestrina TRIM5 isoform TRIM5θ, a deletion which 
impacts negatively on retroviral restriction (Brennan et al. 2007). Experimental 
data  for  TRIM21  suggest  the  presence  of  a  conformationally  rigid  binding 
surface  that  does  not  alter  its  shape  upon  interaction  with  its  substrate 
(induced fit  model)(Keeble  et  al.  2008).  Thus  in  a  manner  reminiscent  of 
immunoglobulins,  a  conserved  backbone  supports  variable  loops  capable  of 
protein protein interaction.  Chapter 1. Introduction 
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The variable regions of primate TRIM5α B30.2 exhibit a substantial number of 
substitutions,  insertions  and  lineage specific  length  polymorphisms.  The 
significance of variation in these domains has been highlighted by the finding 
that the difference in phenotype between rhTRIM5α, which restricts HIV 1, and 
huTRIM5α,  which  does  not,  maps  to  P332R  (P  in  rh)  within  the  v1  domain 
(Perez Caballero et al. 2005a; Stremlau et al. 2005; Yap et al. 2005). Similarly, 
restriction of MLV N by huTRIM5α is specific to acidic residues in the v3 loop 
(E405 and E406) (Perron et al. 2006a). Comparison with TRIM21 reveals that 
these  positions  correspond  to  the  points  of  contact  for  the  protein protein 
interaction  (James  et  al.  2007).  Length  polymorphisms  have  also  been 
documented: v1 is typically longer in the old world (catarrhine) monkeys (17 
amino acids in squirrel monkey versus 46 amino acids in African green monkeys 
(Song et al. 2005a)), whilst v3 is typically longer in the new world (platyrrhine) 
monkeys  (32  residues  in  most  catarrhines  including  apes,  compared  to  41 
residues in squirrel monkeys). For the most part, these length polymorphisms 
are the result of internal tandem duplications. It has been noted that those 
species with most duplications exhibit the widest repertoires of restriction. For 
example, African green monkey (agm) TRIM5α, with an expanded v1 domain, is 
able to target several retroviruses and may have become prevalent due to the 
selective advantage of increased breadth of capsid targets (Keckesova et al. 
2004; Yap et al. 2004). Accordingly, the duplicated sequences in the variable 
loops are also more likely to have substitutions suggesting that the duplicated 
sequence may selectively target different capsids (Sawyer et al. 2005).  
In some primate species, the B30.2 domain of TRIM5α is replaced by host factor 
cyclophilin  A  (CypA),  creating  fusion  protein  TRIMCyp.  CypA  is  known  to 
interact with lentiviral capsid (Luban et al. 1993; Franke et al. 1994; Thali et 
al.  1994)  and  its  association  with  TRIM5  creates  a  potent  restriction  factor 
capable  of  targeting  lentiviruses  whose  capsids  interact  with  CypA,  such  as Chapter 1. Introduction 
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HIV 1 and FIV (Sayah et al. 2004; Lin and Emerman 2006). The first TRIMCyp to 
be described was in the new world species owl monkey (Aotus trivirgatus) and 
formed by a retrotransposition event placing it downstream of exon 7 (Nisole 
et  al.  2004;  Sayah  et  al.  2004).  Subsequently,  TRIMCyps  were  found  in  old 
world pigtail, rhesus and long tailed macaque species (Macaca nemestrina, M. 
mulatta and M. fascicularis respectively) (Newman et al. 2008; Virgen et al. 
2008; Wilson et al. 2008). Remarkably, these TRIMCyps were created by an 
event independent of the owl monkey TRIMCyp as the CypA exon is located 
downstream of exon 8, and the coding transcript is generated by exon skipping. 
This indicates that capsid specific restriction has arisen independently at least 
four times during mammalian evolution, targeting the same viral determinant. 
Since lentiviruses are the only retroviruses known to interact with CypA, the 
independent genesis of TRIMCyps would appear to highlight the strong selective 
pressure  to  devise  novel  restriction  factors  to  circulating  lentiviruses. 
However, no lentiviruses have been discovered in owl monkeys, or indeed any 
platyrrhine monkey, making the pathogen that drove the evolution of the owl 
monkey TRIMCyp uncertain. Once fused with the TRIM5 RBCC (the collective 
term for the RING, B Box and coiled coil), the CypA domain of rhesus TRIMCyp 
appears to have undergone point mutations that allow differential restriction 
of  lentiviruses:  tropism  has  changed  from  HIV 1 binding  to  HIV 2 binding 
through the acquisition of two point mutations that remodel the hydrophobic 
pocket (Price et al. 2009).  
1.5.4 Adaptive evolution of TRIM5α  
Evolution  at  the  molecular  level  is  characterised  by  the  generation  of 
mutations that may be deleterious, in which case natural selection will prevent 
their  spread  (purifying  selection),  or  advantageous,  in  which  case  natural 
selection  will  seek  to  increase  their  prevalence  (Darwinian  or  positive Chapter 1. Introduction 
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selection). In addition, genetic changes may be driven to fixation by random 
genetic drift. Thus the presence of high levels of mutations between copies of 
a  gene  belonging  to  different  species  may  be  the  result  of  very  different 
evolutionary forces. Either 1) changing environmental circumstances may have 
relaxed the effect of purifying selection allowing new mutations to increase in 
frequency  by  genetic  drift  or  2)  positive  selection  has  driven  the  new 
mutations  to  fixation,  suggesting  a  biologically  important  role.  The  two 
scenarios can be differentiated by the calculation of the synonymous (silent) to 
non synonymous (amino acid substituting) changes at the nucleic acid level, 
since synonymous changes are assumed to be neutral with respect to natural 
selection and therefore give a background rate of the accumulation of changes 
(Yang 2005). The ratio of non synonymous to synonymous changes (dN/dS ratio) 
is therefore an indicator of the nature of the selection that has occurred during 
evolution,  with  values  >1,  1  and  <1  representing  positive  selection,  neutral 
selection and purifying selection respectively.  
Primate TRIM5α has been evolving under episodes of positive selection for at 
least  the  past  33  mya  (Sawyer  et  al.  2005).  Evidence  of particularly  strong 
positive selection is found in the hominid lineage and maps to several residues 
in the B30.2 domain variable loops and four residues in the coiled coil domain, 
some displaying a dN/dS ratio as high as 8.8. This analysis highlighted a patch 
of residues in the v1 loop as under very strong adaptive selection, including the 
R332P codon that is largely responsible for the change in specificity between 
hu and rh TRIM5α variants (Perez Caballero et al. 2005a; Stremlau et al. 2005; 
Yap et al. 2005). Analysis of the five confirmed protein coding bovine TRIM5 
paralogues  and  the  murine  TRIM12/TRIM30  genes  reveals  that  positive 
selection of TRIM5α is also present in these species and therefore not unique to 
the primates (Sawyer et al. 2005; Tareen et al. 2009). The selective pressure 
also maps to the v1 loop, consistent with the paralogues evolving to target Chapter 1. Introduction 
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diverse  pathogens.  However,  the  viral  targets  for  most  of  the  genes  is 
unknown,  although  bovine  TRIM5-3  has  been  found  to  restrict  retroviral 
replication in a manner similar to primate TRIM5α, specifically targeting MLV N 
(Ylinen et al. 2006; Si et al. 2006). The data imply that antiretroviral activity 
of  TRIM5α  is  an  ancestral  phenotype  which  has  been  conserved  in  diverse 
mammalian taxa. Furthermore, the repeated findings of positive selection in 
the B30.2 domain are consistent with TRIM5α’s critical role in the permissivity 
of the host to infection by widespread pathogens.  
1.5.5 Contribution of RBCC domain to restriction 
Target specificity of TRIM5α is provided by the B30.2 domain. However, the 
RING,  B Box  and  coiled coil  domains  are  canonical  features  of  TRIM  family 
proteins,  and  each  domain  contributes  to  TRIM5α mediated  restriction.  The 
coiled coil domain is an approximately 100 residue domain encoded by human 
TRIM5α exons 2, 3 and 4. Coiled coil domains typically consist of a 7 residue 
repeat ‘abcdefg’ where amino acids a and d represent hydrophobic residues 
responsible for homo oligomerisation and the other residues are polar (Harbury 
et al. 1995; Lupas et al. 1991). For TRIM5α, the coiled coil and the downstream 
linker  2  region  between  the  coiled  coil  and  B30.2  domain  mediate 
oligomerisation (Mische et al. 2005; Javanbakht et al. 2006a; Langelier et al. 
2008), although conflicting evidence has been provided as to whether it forms 
dimers or trimers. Experiments have been confounded by the rapid turnover of 
TRIM5α and its tendency to form aggregates when purified. These problems 
have been resolved by the use of chimeric protein with the RING domain of 
TRIM21  and  expression  in  insect  cells  to  demonstrate  that  TRIM5α  self 
associates as a dimer (Langelier et al. 2008). Previous confusing results from 
cross linking experiments were obtained due to the anomalously slow migration 
of TRIM5α dimers by SDS PAGE. Mutation of hydrophobic residues predicted to Chapter 1. Introduction 
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form  the  surface  for  self association  dramatically  reduces  capsid  binding 
(Javanbakht  et  al.  2006a)  and  the  efficiency  of  rhTRIM5α  to  restrict  HIV 1 
(Javanbakht et al. 2006a; Mische et al. 2005), suggesting that dimerisation of 
the  protein  is  important  for  increasing  the  avidity  of  the  TRIM5α capsid 
interaction. Coiled coil domains expressed alone (and other truncated TRIM5α 
constructs  such  as  human  splice  variant  TRIM5γ  and  TRIM5δ)  are  able  to 
prevent restriction by full length TRIM5α presumably by forming dimers with 
full length protein in the cytoplasm (Perez Caballero et al. 2005a).  
The RING domain belongs to the E3 ubiquitin ligase class of enzymes which 
facilitate the transfer of ubiquitin from an E2 conjugating enzyme to a lysine 
residue of the target protein. TRIM5α is capable of transferring the ubiquitin 
peptide to itself (auto ubiquitinylation) which is thought to direct the protein 
to proteasome mediated degradation, in turn leading to a high rate of turnover 
(Diaz Griffero et al. 2006a; Javanbakht et al. 2005). It appears that incoming 
retroviral  cores  that  have  been  bound  by  TRIM5α  are  also  subject  to 
proteasome degradation, as inhibition of the proteasome with MG132 prolongs 
the  lifetime  of  cores  in  the  cytoplasm  (Campbell  et  al.  2008)  and  TRIM5α 
appears to increase in turnover rate upon inoculation with a restricted virus 
(Rold  and  Aiken  2008),  suggesting  a  functional  link  between  proteasome 
degradation and restriction. However, deletion of the RING domain impairs but 
does not abolish TRIM5α mediated restriction and the impairment of restriction 
could partly be attributed to alteration of subcellular localisation (Javanbakht 
et  al.  2005).  Likewise  inhibition  of  the  proteasome  with  MG132  does  not 
restore  infectivity  (Anderson  et  al.  2006;  Wu  et  al.  2006),  suggesting  that 
although TRIM5α does mediate proteasomal cleavage of the viral core, this is 
not crucial for its antiviral activity and TRIM5α depends additionally on other 
mechanisms to prevent retroviral infection.  Chapter 1. Introduction 
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The B Box 2 domain is present in the majority of TRIM family proteins and is 
sometimes  accompanied  by  an  adjacent  B Box  1  domain.  The  domains  are 
unique to the TRIM family but their function is poorly characterised (Reymond 
et al. 2001). TRIM5α possesses a single B Box 2 domain which, when deleted, 
severely impacts on retroviral restriction (Stremlau et al. 2006b; Javanbakht et 
al. 2005). Homology modelling with a TRIM29 B Box 2 structure reveals it to be 
a globular structure with a highly charged surface (Diaz Griffero et al. 2007). 
Mutation of some of these residues (such as rhTRIM5α R119) results in the loss 
of  antiretroviral  activity,  despite  retaining  the  ability  to  self associate  and 
interact  with  capsid,  suggesting  that  the  B Box  is  involved  in  an  effector 
function of TRIM5α mediated restriction (Diaz Griffero et al. 2007). The nature 
of this function is unknown but may involve the recruitment of other cellular 
proteins. It also appears that the charged surface is involved in modulating the 
stability of the protein in the cytoplasm and in the formation of higher order 
complexes  of  TRIM5α  (Diaz Griffero  et  al.  2007;  Li  and  Sodroski  2008), 
although,  again  the  mechanism  regulating  its  longevity  is  unknown  but 
independent of proteasome degradation (Diaz Griffero et al. 2007).  
In studying the contributions of the individual domains of TRIM5α, several non 
mutually exclusive hypotheses for the mechanism of TRIM5α antiviral activity 
have been advanced. The simplest model is that incoming cores are bound by 
TRIM5α,  which  is  poly ubiquitinylated  and  with  a  high  level  of  turnover, 
resulting in degradation of viral proteins. Evidence for this model comes from 
the finding that under normal conditions, retroviral cores are degraded by the 
proteasome before they have the chance to reverse transcribe (Wu et al. 2006; 
Anderson et al. 2006). Although this method of restriction may represent the 
likely  fate  of  restricted  viruses  in  vivo,  the  persistence  of  restriction  after 
addition of MG132 suggests that other mechanisms are operating (Campbell et 
al. 2008). The nature of this block is unknown, although interference with the Chapter 1. Introduction 
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uncoating process has been suggested (Stremlau et al. 2006b). Uncoating is a 
poorly defined stage thought to involve the dissassembly of the capsid core and 
a restructuring of the viral proteins in order for reverse transription of the viral 
RNA genome to occur. Evidence that the process occurs is provided by findings 
that CA protein is present only at very low levels after reverse transcription 
(Fassati  and  Goff  2001)  and  electron  microscopy  shows  cores  disintegrating 
soon after fusion (Grewe et al. 1990). Furthermore, restriction factor TRIMCyp 
is  only  able  to  restict  HIV 1  in  the  first  30 60  minutes  post entry  (Perez 
Caballero et al. 2005b). It is thought that uncoating is a temporally regulated 
event that must proceed at the correct speed to allow association with cellular 
factors whilst retaining the ability to perform necessary viral functions, notably 
reverse  transcription  (Forshey  et  al.  2002).  By  following  the  levels  of 
multimeric  or  soluble  capsid  post  infection,  it  was  suggested  that  TRIM5α 
promotes  the  rapid conversion  of  HIV 1  and  MLV N capsid  structures  to the 
soluble (disassembled) form (Perron et al. 2006b; Stremlau et al. 2006b). In a 
similar  manner  CypA,  which  has  been  hypothesised  to  aid  uncoating  by 
performing  a  proline  isomerisation  reaction,  is  able  to  act  as  a  restriction 
factor for HIV 1 when multimerised (Yap et al. 2007; Javanbakht et al. 2007). 
This  supports  the  accelerated  uncoating  hypothesis  but  disruption  of  other 
essential activities such as formation of the reverse transcription complex and 
translocation across the nuclear membrane has not been ruled out. Indeed, the 
accelerated uncoating hypothesis does not explain the effect of mutations of 
charged residues in the B box which ablate restriction. Nor does it explain the 
low  levels  of  retroviral  restriction  by  hu  or  rhTRIM5α  when  exogenously 
expressed in dog cells(Berube et al. 2007). These findings suggest that TRIM5α 
binding to viral cores alone is insufficient for full levels of restriction and the 
protein may recruit other cellular factors that are required for optimal levels 
of restriction.  Chapter 1. Introduction 
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1.6 The role of Cyclophilin A in lentiviral replication 
1.6.1 Cyclophilin A and its inhibitors 
The  cyclophilins  are  a  large  protein  family  found  in  both  prokaryotes  and 
eukaryotes.  The  family  are  members  of  the  peptidyl  proline  isomerases 
superfamily (immunophilins), a name which reflects their ability to catalyse 
cis-trans  isomerisation  around  peptidyl proline  bonds  (Gothel  and  Marahiel 
1999).  The  18  kDa  human  protein  CypA  was  discovered  as  the  intracellular 
receptor  of  immunosuppressive  drug  cyclosporine  A  (CsA)  (Takahashi  et  al. 
1989). There are at least eight Cyp genes expressed in humans, with many 
other mammalian forms also found, all with sequence identity of >50% (Gothel 
and  Marahiel  1999),  but  with  variable  subcellular  localisation.  For  instance 
CypB  is  found  exclusively  in  the  endoplasmic  reticulum  (Price  et  al.  1991), 
whilst CypA is found at high levels in the cytoplasm (3 7 g per mg total protein 
(Ryffel  et  al.  1991)).  CsA  is  a  cyclic  peptide  isolated  from  the  fungus 
Tolypocladium  inflatum  and  is  widely  used  in  immune  suppression  for 
recipients  of  allografts.  CsA  exerts  its  immunosuppressive  effect  by  binding 
CypA  with  a  high  affinity  (IC50  ~6nM  (Liu  et  al.  1991)).  Once  bound,  the 
complex  creates  a  novel  binding  surface  which  is  able  to  bind  and  inhibit 
calcineurin,  a  serine/threonine  kinase  capable  of  dephosphorylating,  and 
hence  activating,  transcription  factor  NF AT  (nuclear  factor  of  activated  T 
cells), which is required for IL 2 expression associated with activated T cells 
(for  review  of  CsA's  role  in  T cell  activation  see  Clardy  1995).  Under  CsA 
inhibition, T cell receptor (TCR) mediated activation and subsequent expansion 
of T cell clones, which rely on this signalling pathway, are therefore inhibited, 
seriously  compromising  cellular  immunity.  Non immunosuppressive  analogues 
of CsA have been manufactured, notably NIM811 and Debio 025, which retain Chapter 1. Introduction 
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their ability to bind CypA, but do not provide the calcineurin binding surface 
(Rosenwirth et al. 1994; Ptak et al. 2008). 
1.6.2 CypA is a cofactor of HIV 1 replication 
CypA was first associated with lentiviral replication when it was found to be 
packaged  into  HIV 1  virions  via  an  association  with  unprocessed  Gag 
polyprotein (Luban et al. 1993; Franke et al. 1994; Thali et al. 1994). These 
studies  found  that  disruption  of  the  interaction  with  CsA  prevented  CypA 
incorporation  into  virions  and  impacted  negatively  on  HIV 1  replication. 
However it is during the early stages of viral infection, not incorporation, that 
CypA  impacts  on  the  viral  lifecycle  (Towers  et  al.  2003).  CypA  binds  to 
incoming  viral  cores  via  an  interaction  between  the  catalytic  hydrophobic 
pocket of the enzyme and an exposed proline rich loop between CA helices 4 
and  5  on  the  external  surface  of  capsid  N terminal  domain  (Gamble  et  al. 
1996). This loop appears to be confined to the lentiviruses as it is absent in 
other groups of retroviruses. However, whilst the CA CypA interaction has been 
demonstrated for HIV 1, SIVagm and FIV (Lin and Emerman 2006; Diaz Griffero 
et  al.  2006b;  Zhang  et  al.  2006)  the  interaction  is  not  a  feature  of  all 
lentiviruses: SIVmac, HIV 2 and EIAV do not bind CypA (Lin and Emerman 2006; 
Yoo et al. 1997; Braaten et al. 1996). 
HIV 1  CA  exists  as  a  mixture  of  cis  and  trans  isomers  around  the  G89 P90 
peptide bond with 14% of molecules in the cis and the remainder in the trans 
conformation (Gitti et al. 1996). Most peptide linkages are made in the trans 
conformation during translation, but peptidyl proline linkages can be made in 
cis or trans, and the activity of peptidyl proline isomerase (PPI) enzymes is 
thought to aid proper folding (Gothel and Marahiel 1999). Isomer heterogeneity 
is therefore rare in folded proteins making HIV 1 CA an unusual case (Fischer et 
al. 1998). It has been shown that CypA catalyses the inter conversion of the CA Chapter 1. Introduction 
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G89 P90 cis and trans isomers, increasing isomerisation by about 100 fold but 
maintaining the same cis:trans ratio in a CsA inhibitable manner (Bosco et al. 
2002).  The  finding  supports  the  idea  that  CypA  performs  a  catalytic  role 
promoting the dissociation of the capsid core upon infection of a target cell. 
HIV 1 CA mutants G89V/A and P90V/A result in a 30 150 fold reduction in CypA 
binding affinity (Yoo et al. 1997) and display a similar phenotype to wildtype 
virus in the presence of CsA, with reduced infectivity in human cells.  
1.6.3 CypA can have alternative effects on lentiviral replication 
The  effects  of  CypA  on  the  replication  of  lentiviruses  are  not  identical  in 
different  contexts.  CsA  treatment  results  in  an  increase  in  HIV 1  infectivity 
upon  entry  to  rhesus  macaque  cells,  but  only  in  the  presence  of  TRIM5α, 
suggesting  that  CypA  promotes  an  isomerisation  that  increases  the 
susceptibility of HIV to post entry restriction (Keckesova et al. 2006; Berthoux 
et al. 2005; Stremlau et al. 2006a). Conversely, a reduction in infectivity of 
HIV 1 in human TE671 cells treated with CsA remains even after knockdown of 
TRIM5α (Keckesova et al. 2006; Sokolskaja et al. 2006). This phenotype is cell 
type specific as TE671 sub clone 17H1, selected for loss of MLV N restriction, is 
permissive  for  HIV 1  in  a  CypA independent  manner  but  maintains  wildtype 
expression levels of TRIM5α, suggesting that in humans, CypA protects HIV from 
an unknown restriction factor (Sayah and Luban 2004). Long term passage of 
HIV 1 in the presence of CsA results in the out growth of mutants A92E and 
G94D (Aberham et al. 1996). Infectivity of HIV 1 bearing these mutations is 
subsequently dependent on the presence of CsA in HeLa but not TE671 cells 
(Hatziioannou et al. 2005; Sokolskaja et al. 2006). Recently it has been shown 
that the CsA dependence in HeLa cells is due to high CypA expression levels in 
HeLa  cells  compared  to  TE671,  but  interestingly  the  HIV  A92E  and  G94D 
mutants do not differ in their affinity for CypA (Ylinen et al. 2009). The finding Chapter 1. Introduction 
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supports the notion of CypA playing a role in uncoating but that the mutants 
arising from CsA inhibition differ in their sensitivity to CypA aided uncoating, 
rather than their affinity for CypA. Also arising from this study is the suggestion 
that the CA CypA affinity appears to be maintained within a narrow range of 
values (all studies to date report Kd values within 5 – 15  M (Yoo et al. 1997; 
Price et al. 2009; Ylinen et al. 2009)) even for the CsA inhibition dependent 
mutants. The reasons for this are unclear, but may  involve maintaining the 
correct  level  of  isomerase  activity  to  uncoat  the  virus  in  the  appropriate 
manner. However research in the field has been hampered by the absence of 
CypA mutants that bind CA but do not perform the isomerase activity. Mutating 
the G89 P90 bond that prevents isomerisation also prevents CypA binding (Yoo 
et  al.  1997),  making  it  difficult  to  distinguish  between  the  relative 
contributions of binding and isomerisation.  
In  some  primate  species,  cyclophilin  replaces  the  B30.2  domain  of  TRIM5α, 
creating TRIMCyp (Wilson et al. 2008; Virgen et al. 2008; Sayah et al. 2004; 
Newman et al. 2008). The CypA domain of the new world primate owl monkey 
(omk) TRIMCyp binds to a similar repertoire of viruses as human cytosolic CypA, 
and accordingly restricts HIV 1 and FIV but does not restrict HIV 2 or SIVmac 
(Sayah et al. 2004; Virgen et al. 2008; Wilson et al. 2008). Newly discovered 
forms of TRIMCyp, created by an independent retrotransposition event in the 
Macaca  genus  (rh),  have  an  altered  capsid  specificity,  specifically  targeting 
HIV 2 but no longer restricting HIV 1 (Wilson et al. 2008; Virgen et al. 2008). 
This switch in specificity is attributable to two substitutions, D66N and R69H. 
These mutations cause a comparatively large (~16Å) rearrangement of a ten 
residue loop at the binding surface of Cyp, changing from a ‘closed fist’ to 
‘open  palm’  conformation  and  permitting  micromolar  binding  to  HIV 2  CA 
(Price et al. 2009). Curiously, FIV is restricted by both rh and omkTRIMCyp 
(Virgen et al. 2008; Wilson et al. 2008; Saenz et al. 2005). So far FIV appears to Chapter 1. Introduction 
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be unique in this property suggesting an alternative CypA binding mechanism 
and  making  an  interesting  comparison  with  the  primate  lentiviruses,  where 
binding is exclusive to either omkTRIMCyp/CypA or to the structurally modified 
rhTRIMCyp. This issue is addressed in Chapter 5, where biophysical techniques 
confirm the dual specificity of FIV and a crystal structural of FIV CA reveals 
structural differences to the primate lentiviruses. 
1.7 Induction of hypermutation by APOBEC3 
1.7.1 Discovery of human APOBEC3G 
The discovery of the role of APOBEC enzymes in the lifecycle of retroviruses 
stems from work on viral infectivity factor (Vif) in HIV 1. Vif is a highly basic 
protein  of  22 29kDa  found  in  all  lentiviruses  with  the  exception  of  equine 
infectious anaemia virus (EIAV; Kawakami et al 1987). Early work on the gene 
(known at that time as gene ‘A’ or  sor) revealed that Vif was required for 
replication  in  certain  ‘non permissive’  cell  lines  including  macrophages, 
monocyte  and  some  T cell  derived  cells  (e.g.  CEM,  H9  and  HUT78)  but 
dispensable in other ‘permissive’ cell lines such as T cell lines CEM SS, Jurkat 
and non lymphoid cells such as HeLa (von Schwedler et al. 1993; Gabuzda et 
al. 1992). It was shown that Vif is packaged into virus particles where it is 
required for the formation of phenotypically normal virions (von Schwedler et 
al. 1993; Ohagen and Gabuzda 2000). Furthermore it was shown that packaging 
of  Vif  into  virus  particles  is  essential  for  overcoming  the  block  in  non 
permissive  cells  (von  Schwedler  et  al.  1993).  Thus  the  phenotype  of   vif 
viruses  is  dependent  on  the  permissivity  of  the  virus  producing  cells:   vif 
viruses produced in permissive cells are infectious for a single cycle regardless 
of the permissiveness of the target cells, whilst  vif viruses produced in non 
permissive cells are uninfectious regardless of the nature of the target cells. Chapter 1. Introduction 
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The factor responsible for the differential permissivity between CEM and CEM 
SS  cells  was  isolated  by  subtractive  cloning  coupled  with  a  cDNA  screen 
(Sheehy et al. 2002). The gene identified was APOBEC3G (huA3G), a member of 
the  cytidine  deaminase  enzyme  family.  There  are  12  members  of  the  gene 
family in the human genome residing in four gene clusters: APOBEC1 and AID 
are  separated  by  1  megabase  on  chromosome  12,  A2  resides  alone  on 
chromosome 6, an expanded cluster of seven A3 genes (A, B, C, DE, F, G and H) 
is located on chromosome 22, and A4 is located on chromosome 1. The family 
takes its name after the apolipoprotein B mRNA editing catalytic polypeptide 1 
(APOBEC1), for which only a single role has been described: to deaminate a 
single nucleoside of APOB mRNA transcripts at position C6666 to generate a 
truncated  protein  (Teng  et  al.  1993).  The  B cell  expressed  protein  AID 
(activation induced  deaminase)  is  responsible  for  the  generation  of  somatic 
hypermutation leading to the diversification of antibody (Martin et al. 2002; Di 
Noia et al. 2007) and also triggers antibody class switching, both operating at 
the  DNA  level  (Muramatsu  et  al.  1999).  The  identification  of  huA3G  as  the 
factor  responsible  for  the  non permissivity  of  certain  cell  lines  therefore 
presented a potential mechanism for its activity: host mutation of viral nucleic 
acids.  
1.7.2 Antiviral activity of human APOBEC3G 
The cytidine deaminases all bear a catalytic domain (CD) that comprises a Zn 
coordinating  H/C X E X23 28 P C X2 C  motif which is  thought to generate  zinc 
hydroxide  that  is  able  to  deaminate  the  pyrimidine  ring  of  cytidine  by 
nucleophilic attack resulting in a uracil residue (Harris and Liddament 2004). 
Several of the huA3 genes (A3B, DE, F and G) possess two CDs: an N terminal 
domain (CD1; also known as the pseudocatalytic domain) that is catalytically 
inactive, and a catalytically active C terminal domain (CD2; Huthoff and Malim Chapter 1. Introduction 
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2007). The domains have distinct functions and antiviral activity of huA3G is 
dependent upon both the domains.  
The  huA3G  CD2  deaminase  specifically  targets  cytosine  residues  of  single 
stranded (ss) minus sense DNA but is catalytically inactive on HIV 1 genomic 
RNA,  double  stranded  DNA  and  RNA DNA  heteroduplexes  (Yu  et  al.  2004b). 
Crystal  and  NMR  structures  of  CD2  reveal  a  positively  charged  nucleic  acid 
binding  groove  that  permits  interaction  with  the  negatively  charged  single 
stranded DNA backbone and brings the target cytosine into close proximity with 
the Zn coordinating catalytic domain (Holden et al. 2008; Chen et al. 2008). 
The deamination activity of CD2 converts cytosine to uracil in the minus strand 
DNA.  Subsequent  reverse  transcription  results  in  a  guanosine  to  adenosine 
transition  in  the  coding  strand  for  the  most  part  of  the  HIV  genome  (the 
exceptions  being  the  U3  region  of  the  5’  LTR  and  the  primer  binding  sites 
which  exist  as  single  stranded  DNA  flaps  after  reverse  transcription  and 
accumulate cytosine to thymine mutations (Yu et al. 2004b)). The mutagenesis 
proceeds from 3’ to 5’ end of the ssDNA, following the generation of single 
stranded  DNA  and  digestion  of  template  RNA  by  reverse  transcriptase  and 
RNaseH  respectively  (Chelico  et  al.  2006).  The  sites  of  mutation  are  not 
completely  random.  Firstly,  gradients  of  A3G induced  mutations  exist, 
increasing in the 5’ to the 3’ end of the positive sense genome which is thought 
to reflect the time that single stranded DNA is exposed to huA3G (Yu et al. 
2004b; Suspene et al. 2006). These gradients reach their peak just 5’ of the 
polypurine tracts which are the origins of reverse transcription (Suspene et al. 
2006;  Yu  et al.  2004b).  Additionally,  mutational  hotspots  for APOBECs  have 
been identified: most prevalently for huA3G, the GG dinucleotide (substrate 
residue underlined) is most commonly mutated, and in particular in the TGGG 
tetranucleotide (Yu et al. 2004b; Bishop et al. 2004b; Suspene et al. 2006; 
Harris  et  al.  2003).  Interestingly,  in  protein coding  regions,  this  mutation Chapter 1. Introduction 
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frequently results in a TGG to TAG change which alters a tryptophan codon to a 
stop codon, potentially causing a damaging truncating mutation to the viral 
protein. Thus the activity of APOBEC3G against HIV 1  vif is thought to be the 
introduction of mutations (hypermutation) to such a level (as many as 10% of 
guanosines  may  be  mutated  to  adenosines)  that the  virus is  impaired  in  its 
ability to produce infectious progeny virions. When the level of hypermutation 
renders the virus unable to faithfully replicate and therefore unable to sustain 
infection it is said that the error catastrophe threshold has been surpassed.  
1.7.3 Encapsidation of human APOBEC3G 
The fact that the permissivity of the virus producing cell rather than the target 
cell is the determinant for viral replication suggests that APOBEC3G present in 
the target cell is not sufficient for inhibition of viral replication. Indeed it has 
been shown that huA3G is encapsidated into HIV 1  vif and this ability is likely 
to  depend  on  interaction  between  huA3G  CD1  and  both  viral  Gag  p55 
nucleocapsid region and viral RNA (Mangeat et al. 2003; Khan et al. 2005). The 
precise mechanisms and relative contributions of each of these interactions is 
currently under study but is thought to involve multimers of huA3G forming 
complexes with viral RNA, cellular RNA species 7SL and p55 polyprotein which 
are then packaged into budding virus particles (Svarovskaia et al. 2004; Wang 
et al. 2007). Final levels of huA3G are dependent on the levels of expression in 
the  virus  producing  cell,  calculated  at  7  enzyme  copies  per  virion  when 
produced in PBMCs but capable of much higher levels of incorporation when 
overexpressed in vitro (Xu et al. 2007). Interestingly, even in the presence of 
Vif, huA3G particles are thought to be packaged into HIV 1 particles with 0.3 to 
0.8  molecules  per  virion  (Nowarski  et  al.  2008),  and  low  levels  of  G  to  A 
mutations are observed in high passage number HIV 1 cultures (Zhang et al. 
2003).  As  with  many  pre integration  stages  of  the  retroviral  lifecycle, Chapter 1. Introduction 
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interactions of huA3G with the reverse transcription complex in the target cell 
are  much  less  well  understood,  but  presumably  require  interactions  that 
prevent disassociation of huA3G from the target nucleic acids and allow the 
transition from RNA binding to single stranded DNA cytidine deamination. 
It has been reported that induced hypermutation is not sufficient to explain 
the antiviral activity of huA3G and huA3F, giving rise to the possibility of a 
deamination independent role of APOBECs on viral replication. Mutation of the 
conserved  zinc  coordinating  histidine  and  cysteine  residues  or  the  catalytic 
glutamic acid residues of CD2 abolishes deaminase activity but does not fully 
destroy antiviral activity (Newman et al. 2005). Recently, a likely mechanism 
for  deaminase independent  activity  has  been  proposed  which  involves  the 
inhibition  of  the  progression  of  the  reverse  transcriptase  enzyme  along  the 
template  RNA  in  the  newly  infected  cell  (Bishop et  al.  2008).  However the 
relative contributions of the deaminase dependent and  independent roles of 
huA3G  are  not  fully  clear  and  may  have  different  relative  contributions 
depending on the cell type in question (Thielen et al. 2007). 
1.7.4 Antiviral activity of other human APOBEC3 genes 
The  presence  of  an  expanded  gene  family  of  APOBEC3  genes  raises  the 
possibility that other members of the family possess antiviral activity. Several 
studies have now been performed confirming that this is indeed the case and 
anti lentiviral  activity  has  been  associated  with  several  of  the  two domain 
APOBECS, namely 3B (Bishop et al. 2004a), 3DE (Dang et al. 2006), 3F (Zheng 
et al. 2004) and anti SIVmac activity has been associated with the one domain 
A3C (Yu et al. 2004a; Bishop et al. 2004a). Of these, the gene with largest 
impact on HIV 1 replication is huA3F which is widely co expressed with huA3G 
in non permissive cells (Wiegand et al. 2004; Liddament et al. 2004; Zheng et 
al. 2004). Strong evidence of the importance of huA3F in HIV 1 replication is Chapter 1. Introduction 
 
55 
 
that, like huA3G, HIV 1 Vif counteracts its activity and its preferred mutational 
hotspot (WGAA where W is A or T) is detectable in clinical isolates of HIV 1 
(Fitzgibbon  et  al.  1993).  However  further  analysis  reveals  that  huA3G’s 
preferred substrate (GG dinucleotide) is more frequently mutated than huA3F’s 
(GA), suggesting that the role of huA3G is greater in the biological context of 
HIV 1 replication (Zennou and Bieniasz 2006). Interestingly, the antiretroviral 
activity of huA3B is resistant to HIV 1 Vif in tissue culture experiments but 
expression is very low in CD4+ T cells, making it unlikely to severely hinder 
HIV 1 replication (Bogerd et al. 2007).  
Also  of  significance  is  the  breadth  of  targets  that  APOBECs  are  able  to 
deaminate whilst being able to distinguish self from non self. Of the human A3 
genes,  all  seven  have  now  been  associated  with  antiretroviral  or 
antiretroelement  activity  with  individual  enzymes  such  as  huA3F  able  to 
deaminate  targets  as  diverse  as  HIV 1  (Wiegand  et  al.  2004),  AluI,  a 
transposable  element  present  in  multiple  copies  in  the  human  genome 
(Muckenfuss et al. 2006), Ty1, a yeast transposable element (Schumacher et al. 
2005)  and  hepadnavirus  hepatitis  B  virus  (Rosler  et  al.  2005),  all  of  whose 
lifecycles involve RNA intermediates. This suggests conserved mechanisms for 
interaction and deamination of target nucleic acids.  
1.7.5 The role of Vif in overcoming APOBEC3G and 3F restriction 
HIV 1 viral infectivity factor (Vif) is a small accessory protein of 23kDa which 
allows the virus to replicate almost unaffected by the presence of huA3G and 
huA3F.  Vif  acts  to  decrease  the  levels  of  huA3G  and  huA3F  protein  levels 
dramatically in T cells, reducing the half life of APOBECs from hours to as little 
as  5  minutes  (Stopak  et  al.  2003;  Marin  et  al.  2003;  Marin  et  al.  2003; 
Conticello et al. 2003). Crucial to this activity are three interactions made by 
Vif: 1) the Vif motif SLQ(Y/F)LA which resembles mammalian BC box domain Chapter 1. Introduction 
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present in SOCS box proteins and recruits the cellular factor elongin C, an E3 
ubiquitin ligase (Mehle et al. 2004b; Yu et al. 2003) 2) a non canonical zinc 
coordinating HCCH motif which interacts with cullin5 (Yu et al. 2004c; Mehle et 
al. 2004a) and 3) the N terminal YRHHY and DRMR domains that interact with 
huA3G  and  huA3F  respectively  (Russell  and  Pathak  2007).  The  interactions 
result  in  the  recruitment  of  a  ubiquitylation  complex  comprising 
Vif/elonginC/elonginB/APOBEC3/cullin5/Rbx1 that polyubiquitylates the target 
APOBEC  and  induces  proteasome mediated  destruction  (Marin  et  al.  2003; 
Sheehy et al. 2003; Yu et al. 2003).  
Vif proteins exhibit a certain level of species specificity. For example, Vif from 
HIV 1 is unable to counteract the A3G from African green monkeys (agmA3G). 
This specificity was found to map to the Vif A3G interaction site: in huA3G, 
128DPD130  is  responsible  for  the  interaction  with  Vif  DRMR  motif  whilst  in 
agmA3G,  a  D128K  substitution  allows  the  APOBEC  to  escape  Vif mediated 
destruction  (Bogerd  et  al.  2004;  Mangeat  et  al.  2004).  However,  SIVagm 
overcomes  this  mutation  as  its  Vif is  able  to  bind  agmA3G  and  mark  it  for 
proteasome destruction. Thus the site of interaction between Vif and APOBEC 
represents a potential arms race battle ground in the host virus relationship.  
1.7.6 Positive selection of APOBECs 
In a similar manner to TRIM5α, primate APOBEC3 genes have been exposed to 
periods  of  intense  positive  selection  over  the  past  33  mya,  indicating  the 
importance of these genes in protecting against retroviral infection (Sawyer et 
al. 2004; OhAinle et al. 2006). Residues under positive selection in A3G map to 
the  catalytic  domain,  pseudocatalytic  domain  and  to  the  Vif interacting 
domain, but evidence of ancient adaptive selection is also found outside these 
regions  (Sawyer  et  al.  2004).  This  is  interpreted  as  the  results  of  previous 
antagonistic  host virus  relationships  with  now extinct  retroviruses.  However Chapter 1. Introduction 
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the  targets  of  previous  episodes  of  positive  selection  are  unknown  and  are 
likely  to  be  extinct,  save  for  any  sequences  remaining  as  endogenised 
genomes. Interestingly, a human endogenous retrovirus, HERV K, was found to 
be targeted by huA3F, and to a lesser extent huA3G, but not by any TRIM5α 
orthologues examined (Lee and Bieniasz 2007). High expression of A3 is found 
not only in T lymphocytes, the target of current lentiviral infections, but also 
in  testis  and  ovary  tissue,  organs  that  must  be  infected  by  endogenous 
retroviruses in order to ensure their propagation (Jarmuz et al. 2002; Sheehy 
et  al.  2002).  Thus  it  seems  likely  that  the  APOBEC  family  targets  both 
horizontally transmitted and endogenous retroviruses, and the diverse nature 
of the targets goes some way to explaining the maintenance of multiple A3 
gene copies. 
1.7.7 An expanded cluster of feline APOBEC3 genes 
Recently an analysis of feline APOBECs in the nascent cat genome located the 
genomic positions of APOBEC1, 2, 3 and 4 (Munk et al. 2008). Interestingly, 
four  APOBEC3  genes  were  found  in  an  expanded  cluster  on  domestic  cat 
chromosome B4, comprising three copies of APOBEC3C  (feA3Ca, feA3Cb and 
feA3Cc) and one copy of APOBEC3H. All the feline A3 genes identified possess a 
single  catalytic  domain.  Comparisons  with  other  felids  revealed  that  the 
duplications of feA3C occurred in two successive events, one duplication of the 
ancestral feA3C which generated feA3Cc took place after the divergence of the 
Felis and Panthera lineages about 10.8 mya and a subsequent duplication of 
the same ancestral gene generating feA3Ca and feA3Cb took place after the 
divergence with pumas about 6.7 mya (Johnson et al. 2006; Munk et al. 2008). 
Of  particular  interest  was  the  finding  that  the  A3C  locus  underwent 
independent duplication events in other lineages: in the Panthera lineage a 
duplication gave rise to two A3C genes in the modern lion (liA3C1 and liA3C2) Chapter 1. Introduction 
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and in lynxes, three duplications gave rise to four current A3C genes. Analysis 
of  the  felid  A3C  genes  revealed  strong  positive  selection,  suggesting  strong 
selection  of  new  variants  that  confer  benefits  to  the  host,  selection 
presumably imposed by pathogens. In contrast the A3H gene was present as a 
single copy in all felids examined and is not under positive selection, leading 
the  authors  to  suggest  its  viral  target  may  be  an  endogenous  retrovirus. 
Interestingly a read through transcript comprising components of feA3Ca, 3Cb 
and 3H, generating a two domain protein was detected in domestic cats and 
was  also  found  in  lions,  tigers,  pumas  and  lynxes  and  referred  to  as 
APOBEC3CH. 
 
Figure 1-3 Representation of feline APOBEC3 genomic locus and transcripts. The 
feline APOBEC3 genes reside in a cluster extending ~30kb on domestic cat chromosome 
B4 (black line). Previously described transcripts (Munk et al. 2008) are represented by 
dashed grey lines. Readthrough transcript A3CH is also shown and incorporates exons 1-
3 from A3Ca, an exon 4 variant from A3Cb that lacks the terminal stop codon and exons 
2-5 of A3H.  
Munk et al. (2008) tested the antiviral activity of domestic cat APOBEC3 genes 
against feline retroviruses and found that while single domain protein feA3C 
was  able  to  restrict  Feline  Foamy  Virus  (FFV),  none  of  the  single  domain 
proteins were active against FIV (Munk et al. 2008; Lochelt et al. 2005). In 
contrast,  the  two domain  A3CH  potently  inhibited  infectious  FIV  virus 
production,  suggesting  that,  like  human  A3G,  two  domains  are  required  for 
virion packaging and deaminase activity.  Chapter 1. Introduction 
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1.7.8 Vif of Feline Immunodeficiency Virus 
Like HIV, the FIV genome bears a vif gene but homology at the protein level is 
minimal save the BC box SLQ(Y/F)LA motif. The presence of this motif suggests 
that  like  HIV 1,  FIV  recruits  the  elonginC  ubiquitylation  complex  to  induce 
degradation of A3. Conflicting data exist for the subcellular localisation of FIV 
Vif.  Initially,  it  was  reported  Vif  localises  predominantly  to  the  nucleus 
(Chatterji  et  al.  2000),  unlike  HIV  Vif  which  localises  to  the  cytoplasm 
(Goncalves et al. 1994). Furthermore, Vif was not detected in FIV particles, 
suggestive perhaps of an alternative mechanism of action. However, these data 
are  potentially  explained  by  problems  in  exogenous  Vif  expression  as  the 
protein has a high turnover and nuclear export of transcripts is inefficient for 
HIV 1  Vif  (Nguyen  et  al.  2004).  Indeed  a  further  study  has  shown  that  a 
eukaryotic  codon optimised  Vif  derived  from  FIV Oma  (from  Pallas  cat) 
invariably and uniquely localises to the cytoplasm (Paul et al. 2007).  
1.8 Scope of this thesis 
This  thesis  compares  the  host  and  viral  factors  that  affect  replication  and 
cross species transmission of lentiviruses in domestic and non domestic cats. 
Specific attention is paid to the domestic cat and African lion, as these species 
are thought to represent recent and ancient lentiviral infections respectively. 
It  is  anticipated  that  antagonistic  relationships  between  host  and  virus  will 
have  promoted  changes  in  lion  factors  that  interact  with  viral  proteins.  In 
particular, attention is given to the restriction factors which, in primates, are 
under positive selection driven by retroviral infection, and the hypothesis that 
lentiviral restriction will be more potent in the lion is tested.  
·  Chapter 3 explores recent findings that FIV strains with highly divergent 
env genes are present in wild African lion populations. The study finds Chapter 1. Introduction 
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that the diversity within env corresponds to alternative receptor usage 
with  implications  for  the  evolution  and  pathology  of  infection  in  this 
species.  
·  Chapter 4 investigates the post entry restriction factor TRIM5 in cats and 
finds  that  a  mutation  that  ablates  function  is  present  in  the  felids. 
Further analysis reveals that the mutation is widespread amongst the 
Feliformia, dating the time of mutation to just after the Caniformia 
Feliformia  split,  with  implications  for  cross species  transmission  and 
control of lentiviral infection in the carnivores.  
·  In Chapter 5, the lentiviral co factor cyclophilin A is examined in the 
context of FIV replication. Tissue culture experiments and biophysical 
assays reveal the interaction is important for replication and occurs with 
a conserved binding affinity. Furthermore, a crystal structure is solved 
for FIV capsid and feline CypA, the first reported  structures for both 
these proteins, and provides insight into the mechanism of the CA CypA 
interaction.  
·  Finally in Chapter 6, the ability of lentiviruses to infect domestic cat and 
lion  cells  is  investigated and  a  post entry  block  to  replication in  lion 
cells  is  described.  Investigation  of  APOBEC3  genes  from  both  species 
finds that these restriction factors are active in felids, particularly in 
lions. The study provides evidence that is in concordance with theories 
of host virus antagonistic relationships and shows evidence that a lack of 
TRIM5α  can  be  compensated  for  by  other  post entry  restriction 
mechanisms.  
  
Chapter 2.  Materials and Methods 
2.1 Molecular cloning  
2.1.1 Nucleic acid extraction and PCR 
Total RNA was prepared from domestic cat derived cell lines CrFK and Mya 1 as 
well as non domestic cat T cells by homogenising 10
6 cells using QIAshredder 
Spin  Columns  (Qiagen,  Crawley,  UK)  and  extraction  with  RNeasy  Mini  Spin 
Columns (Qiagen) in a UV treated laminar flow hood. RNA was eluted in RNase 
free  water  (Invitrogen,  Paisley,  UK)  prior  to  quantification  of  RNA  by 
spectroscopy at 260 nm and storage at  80 °C. First strand cDNA synthesis was 
performed using 1  g RNA with an oligo d(T) primer and AffinityScript Reverse 
Transcriptase  (Stratagene,  Stockport,  UK),  according  to  the  manufacturer’s 
instructions  before  downstream  applications.  DNA  was  prepared  from  tissue 
culture samples by harvesting from 10
6 cells with DNeasy Blood and Tissue kit 
(Qiagen). DNA extractions from non domestic Feliform species used 50 100 mg 
brain tissue or 1 ml blood and were performed using the same kit using the 
appropriate  protocol.  All  DNA  preparations  were  eluted  with  EB  buffer  and 
stored at  20 °C.  
Polymerase  chain  reaction  (PCR)  was  performed  using  Phusion  HotStart 
(Finnzymes, Hitchin, UK) polymerase. Reactions were set up on ice in a PCR Chapter 2. Materials and Methods 
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clean  room  UV treated  laminar  flow  hood.  Reaction  mix  and  cycling 
parameters  were  typically  as  per  manufacturer’s  instructions  although 
optimisation  of  annealing  temperature  was  occasionally  necessary  by 
performing  multiple  reactions  as  a  gradient.  Standard  conditions  were  HF 
buffer 4  l, dNTPs 200  M each, primers 0.5  M each, DMSO 3% v/v, 0.02 U/ l 
Phusion,  50 200  ng  template  DNA.  For  FIV Ple  B  458  env,  Phusion  proved 
unsuccessful and KOD HotStart (Novagen, Nottingham, UK) was used instead. 
Lyophilised primers were ordered from MWG Operon and were resuspended in 
sterile distilled water to a stock concentration of 100 pmol/ l and to working 
stock concentrations of 10 pmol/ l. Primers were stored at  20 °C. A list of 
primers used is displayed in Appendix 1 and buffers and solutions is displayed 
in Appendix 2. 
2.1.2 Cloning techniques 
For molecular cloning, PCR products were purified by running on a 0.8 1.5% 
agarose  gel,  made  with  TBE  buffer.  DNA  bands  were  observed  on  a  UV 
transilluminator  and  excised  using  a  sterile  scalpel.  Gel  extraction  was 
performed using QIAquick Gel Extraction Minicolumns (Qiagen) and DNA was 
eluted in 35 50  l EB. Purified PCR products and vectors were digested using 
restriction endonucleases at 1 U/ l at 37 °C for 1 hr 30 min in 20 μl reactions 
with the buffer recommended by the manufacturer (Invitrogen). Digested DNA 
was purified using QIAquick PCR purification kit (Qiagen) and ligated using T4 
DNA  ligase  at  1  U/ l  at  15  °C  overnight.  DNA  was  transformed  into  DH5α 
chemically  competent  Escherichia  coli  (Invitrogen)  using  the  heat  shock 
protocol according to the manufacturer and plated onto agar plates bearing 
ampicillin or kanamycin at 50 μg/ml (Sigma Aldrich, Dorset, UK). Colonies were 
picked and grown in 5 ml LB nutrient broth at 37 °C on an orbital shaker set to 
200 rpm. When cloning env genes, an incubation temperature of 30 °C was Chapter 2. Materials and Methods 
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used to aid plasmid stability. Plasmid DNA was extracted from cultures using 
QIAprep Spin Miniprep kit (Qiagen) and digested as previous. Clones bearing 
inserts were identified by agarose gel electrophoresis and a large scale DNA 
prep was performed by inoculating 500 ml LB flasks with bacterial clones. DNA 
was  prepared  from  overnight  cultures  using  PureLink  HiPure  Filter  Plasmid 
Maxiprep  Kit  (Invitrogen).  Pelleted  DNA  was  resuspended  in  TE  buffer  and 
stored at 4 °C. Glycerol stocks of clones were made by diluting cultures to a 
final concentration 15% glycerol (v/v).  
2.1.3 Sequencing of DNA 
Chain termination sequencing reactions were set up in house using BigDye v1.1 
and  thermally  cycled  according  to  manufacturer’s  instructions  (Applied 
Biosystems, Warrington, UK). Reactions were precipitated using 70% ethanol, 
resuspeded in 20 μl HiDi (Applied Biosystems) and ran on an ABI 7000 genetic 
analyser using the E80 protocol (Applied Biosystems). Sequence traces were 
analysed in DNA Dynamo (Blue Tractor Software, UK). 
2.1.4 FIV Envelopes 
FIV Ple E Sangre env gene was PCR amplified using primers (LLV E 5’ Sal and 
LLV E 3’ Not) directed to published FIV Ple subtype E 1027 sequence (Genbank 
FJ22537).  Template  cDNA  was  obtained  from  total  cellular  RNA  of  Mya 1 
infected with FIV Ple E Sangre following first strand cDNA synthesis. FIV Ple B 
458  env  was  amplified  from  viral  supernatant  pelleted  in  an  SW28 
ultracentrifuge rotor at 28,000 rpm in a Beckman L8 70 ultracentrifuge. Viral 
membrane and protein cores were disrupted using 0.1% Triton X 100 PBS and 
RNA was extracted using RNeasy miniprep kit (Qiagen) and reverse transcribed 
as above. PCR amplification was performed using primers (LLV B 5’ Sal and 
LLV B 3’ Not) directed to published FIV Ple B sequence (Genbank EU117991). Chapter 2. Materials and Methods 
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Amplicons were cloned into eukaryotic expression vector VR1012 using SalI and 
NotI digestion sites. Cloned VR1012 env plasmids were used for the generation 
of HIV luciferase pseudotypes and were assayed onto target cells in 96 well 
plates as described below. 
2.1.5 CD134 and CXCR4 
Feline variants of CD134 and CXCR4 have been cloned and described previously 
(Shimojima et al. 2004; Willett et al. 1997b). Lion homologues of CD134 and 
CXCR4 were amplified from Angola 1 cDNA using primers directed to the feline 
homologues  (feCD134  F,  feCD134  R,  feCXCR4  F  and  feCXCR4  R;  Genbank 
accession numbers AB1288982 and U63558 respectively) and the products were 
cloned  into  pCR  2.1 TOPO  vector  (TOPO  TA  cloning  kit,  Invitrogen)  and 
sequenced. Lion CXCR4 and CD134 sequences were deposited in Genbank with 
accession  numbers  EU915482  and  EU915483  respectively.  For  expression  in 
eukaryotic cells, fragments were then sub cloned into pDONAI (Takara, Lonza 
Ltd, Wokingham, UK) using BamHI and SalI restriction sites. 
2.1.6 TRIM5 
Forward  primers  directed  to  conserved  regions  of  the  RBCC  domain  (Ts2, 
feT5fwd  and  Ts3)  and  reverse  primers  from  non variable  regions  within  the 
B30.2 domain (Ts12, feT5rev and Ts16) were used in RT PCR reactions using 
cDNA from domestic cat cell lines CrFK and Mya 1. Products were obtained for 
the  Ts3 Ts12  and  feT5fwd feT5rev  RT PCR  reactions.  These  amplicons  were 
then sequenced and used to probe the nascent cat genome project database 
(Pontius and O'Brien 2007) using the NCBI BLAST tool (Altschul et al. 1990). The 
BLAST search returned sequences of whole genome shotgun (WGS) fragments 
bearing exact matches to exon 2 (GenBank accession number AANG01555594) 
and exon 8 (AANG01581224) that had been assembled to chromosome D1 of the Chapter 2. Materials and Methods 
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cat genome. From these fragments, PCR primers directed to the 5’ end (wam4) 
and 3’ end (wam13) of the open reading frame were designed, and the full 
length product was sequenced. Cloning primers wam4e and wam13c were used 
to amplify RT PCR products from Mya 1 template cDNA and the amplicon was 
cloned into expression vector CXCR using EcoRI and Csp45I to produce feCTCR. 
Correct  insertion  of  feTRIM5  was  verified  by  cycle  sequencing.  Rapid 
amplification  of  cDNA  ends  (RACE)  was  performed  using  5’/3’  Second 
Generation  RACE  Kit  (Roche)  using  cDNA  from  Mya 1  cells  according  to 
manufacturer’s instructions. A PCR based mutagenesis strategy was employed 
to introduce a stop codon at proline 306 of huTRIM5α to generate huTRIM5 
P306STOP.  Forward  and  reverse  mutagenic  primers  (huT5stopF  and 
shuT5stopR) were used with flanking CXCR specific primers (GT282 and GT283) 
in two individual reactions. The resulting products were mixed 1:1 and used as 
a template for a reaction using the flanking primers. The product was cloned 
into  CXCR  using  EcoRI  and  Csp45I  restriction  sites.  The  sequence  of  feline 
TRIM5 was deposited in Genbank (Accession number: GQ183880). A separate 
TRIM5 exon 8 PCR was also used in order to screen other carnivore species for 
the sequence of the TRIM5 B30.2 domain. Degenerate primers (gex8 feT5 f and 
gex8T5 r) were designed that allowed amplification from genomic DNA from 
divergent  carnivore  species,  cat  and  dog.  Expected  sizes  of  amplicon  were 
525bp for dog and 536bp for cat and sequencing was performed directly from 
PCR products. 
2.1.7 Capsid and cyclophilin A 
N terminal capsid domain (CA
N) was amplified from a molecular clone of FIV 
Fca  GL8  and  from  cDNA  from  Mya 1  cells  infected  with  FIV Ple  B  458.  The 
region amplified spans residues 136 273 of GL8 gag, and is analogous to the 
monomeric HIV 1 CA domain whose structure has been solved previously (Yoo Chapter 2. Materials and Methods 
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et al. 1997). For FIV Fca, the expressed protein has a molecular weight of 15 
kDa and is expressed with a C terminal His tag, giving a total mass of 16.4 kDa. 
Primers used were G8 CAN5’ Nde, G8 CAN 3’Mlu, LLV CA 5’ Nde, and LLV CA 3’ 
Mlu.  For  putative  feline  cyclophilin  A  genes  encoded  by  Genbank  contigs 
AANG01610851  and  AC235013,  Mya 1  RNA  was  treated  with  DNase  I  on  the 
Qiagen RNeasy column prior to elution as indicated by the manufacturer and 
subsequent  amplification.  Differentiation  between  the  two  sequences  was 
performed  by  using  alternative  5’  primers:  feCypA  R69  5’  amplifies  the 
sequence present in AANG01610851, whilst feCypA C69 5’ amplifies the ORF 
present in Genbank: AC235013. 3’ primer for both sequences was feCypA R/C 
3'.  Once  the  nature  of  the  CypA  expressed  in  T cell  was  identified  as 
AANG01610851, cDNA from Mya 1 and Angola 1 was used as a template for PCR 
using primers feCypA Nde 5’ and feCypA Mlu 3’. Fragments were cloned into 
prokaryotic expression vector pOPTH. 
2.1.8 APOBEC3 and vif 
Feline and lion APOBECs were amplified from cDNA derived from Mya 1 and 
Angola 1 T cells respectively. Primers were based on published domestic cat 
sequences single domain proteins feA3H (EU109281; primers feA3H F and feA3H 
R)  and  feA3Ca  (AY971954;  primers  feA3C  F  and  feA3C  R).  For  read through 
transcripts, forward primer feA3C F was used in conjunction with feA3H R. The 
amplicons  were  cloned  into  VR1012  using  SalI  and  NotI  restriction  sites 
introduced by the primers. FIV Fca vif was cloned from a molecular clone of 
strain  GL8  using  primers  GL8  Vif  F  and  GL8  Vif  R,  whilst  FIV Ple  vifs  were 
cloned from proviral DNA isolated from infected Mya 1 cells. Primers used were 
LLV E Vif F and LLV E Vif R for FIV Ple E and for FIV Ple B, sufficient homology 
to the E strain was present to use the LLV E Vif F forward primer with strain Chapter 2. Materials and Methods 
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specific  reverse  primer  LLV B  Vif  R.  Clones  were  sequenced  as  described 
above. 
2.2 Cells and viruses 
2.2.1 Adherent cells 
Adherent  cell  lines  were  grown  in  disposable  plastic  tissue  culture  dishes 
(Corning,  Ewloe,  UK)  and  maintained  in  Dulbecco's  modification  of  Eagle's
 
medium (DMEM; Invitrogen) supplemented with 10% foetal bovine serum,
 2 mM 
glutamine, 0.11 mg/ml sodium pyruvate, 100 IU/ml penicillin,
 and 100  g/ml 
streptomycin.  Each cell  line  has  certain  growth  characteristics and  so  were 
split when confluent rather than at a regular time point. When confluent, the 
monolayer was washed with PBS, and dissociated from the culture plate by 
incubation with 0.5 2ml 0.05% trypsin (Invitrogen) for a few seconds or minutes 
at 37°C. Trypsin activity was stopped by suspension in complete DMEM. Cells 
were  then  pelleted  at  1000  rpm  (~400  xg)  in  a  benchtop  centrifuge  before 
resuspension in complete DMEM and seeding of new cultures at the required 
density.  Where  required,  culture  medium  was  supplemented  by  selection 
antibiotics  G418  (400 g/ml;  Invitrogen)  or  puromycin  (1.25   g/ml;  Sigma 
Aldrich).  
2.2.2 Suspension cells  
Cells  in  suspension  were  cultured  in  RPMI  1640  medium  (Invitrogen) 
supplemented  with  10%  foetal  bovine  serum,
  2  mM  glutamine,  0.11  mg/ml 
sodium  pyruvate,  50   M  β mercaptoethanol,  100  IU/ml  penicillin,
  and  100 
 g/ml streptomycin. Cells were passaged by centrifugation at 1000 rpm and 
resuspension in complete RPMI at the required density. Selection antibiotics 
were used as for adherent cells. Cell lines frequently used in this study the Chapter 2. Materials and Methods 
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canine lymphocytic leukaemia (CLL) and feline MCC lines (Cheney et al. 1990). 
CLL was generated by prolonged in vitro culture of leukaemic domestic dog 
PBMCs; the established line is CD3
+ CD4
− CD8
− CD134
−. When stably transduced 
with FIV primary receptor CD134, these cells can support replication of FIV to 
high  titre  (Willett  et  al.  2006a).  MCC  is  a  CD134
−  domestic  cat  cell  line 
amenable to ectopic expression of CD134 variants to dissect the role of CD134 
on FIV entry (Willett et al. 2006a; Willett et al. 2006b). 
2.2.3 Primary T cells 
Domestic cat primary T cell line Mya 1 (Miyazawa et al. 1989) was cultured in 
RPMI 1640 medium supplemented as above. A source of interleukin 2 (IL 2) was 
provided  by  further  supplementing  the  medium  with  previously  frozen 
conditioned medium from a murine cell line
 (L2.3) transfected with a human 
IL 2 expression
 construct (1:50 dilution, equivalent to 100 U/ml of recombinant 
human IL 2; provided by T. Miyazawa). African lion, European wildcat, puma, 
tiger, Amur leopard and cheetah peripheral blood mononuclear cells (PBMCs) 
were  cultured  as  above  and  T cells  were  expanded  by  stimulation  with 
concanavalin A (2 g/ml; Sigma Aldrich) periodically. Blood samples from which 
PBMCs were obtained were kindly provided by Sarah Cleaveland, University of 
Glasgow, UK and John Lewis, ALTA Amur Leopard Conservation. PBMCs were 
also expanded from a seronegative Angolan lion and were periodically frozen 
down to generate a large back stock and referred to as Angola 1. Lion samples 
were collected by Pieter Kat and Rodrigo Serra of the Investigacao Veterinaria 
Independente, Lisbon, Portugal. Cells were grown in a cyclical manner, with a 
blasting  stage  following  ConA  stimulation  in  which  polarised  T cells  were 
apparent.  During  this  stage,  cells  were  grown  at  high  density  in  order  to 
promote cell cell interactions, but large clumps were broken up in order to 
prevent  isolation  from  nutrients.  Blasts  were  preferentially  selected  for  by Chapter 2. Materials and Methods 
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centrifugation at 800 rpm without brake, and resuspended in the same volume 
of medium. When a sufficient density of cells was obtained, cells were either 
split 1 in 2 or expanded to a larger tissue culture flask. During this phase, 
culture typically existed as single cell blasts until next ConA stimulation or in 
the  case  of  Mya 1,  sufficient  density  was  obtained  for  clumping  to 
recommence.  
Cell line  Species  Adherent or 
Suspension 
Reference 
3201  Cat  S  (Hardy, Jr. et al. 
1980) 
AH927  Cat   S  Nelson Rees, WA 
Angola 1  Lion  S  This study 
CLL  Dog  S  (Willett et al. 2006a) 
CrFK  Cat  A  (Crandell et al. 1973) 
HEK 293T  Human  A  (Graham et al. 1977) 
HeLa  Human  A   
HT1080  Human  A  (Rasheed et al. 1974) 
MCC  Cat  S  (Cheney et al. 1990) 
MDTF  Mouse  A  (Lander and 
Chattopadhyay 1984) 
Mv1 Lu CCL 64  Mink  A  (Henderson et al. 
1974) 
Mya 1  Cat  S  (Miyazawa et al. 1989) 
NP2  Human  A  (Soda et al. 1999) 
TE671  Human  A  (Stratton et al. 1989) 
Table 2.A Cell lines used in this study 
 
2.2.4 Replication competent FIV  
Supernatant containing clonal FIV was produced by transfection of 293T cells 
with  full  length  FIV  molecular  clones  using  Superfect  transfection  reagent. Chapter 2. Materials and Methods 
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Strains used in this study include Glasgow 8 (GL8), a field isolate from the UK 
(Hosie and Jarrett 1990), B2542, a clade B USA isolate (Diehl et al. 1995) and 
PPR, a clade A USA isolate from a cat in the symptomatic stage of infection 
(Phillips  et  al.  1990).  Three  days  post transfection,  293T  cells  were  co 
cultivated with Mya 1 cells and FIV replication was monitored by p24 ELISA. 
293T cells were removed and infected cultures were expanded by addition of 
fresh Mya 1 cells. Supernatant was collected, filtered at 0.45 m and frozen in 
1ml aliquots at  80 °C until required.  
FIV Ple was isolated from lion PBMCs prepared from whole blood of an FIV 
positive lion sampled in the Moremi reserve in Botswana (Sangre). Sangre was 
an eight year old male lion in good health at the time of sampling and was 
previously confirmed as seropositive by western blot. In order to expand the 
viral stock from Sangre, concanavalin A stimulated PBMCs were co cultivated 
with Mya 1 cells and confirmation of replication competent virus was sought by 
reverse  transcriptase  assay  (see  2.3.2).  Aliquots  of  viral  supernatant  were 
stored and frozen at  80 °C for future use and infected cells were pelleted and 
harvested for total cellular RNA. 
2.2.5 Tissue culture infection with replication competent FIV  
Infections were performed by incubating target cells with viral inocula. For 
adherent lines, cells were seeded at low density (1x10
5 cells per well in a 6 
well plate) and left to adhere overnight. Standard conditions for suspension 
cells  were:  1x10
6  Mya 1/primary  PBMC  or  5x10
5  CLL CD134  in  a  5  ml  tube 
(Falcon). Cells were then incubated with viral inoculum (100 500 l) diluted 1 in 
2  with  complete  medium  as  appropriate  at  37  °C  for  3  hours.  Cells  were 
washed  twice  with  PBS  and  resuspended  in  complete  medium.  Cell free 
aliquots were taken periodically and frozen at  80 °C until required for viral 
quantification by p24 ELISA or reverse transcriptase assay. Chapter 2. Materials and Methods 
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2.2.6 Drugs and inhibitors 
Inhibitors of cyclophilin, cyclosporine A (CsA; Sigma), NIM811 (a kind gift of 
Prof.  Anthony  Page,  University  of  Glasgow)  and  Debio 025  (obtained  from 
Debiopharm)  were  diluted  to  5  mM  working  stock  in  ethanol  or  DMSO  and 
stored at  20 °C until required. Toxicity was measured by incubating cell lines 
Mya 1 and CLL with CsA, NIM811 and Debio 025 at 2  M for five days before 
enumerating live cells using a haemocytometer with Trypan blue (Invitrogen) 
dye  exclusion  as  a  marker  for  viability.  The  effect  of  the  drugs  on  the 
replication of FIV in canine and feline cells was assayed by incubating 10
6 CLL 
or Mya 1 with FIV Fca GL8 for three hours before washing twice with PBS and 
resuspension in 1 ml RPMI, supplemented with IL 2 in the case of Mya 1, with 
CypA inhibitors at 2  M or an equivalent volume of solvent. 
Proteasome  inhibitor  MG132  (N (benzyloxycarbonyl)leucinylleucinylleucinal) 
and  As2O3  were  obtained  from  Sigma.  MG132  was  prepared  by  dissolving  in 
ethanol at a stock concentration of 1 mg/ml and stored at  20 °C. As2O3 was 
prepared as (Berthoux et al. 2003) by initially dissolving in 1 M NaCl before 
neutralisation with HCl to final pH 7.0. The solution was diluted further to a 
concentration of 1 mM with PBS, filter sterilised at 0.2  m before storage at  
20  °C.  1  x  10
5  cells  were  incubated  with  MG132  or  As2O3  for  3  hr  before 
aspiration of the drug and washing with PBS. Cells were reseeded in 100  l 
replete RPMI with IL 2 and challenged with pseudotype. 
AMD3100  (Donzella  et  al.  1998),  a  bicyclam  inhibitor  of  the  FIV  Env CXCR4 
interaction (Egberink et al. 1999; Richardson et al. 1999), was prepared for 
tissue culture by dissolving in PBS and filter sterilising at 0.2 m and stored at  
20 °C. Inhibition of Env CD134 interaction was performed using trimeric sFc 
TNC CD134L. The preparation and purification of this construct was performed 
previously  (Willett  et  al.  2009).  The  construct  consists  of  a  haemagglutinin Chapter 2. Materials and Methods 
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signal peptide, the hinge and Fc domain of human IgG1 (residues 104–330 of 
GenBank: P01857),  a  linker  with  sequence  RSPQPQPKPQPKPEPEGSLH,  the 
trimerisation  domain  of  chicken  tenascin C  (TNC),  a  linker  with  sequence 
GTGGGSGGRGLQ,  and  the  extracellular  domain  (residues  52–183)  of  feline 
CD134L. The construct had previously been transfected into 293T cells using 
Superfect  (Qiagen)  by  other  lab  members  and  supernatant  harvested  after 
three days and concentrated 10 fold using an Amicon 10kDa molecular weight 
cut  off centrifuge  spin concentrator  (Millipore) and  stored  at   80  °C  before 
use. 
2.2.7 Stable transduction of cell lines 
In  order  to  create  cell  lines  stably  expressing  TRIM5,  pseudotyped  MLV 
infectious particles were produced by transfecting HEK293T cells with plasmids 
CMVi, a cytomegalovirus promoter driven MLV gag pol expression vector, pMDG 
bearing  pantropic  vesicular  stomatitis  virus  G glycoprotein  (VSV G)  envelope 
and CTCR which encodes a dsRed reporter gene (Clontech, Wokingham, UK) 
and the desired TRIM5 under the control of the cytomegalovirus promoter as 
previously  described  (Besnier  et  al.  2002),  except  that  Superfect  (Qiagen) 
transfection  agent  was  used  according  to  manufacturer’s  instruction. 
Supernatant  was  harvested  3 days  post transfection,  filtered at  0.45 m  and 
used  to  transduce  target  cell  lines  plated  at  5x10
4  cells  per  well  in  6 well 
plates. Successful transduction was confirmed by enumerating RFP expressing 
cells on a
 Beckman Coulter EPICS MCS XL flow cytometer. Data were analyzed 
using
 EXPO 32 ADC Analysis (Advanced Cytometry Systems). 
Lion CXCR4 was expressed as a fusion protein with enhanced green fluorescent 
protein as has previously been described for feCXCR4 (Willett et al. 2002). For 
stable dual expression of CXCR4 and CD134 in the NP2 cell line, cells were first 
transduced  with  pDONAI  vectors  bearing  lion  or  domestic  cat  CXCR4 eGFP Chapter 2. Materials and Methods 
 
73 
 
fusion proteins and stable transductants were transduced again with lion or 
domestic  cat  CD134  and  immuno enriched  by  staining  firstly  with  7D6  anti 
feline  CD134  (AbD  Serotec,  Oxford,  U.K.)  then  goat anti mouse  IgG coated 
microbeads (Miltenyi Biotec Ltd., Bisley, U.K.) followed by enrichment on MS 
columns using an OctoMACS™ separator (Miltenyi Biotec Ltd.). Eluted cells were 
maintained in G418 supplemented medium and expanded in culture for use in 
pseudotype infection assays. 
2.2.8 Pseudotype production 
Retroviral particles capable of single round infection, which deliver a marker 
gene to the target cell, were used to analyse viral and cellular determinants of 
infection. The constructs allow the generation of retrovirus particles that bear 
reporter  genes  that  allow  the  efficiency  of  transduction  to  be  assayed. 
Pseudotypes  in  this  study  bore  either  luciferase  (luc)  or  green  fluorescent 
protein  (GFP)  and  transduction  was  quantified  using  alternative  techniques. 
The  use of  vesicular stomatitis  virus  G glycoprotein (VSV G) allows  efficient 
entry to mammalian cells and obviates the effects of differential expression of 
receptors. Pseudotypes are denoted VIRUS reporter(ENVELOPE). For example 
HIV luc(FIV) indicates an HIV particle, bearing a luciferase gene, pseudotyped 
with FIV Env.  
HIV luc(FIV)  vectors  were  prepared  in  HEK293T  cells  by  two plasmid  co 
transfection. The day before transfection, 4x10
6 293T cells were seeded in 10 
cm poly D lysine coated plates (BD). To transfect, 10  l Superfect transfection 
reagent  (Qiagen)  was  mixed  with  7.5   g  pNL4 3 Luc E
−R
−,  an  HIV 1  NL4 3 
strain based  vector  with  firefly  luciferase  inserted  into  the  nef  gene  and 
defective env and vpr genes (Connor et al. 1995), and 7.5  g VR1012 env, a 
mammalian  expression  plasmid  bearing  FIV  env  in  300   l  serum free  DMEM. 
Complexes were allowed to form at room temperature for 15 minutes before Chapter 2. Materials and Methods 
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addition of 3 ml complete DMEM and incubation on 293T cells at 37 °C for 3 
hours. Cells were then washed with PBS to reduce toxic effect and prevent any 
transfection  complexes  affecting  downstream  procedures.  10  ml  fresh, 
complete DMEM was added to cells and supernatant was harvested after 72 
hours incubation at 37 °C. Supernatant was filtered at 0.45 m, aliquoted and 
frozen at  80 °C.  
For other retroviral vectors, a three plasmid co transfection protocol was used. 
Plasmids expressing a gag pol, a viral vector and pMDG were transfected into 
293T cells at a ratio of 1:1:1 (5  g each). The protocol follows that of (Besnier 
et al. 2002) except that Superfect (Qiagen) was usually used instead of Fugene 
6, as higher titres were given by the former. Plasmids used for production of 
VSV G  pseudotyped  N   and  B tropic  MLV,  HIV 1,  HIV 2,  SIVmac  and  FIV  are 
given  in  Table  2.B.  Supernatant  was  collected  after  three  days,  filtered  at 
0.45 m and stored at  80 °C. When produced in the presence of drugs, NIM811 
and cyclosporine A, pseudotypes were pelleted in a Beckman ultracentrifuge in 
an SW40 rotor over a 2 ml 20% sucrose cushion to remove drugs. The pellet was 
resuspended in 1 ml DMEM (10 fold concentration) before use. 
 
Plasmid 
name 
Derived 
from 
Function  Reporter   Reference 
pCIG3N  MLV N  gag pol    (Bock et al. 2000) 
pCIG3B  MLV B  gag pol    “ 
CNCG  MLV  packaged sequence  GFP  “ 
CNCR  MLV  packaged sequence  dsRed  “ 
p8.91  HIV 1  gag pol ( Vif)    (Naldini et al. 1996) Chapter 2. Materials and Methods 
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p8.2  HIV 1  gag pol (+Vif)    “ 
SIN CSGW  HIV 1  packaged sequence  GFP  “ 
SIN CSRW  HIV 1  packaged sequence  dsRed  “ 
pNL4 3 
Luc E
−R
− 
HIV 1  gag pol and 
packaged sequence 
luciferase  (Connor  et  al. 
1995) 
SIV4+  SIV mac  gag pol ( Vif)    (Negre et al. 2000) 
SIV3+  SIVmac  gag pol (+Vif)    “ 
SIV eGFP  SIV mac  packaged sequence  GFP  “ 
pSVR NBDM  HIV 2  gag pol    (Griffin et al. 2001) 
pSVR NB 
GFP  H 
HIV 2  packaged sequence  “ 
FP93  FIV  gag pol    (Poeschla  et  al. 
1998) 
GinSin  FIV  packaged sequence  GFP  “ 
pMDG  VSV  envelope    (Yee et al. 1994) 
Table  2.B  Plasmids  used  for  pseudotype  production.  Packaged  sequence  denotes 
plasmids that encode an RNA genome that is packaged within pseudotypes. 
2.2.9 Pseudotype assay 
For luciferase reporter gene assays, 5x10
4 target cells were seeded in 50  l 
complete medium in a CulturPlate 96 assay plate (Perkin Elmer, Waltham, MA, 
USA). For adherent cell lines, the cells were allowed to settle overnight whilst 
suspension  cells  were  used  immediately.  50 l  supernatant  containing  the 
pseudotype was added to wells and each condition was repeated in triplicate. 
Expression of luciferase was quantified after 48 72 hours by addition of 100 l Chapter 2. Materials and Methods 
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Steadylite HTS luciferase substrate (Perkin Elmer) and measurement by single 
photon counting on a MicroBeta luminometer (Perkin Elmer).  
When using GFP or dsRed reporter genes, target cells were seeded at 1x10
5 
cells per well in a 6 well plate and allowed to adhere overnight. Supernatant 
was thawed and titrated onto target cells in the presence of hexadimethrine 
bromide (polybrene; Sigma Aldrich) dissolved in PBS at 5  g/ml. After 48 72 hr, 
GFP expressing cells were harvested and pelleted in 5 ml flow cytometry tubes 
(Falcon). Cells were resuspended in 0.5 1 ml PBA buffer and kept on ice. GFP 
positive  cells  were  enumerated  by  observing  10,000  events  on  a  Beckman 
Coulter EPICS MCS XL flow cytometer. Gates were adjusted so that negative 
control untransduced cells gave 0% infection. Data were analyzed using
 EXPO 
32 ADC Analysis (Advanced Cytometry Systems). Where necessary, multiplicity 
of infection (moi) was subsequently calculated using the formula moi =  lnP[0] 
where P[0] is the proportion of uninfected cells. 
A  modified  protocol  was  employed  for  the  production  of  FIV GFP(VSV) 
pseudotypes in the presence of APOBEC proteins. 293T cells were plated at 2 x 
10
5 cells per well in a 24 well plate and allowed to adhere overnight at 37 °C in 
500   l  replete  medium.  The  next  day,  transfections  were  performed  using 
Superfect (Qiagen) transfection reagent with a modified protocol. 0.3  g each 
of pMDG, GinSin, FP93, 0.5  g VR1012 A3 and, where indicated, 0.5  g VR1012 
Vif or empty vector were mixed in 20 l serum free DMEM before addition of 2 
 l  Superfect.  Transfection  complexes  were  allowed  to  form  for  15  minutes 
before the addition of 50  l replete DMEM and dropwise addition to the 293T 
cells.  Medium  was  not  changed  after  this  stage.  Supernatant  was  collected 
three days post transfection and centrifuged at 5,000 xg to remove cellular 
debris. The titre of infectious virus was assayed by plating onto 293T or CrFK Chapter 2. Materials and Methods 
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cells in the presence of polybrene (5  g/ml) and GFP expression monitored 
after three days by flow cytometry. 
2.2.10 RNA interference 
Small hairpin (sh) RNAs against domestic cat TRIM5 were designed using shRNA 
Sequence  Designer  (Clontech).  The  chosen  target  sequences  for  constructs 
feT5sh1  and  feT5sh2  were  GCATCACTGCAAAGACCAA  and 
CTGTAAGACGGATGGGAAG  respectively,  or  a  firefly  luciferase  sequence  for 
shLuc  negative  control.  Top  and  bottom  strand  60bp  oligonucleotides  were 
designed using Clontech online shRNA Sequence Designer and synthesised by 
Eurofins  MWG  Operon.  Nucleotides  were  annealed  by  heating  to  95  °C  and 
cooling slowly to room temperature. Annealed oligonucleotides were cloned 
into  pSIREN  Retro Q  (Clontech)  using  BamHI  and  EcoRI  restriction  sites 
according  to  manufacturer’s  instructions.  Infectious  MLV  particles  were 
generated by co transfecting pSIREN Retro Q feT5sh1, feT5sh2 or shLuc with 
CMVi  and  pMDG  as  above.  Supernatant  was  used  to  transduce  CrFK  cells 
expressing  feline  CD134  (Shimojima  et  al.  2004),  which  were  exposed  to 
puromycin selection 2 days post transduction. Knockdown of endogenous TRIM5 
in  these  cells  was  monitored  by  RT PCR  on  serial  dilutions  of  cDNA  using 
primers  wam4  and  wam13c.  RNA  was  prepared  and  reverse  transcribed  as 
above using 1 g total RNA isolated from 10
6 cells. Reaction conditions were 98 
°C 60s, then 30 cycles of 98 °C 10s, 67 °C 30s, 72 °C 30s then 72 °C 2mins on 
1 l  target  cDNA  with  Phusion  High Fidelity  DNA  Polymerase  (New  England 
Biolabs),  using  the  reaction  components  described  above  (Section  2.1.1). 
Agarose  gel  electrophoresis  images  were  scanned  using  an  Epson  3200 
Perfection flat bed scanner; contrast and brightness were adjusted in Adobe 
Photoshop. Chapter 2. Materials and Methods 
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2.3 Quantitative techniques and immunoloblotting  
2.3.1 p24 ELISA 
For monitoring the levels of infection in replication competent FIV assays, cell 
free supernatant from infected cells was collected periodically and stored in a 
96  well  plate  at   80  °C  until  required.  Viral  replication  was  measured  by 
enzyme linked  immunosorbent  assay  (ELISA)  of  FIV  p24  ELISA  by  coating 
immunoabsorbant 96 well plates (Greiner Bio One, Stonehouse, UK) with 100 l 
anti p24 antibody vpg 62 diluted 1 in 500 with serum free DMEM and incubated 
at  4  °C  overnight.  Plates  were  blocked  with  125 l  2%  milk  powder  (ASDA) 
dissolved  in  PBS  for  2h  before  washing  with  0.2%  Triton  X 100  PBS. 
Alternatively  pre coated  ELISA  plates  (Pet check  anti FIV  IDEXX,  Chalfont  St 
Peter, UK) were used. Antigen capture was performed using 100 l thawed cell 
culture supernatant with 10 l 0.5% Triton X 100 dissolved in PBS to release 
viral  cores  at  room  temperature  for  30min.  Plates  were  washed  with  ELISA 
wash buffer according to manufacturer’s instructions and 100 l anti FIV HRPO 
conjugate  Ab  (IDEXX)  was  added  before  development  with  HRPO  substrate 
(IDEXX). Plates were read on an Ascent Multiscan plate reader (Labsystems) at 
450nm. 
2.3.2 Quantification of reverse transcriptase activity 
In cases when p24 ELISA was not appropriate, for example when monitoring 
non domestic  cat  strains  of  FIV  for  which  no  commercial  antibodies  are 
available,  reverse  transcription  activity  was  assayed  using  a  Lenti RT 
nonisotopic RT assay kit (Cavidi Technology, Uppsala, Sweden). The technique 
uses sample dilution buffer (SDB) to release RT which is quantified by its ability 
to  reverse  transcribe  a  poly(rA)  template  using  an  oligo(dT)  primer  and 
incorporation  of  nucleotide  analogue, 5 bromo deoxyuridine 5′ triphosphate Chapter 2. Materials and Methods 
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(BrdUTP) during incubation at 33 °C. The reaction is stopped by washing in 
ELISA wash buffer or with wash buffer supplied with the kit and BrdU levels 
quantitated  using  an  anti BrdU  Ab  and  chromogenic  detection  by  alkaline 
phosphate conjugated  secondary  Ab  using  para nitrophenyl  phosphate 
substrate followed by reading on an Ascent Multiscan plate reader at 405 nm. 
2.3.3 Real time PCR 
TRIM5  knockdown  was  quantified  using  real time  PCR  with  primers  feT5 
TaqMan 5’ and feT5 TaqMan 3’ and fluorescently labelled feT5 Probe 5’ 3’. 
RNA was prepared from CrFKs or CrFKs transduced with feT5sh1 and feT5sh2 
and  2 g  was  used  in  reverse  transcription  using  Roche  High  Fidelity 
Transcriptor  with  an  oligo  d(T)  primer  in  a  20   l  reaction  according  to 
manufacturer’s instructions. 2  l of the resulting cDNA was mixed with primer 
at 0.24 pM and probe at 0.12 pM and was used in a reaction with 2x Universal 
TaqMan Mastermix (Applied Biosystems) in a 50  l reaction. Cycling conditions 
were 95 °C 5 min, followed by 40 cycles of 95 °C 15s, 55 °C 60s on an ABI 7500 
thermal  cycler  (Applied  Biosystems).  Data  were  analysed  using  Sequence 
Detection Software v1.4 (Applied Biosystems). 
2.3.4 SDS PAGE & Immunoblotting 
For  the  analysis  of  seroprevalence  in  wild  lions,  FIV Ple  458 infected  Mya 1 
supernatant  was  filtered  at  0.45   m  and  virus  was  pelleted  in  an  SW28 
ultracentrifuge  rotor  (Beckman,  UK)  at  28,000  rpm.  The  viral  pellet  was 
resuspended in SDS loading buffer. For Ranbp2 western blot, 1,000 293T cells 
were lysed directly with SDS PAGE loading buffer. Proteins were boiled for 5 
min  before  being  run  on  Tris Acetate  minigels  (Invitrogen).  Antigens  were 
transferred to nitrocellulose membrane using rapid dry blotting system (iBlot, 
Invitrogen) and blotted overnight in Western Blocking Buffer. Antigens were Chapter 2. Materials and Methods 
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detected  using  lion  sera  from either  field  isolates  or pooled  sera  from  FIV 
seronegative or seropositive domestic cats. For Ranbp2, a rabbit monoclonal 
Ab was used (AbCam ab2938) at 1:1000 dilution. Bound antibody was detected 
using biotinylated goat anti cat IgG for FIV Ple antigens or anti rabbit IgG for 
Ranbp2  (Vector  laboratories)  followed  by  chromogenic  development  by  the 
Vectastain® ABC system (Avidin: Biotinylated enzyme Complex) and 5 bromo 4 
chloro 3 indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) substrate.  
2.3.5 Far western blot 
For  far  western  blotting  (also  known  as  overlay  assay),  HeLa  and  CrFK  cell 
lysates were fractionated by incubation with CHAPS lysis buffer on ice for 10 
min to lyse cell membranes before centrifugation in a benchtop centrifuge for 
10  min  at  13k  rpm  (~16,000  xg).  Supernatant  (cytoplasmic  extract)  was 
removed and diluted in 2x SDS PAGE loading buffer. The pellets (nuclei) were 
resuspended  by  dropwise  addition  of  1x  SDS PAGE  loading  buffer  without 
bromophenol blue, with vigourous vortexing after the addition of each drop, 
before  dilution  in  2x  SDS PAGE  buffer  corrected  for  levels  of  bromophenol 
blue. For 293T cells, 1,000 cells were lysed directly with 1x SDS PAGE loading 
buffer. Proteins were subjected to SDS PAGE and transferred to nitrocellulose 
membranes as above and incubated overnight in FW blocking buffer at 4 °C in 
the  absence  of  harsh  detergent  to  promote  protein  refolding.  Far  western 
protocol follows (Einarson et al. 2007), but uses immunodetection in place of 
autoradiography. 30 90  g recombinant CA or CA
N was diluted in FW interaction 
buffer and allowed to bind at 4 °C with gentle shaking. The membranes were 
washed three times for 10 min each with FW wash buffer 1 before a final wash 
with FW wash buffer 2. A western blot for capsid was then performed using a 
mixture  of  monoclonal  mouse  anti FIV  CA  antibodies  AE11,  DF3  and  DF10 Chapter 2. Materials an
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Biophysical and structural techniques 
Recombinant protein purification  
Expression, purification and biophysical techniques were performed at the MRC 
Laboratory of Molecular Biology, Cambridge in collaboration with Dr Leo James 
with guidance from Amanda Price. His tagged proteins were expressed in 2l 
cultures grown in TY broth at 37 °C by induction with 0.1 mM IPTG. Cells 
were lysed on ice with Bug Buster (Novagen) with 3 min sonication and proteins 
NTA beads (Qiagen), washed with Beads W
 + 300 mM imidazol (Figure 2 1).  
affinity purification of His-tagged proteins. CypA variants from lions 
and domestic cats as well as FIV-Fca and FIV-Ple capsid N-terminal domains (CA
were  cloned  and  expressed  as  His-tagged  recombinant  proteins.  Ni
chromatography  was  used  to  purify  protein  from  bacterial  lys
washed twice (W1 and W2) before a two-stage elution (E1 and E2). 10
each stage were analysed by SDS-PAGE. 
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nd Methods 
Eluted  proteins  were  pooled  and  loaded  onto  a  gel  filtration  column  (GE 
Healthcare)  and  collected  in  4ml  fractions  on  an  Akta  FPLC  System  (GE 
Figure 2 2). Sample buffer was 20mM Tris pH 7.4, 100mM NaCl, 
1mM DTT for all proteins. For capsid and mutants of capsid, an additional Q 
exchange  chromatography  (GE  Healthcare)  chromatography  step  was 
performed in order to remove low molecular weight contaminants (
Protein was eluted by increasing salt concentration, using 10% buffer B (75mM 
Tris pH 8.0, 1M NaCl). Pure protein preparations were pooled, desalted and 
concentrated  using  Amicon  centrifuge  concentrators  (Millipore).  Protein 
 frozen in liquid nitrogen and stored at  
Gel filtration of recombinant proteins. CypA and capsids were purified by
gel filtration and fractions were run on an SDS-PAGE gel to assess protein purity. Shown 
and feCypA as representative proteins. CypA was deemed sufficiently 
pure after this stage and fractions were pooled, concentrated and frozen for futur
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). Sample buffer was 20mM Tris pH 7.4, 100mM NaCl, 
1mM DTT for all proteins. For capsid and mutants of capsid, an additional Q 
exchange  chromatography  (GE  Healthcare)  chromatography  step  was 
weight contaminants (Figure 2 3). 
Protein was eluted by increasing salt concentration, using 10% buffer B (75mM 
Tris pH 8.0, 1M NaCl). Pure protein preparations were pooled, desalted and 
rifuge  concentrators  (Millipore).  Protein 
 80 °C prior to use. 
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Figure 2-3 Ion exchange chromatography for FIV
increasing the proportion of buffer B. Lanes 1
B, whilst the final fraction,
was repeated for all capsid variants and mutants. Pure proteins were pooled, concentrated 
and snap-frozen before further use.
2.4.2 Isothermal Titration Calorimetry
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cell in order to keep the temperature in the cells the same. Thus, the raw data 
produced from each experiment is a time
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the first few injections of species B will result in all B being bound, giving 
several  large  spikes.  As 
nd Methods 
Ion exchange chromatography for FIV-Fca CA
N.
increasing the proportion of buffer B. Lanes 1-5 are taken from fractions eluted with 10% 
B, whilst the final fraction, bearing contaminants, was eluted with 50% B. The process 
was repeated for all capsid variants and mutants. Pure proteins were pooled, concentrated 
frozen before further use. 
Isothermal Titration Calorimetry 
ITC  is  a  technique  that  measures  the  change  in  heat  associated  with  the 
interaction  of  two  molecular  species  (technique  reviewed  in  Pierce  et  al. 
. The apparatus consists of a reference cell and a reaction cell pre
with  one  of  the  interacting  samples  (species  A)  into  which  species  B  is 
repeatedly injected. Changes in enthalpy in the reaction cell associated 
each injection of B produce a change in the power supplied to the reference 
cell in order to keep the temperature in the cells the same. Thus, the raw data 
produced from each experiment is a time dependent series of spikes measured 
in  cal/s, with negative values indicating an exothermic reaction. Typically, 
the first few injections of species B will result in all B being bound, giving 
several  large  spikes.  As  the  fraction  of  unbound  species
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with  one  of  the  interacting  samples  (species  A)  into  which  species  B  is 
repeatedly injected. Changes in enthalpy in the reaction cell associated with 
each injection of B produce a change in the power supplied to the reference 
cell in order to keep the temperature in the cells the same. Thus, the raw data 
dependent series of spikes measured 
ative values indicating an exothermic reaction. Typically, 
the first few injections of species B will result in all B being bound, giving 
species  A  decreases, Chapter 2. Materials and Methods 
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subsequent injections will result in smaller changes in enthalpy until no binding 
is observed. Integration of the spikes allows the calculation of the total change 
in heat for each injection and curve fitting, along with accurate measurements 
of  the  concentrations  of  the  species,  allows  the  calculation  of  molar 
stoichiometry (N), dissociation constant (Kd) and the molar change in enthalpy 
( H). The dissociation constant, Kd, is a measure of the strength of interaction 
and has a value in molar concentration that corresponds to the concentration 
at which half of the binding sites are occupied, so that lower values represent 
stronger  binding.   H  has  a  value  in  cal/mol,  reflecting  the  change  in  heat 
associated with one mole of interactant binding its ligand. The change in heat 
reflects the preference of the ligand for its binding partner over the solvent, 
with  negative  values  indicating  enthalpically  favoured  interactions.  In  the 
context  of  protein protein  interactions,  hydrogen bonding,  burial  of 
hydrophobic solvent exposed surfaces and Van der Waals can all contribute to 
the  H.  
For  the  experiments  in  this  study  an  ITC200  (MicroCal)  machine  was  used, 
previously  calibrated  with  EDTA  CaCl2  according  to  manufacturer’s 
instructions. Cell and syringe samples were dialysed overnight at 4 °C into the 
same beaker of potassium phosphate buffer (20 mM KxHxPO4, 20 mM NaCl, 5 
mM  β mercaptoethanol,  pH  7.0).  Proteins  were  then  diluted  to  600   M  for 
syringe  sample  and  60   M  for  cell  sample  and  re quantified  by  measuring 
absorbance at 280 nm. ITC was performed at 10 °C. 
2.4.3 X ray crystallography 
Initial crystal screens varying in buffer constitution were performed in 200 nl 
droplets comprising 100 nl protein and 100 nl reservoir buffer in sitting drop 
vapour diffusion 96 well plates. Reservoir buffers and protein were dispensed 
by  Screenmaker  96+8  robot  (Innovadyne).  Proteins  were  at  a  typical Chapter 2. Materials an
 
 
concentration of 12 mg/ml. Domestic cat CypA and CypA
were dialysed into 20 mM HEPES, 20
7.0, whilst FIV CA
N 
7.4. Screens were set up in 15x 96
hits (Figure 2 4). Conditions were
in the relative concentrations of cryoprotectants PEG 4000 and glycerol, and by 
the use of additive screens (Hampton Research). The final conditions for FIV 
CA
N were 0.16 M ammonium sulphate, 0.08 M sodium ace
w/v PEG 4000 and 20% v/v glycerol.
 
Figure 2-4 FIV capsid N
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FIV capsid N-terminal domain crystals. From a 15x 96 well plate screen, 
crystals were found in conditions shown (left). An additive screen
but did not yield larger crystals. Final conditions excluded additives.
For  CypA  and  CypA peptide  complexes,  crystals  were  obtained  in  2.4M 
ammonium phosphate, 0.1M Tris, pH8.5. CA
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were  found  to  consist  of  single  protein  species.  Data  were  collected  on  a 
Rigaku rotating anode X ray set with Mar research image plate and solved by 
Dr. Leo James. Figures were generated by manipulation of pdb files in PyMol. 
Superimposition  of  structures  was  performed  using  EBI  DaliLite  server 
(http://www.ebi.ac.uk/DaliLite) and aligned pdb files were viewed in PyMol. 
2.5 In silico techniques 
2.5.1 Phylogenetic analysis 
Amino acid sequences of full length TRIM open reading frames and viral FIV Ple 
E Sangre, FIV Ple B 1027 and FIV Fca GL8 sequences were aligned using Clustal 
W (Thompson et al. 1994) with manual adjustment in Bioedit (Hall 1999). env 
and gag alignments were created using multiple alignments of FIV sequences 
available in Genbank. The codon optimised nucleic acid sequences were used 
to construct trees using the Neighbour Joining method in Mega 4.0 software 
(Tamura  et  al.  2007;  Saitou  and  Nei  1987)  with  1000  replicates  to  allow 
calculation  of  bootstrap  values.  The  evolutionary  distances  were  computed 
using the Maximum Composite Likelihood method (Tamura et al. 2004) and are 
in  the  units  of  the  number  of  base  substitutions  per  site.  All  positions 
containing gaps and missing data were eliminated from the dataset, meaning 
for  TRIM5  that  only  the  RBCC  domain  was  used  in  the  analysis.  For  viral 
sequences,  almost  identical  trees  were  obtained  using  Maximum  Likelihood 
method (not shown), suggesting that the trees shown represent a robust fit. N 
linked  glycosylation  sites  were  predicted  using  NetNGlyc  online  tool 
(http://www.cbs.dtu.dk/services/NetNGlyc) to locate NX(S/T) motifs, where X 
is any amino acid except proline. Routine manipulation of sequences, primer 
design  and  analysis  of  sequencing  runs  was  performed  with  DNADynamo 
(BlueTractor Software). Chapter 2. Materials and Methods 
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2.5.2 Graphs and statistics 
All  graphs  were  drawn  with  SigmaPlot  8.0  and,  where  shown,  error  bars 
represent  the  standard  error.  Unpaired  two tailed  student’s  t tests  were 
performed using the same software. 
2.5.3 Homology modelling 
Templates  for  a  homology  model  of  feline  A3H  were  sought  using  HHpred 
software (Soding et al. 2005) to identify the human A2 (2NYT; Prochnow et al. 
2007) and A3G CD2 (3E1U; Holden et al. 2008) structures as sharing the highest 
degree  of  homology  with  the  query  protein.  Conservation  of  secondary 
structures  was  confirmed  using  the  Ali2D  software  on  the  Max  Planck 
Bioinformatics  Server  (http://toolkit.tuebingen.mpg.de),  which  predicted  a 
shared secondary structure with A3G CD2. Subsequently, MODELLER 9v3 (Eswar 
et al. 2007) was used to create a 3 dimensional model of feline A3H using both 
A2 and A3G CD2 crystal structures as templates. For feline CD134, the crystal 
structure of the human homologue (2HEY; Compaan and Hymowitz 2006) was 
used  as  a  template.  Predicted  structures  were  superimposed  on  A3G  CD2 
crystal  structure  using  Dailite  and  structures  were  viewed  in  PyMol. 
Chapter 3.  Receptor  tropism  of  feline 
immunodeficiency virus isolates from African 
lions. 
3.1 Summary 
The feline immunodeficiency virus (FIV) is a major pathogen of domestic cats 
but also infects non domestic species including the African lion (Panthera leo). 
Recent analysis of the proviral genome of two African lion FIV (FIV Ple) field 
isolates  belonging  to  subtypes  B  and  E  suggests  that  the  env  open  reading 
frame of the E subtype shares greater homology with FIV strains that infect 
domestic cats (FIV Fca) than to other strains of FIV Ple (Pecon Slattery et al. 
2008a). In this study we ask whether this shared identity between FIV Fca and 
FIV Ple E corresponds with shared receptor tropism. Despite only 53% amino 
acid identity in Env SU, FIV Ple E is found to share use of CD134 as the primary 
receptor for attachment. Furthermore, infection by FIV Ple E is also CXCR4 
dependent  and  can  be  inhibited  by  CXCR4  antagonist  AMD3100  and  soluble 
trimeric CD134 ligand. We also confirm previous studies which have suggested 
that FIV Ple B uses an alternative entry receptor (Smirnova et al. 2005; Willett 
et al. 2006a): productive infections of the B subtype could be established in 
CD134 negative lines, whilst replication of the E subtype was dependent on 
ectopic expression of feline CD134. The shared usage of CD134 and CXCR4 in Chapter 3. Receptor tropism of FIV in African lions 
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FIV Fca and FIV Ple E suggests that a relative of FIV Fca has recombined with 
African lion strains of FIV, preserving its use of receptor. The findings give an 
indication of the in vivo cell tropism of FIV Ple E and have implications for 
future research into the pathogenicity of FIV in wild lion populations.  
3.2 Results 
In the light of findings that lentiviruses with divergent env genes circulate in 
African  lion  populations  (Pecon Slattery  et  al.  2008a),  it  was  attempted  to 
assess  whether  diversity  between  FIV Ple  subtypes  B  and  E  extended  to 
alternative receptor usage.  
3.2.1 Sera from wild lions show immunoreactivity to FIV Ple 
A representative of FIV Ple subtype B was available (FIV Ple B 458), but not a 
subtype E virus. A panel of lion sera was therefore obtained from wild lions in 
the Moremi reserve in the Okavango Delta, and screened for seroreactivity to 
viral antigens. Proteins of pelleted FIV Ple 458 (B subtype) were run on an SDS 
PAGE gel, transferred to a nitrocellulose membrane and blotted using the sera 
of 27 wild lions (Figure 3 1). As controls, pooled sera from uninfected and FIV 
Fca infected  cats  were  also  included  in  the  assay.  Immunoreactivity  to  the 
principal determinant p24 is found in 24 of the 27 serum isolates (89%), in line 
with previous estimates of populations east of the Kalahari desert (Kalahari 
game reserve 71% positive (Ramsauer et al. 2007); Okavango Delta 96% (Roelke 
et  al.  2009);  Serengeti  ~100%  positive  (Brown  et  al.  1994)).  Unlike  typical 
immune  responses  to  FIV Fca  and  HIV 1,  previous  studies  have  found  only 
immunoreactivity in FIV Ple infections to the proteins derived from the Gag 
polyprotein. Here we find evidence of a humoral response to Env in 13 out of 
24 (54%) of the seropositive lions. The specificity of the immunoreactivity to 
Env is revealed by the fact that serum from an infected domestic cat does not Chapter 3. Receptor tropism of FIV in African lions
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Sangre by RT PCR and the amplicon was cloned into VR1012 using SalI and NotI 
digestion sites. The Env of FIV Ple B 458 (Brown et al. 1994) was also cloned 
and used as a representative of FIV Ple B subtype. Analysis of the sequences 
reveals that FIV Ple E Sangre shares 88% amino acid identity with the FIV Ple E 
1027  isolate  used  for  the  genomic  sequence  of  FIV Ple  E  subtype  (Pecon 
Slattery et al. 2008a) and 53% identity with FIV Fca GL8. A Neighbour Joining 
tree was constructed by aligning the entire gag and env genes from several 
published FIV isolates available in the NCBI GenBank (Figure 3 2). In a similar 
finding to (Pecon Slattery et al. 2008a), phylogenetic relationships for the two 
genes  show  substantial  differences,  suggesting  alternative  evolutionary 
histories for the gag and env genes, and highlighting the relevance of inter 
genomic recombination events in the evolution of FIV. The env gene of the 
virus isolated from Sangre is found to cluster closely with FIV Ple E 1027 (E 
subtype),  and  distally  from  other  FIV Ple  strains  B  and  C,  confirming  its 
identity as a subtype E virus. More widely, the env gene phylogeny forms two 
distinct groupings: those related to the puma group, including FIV Ple B and 
FIV Oma and those related to the domestic cat group, including both FIV Ple E 
1027 and FIV Ple E Sangre.   Chapter 3. Receptor tropism of FIV in African lions
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Figure  3-2  Phylogenies  of  FIV  gag  and  env  reveal  contrasting  evolutionary 
relationships.  Neighbour-Joining  trees  were  constructed  using  full  coding  regions  of 
published FIV sequences available in Genbank as well as FIV-Ple E Sangre env, with 
bootstrap of 1000 iterations. When phylogenetic analysis is performed  using the gag 
gene, the tree bears four discernable groups: the puma, domestic cat, lion/Pallas cat and 
outlier FIV-Pco 14. In contrast, when a tree is drawn with env, FIV-Ple E groups with 
FIV-Fca, whilst FIV-Oma and FIV-Ple B 458 (EU117991) form a monophyletic group 
and bear more similarity to FIV-Pco. FIV-Ple E Sangre clusters closely with published 
FIV-Ple E 1027 (EU117992), confirming its identity as a lion clade E virus. 
Alignment of FIV Ple E Sangre, FIV Ple B 458 and FIV Fca GL8 Envs (Figure 3 3) 
reveals that FIV Ple E Sangre is a chimeric env, bearing homology with FIV Ple 
B 458 in the N terminus of SU and the C terminus of TM. The central region 
more closely resembles FIV Fca GL8, with 58% identity in this region, compared 
to 33% in the FIV Ple B 458 homology region. Furthermore, the FIV Ple strains 
share  an  82  residue  N terminal  sequence  not  present  in  the  domestic  cat 
strains. The functional significance of this is unknown but may represent extra 
signal  peptide/leader  sequence.  Several  other  important  structural  features 
are  also  conserved  between  FIV Fca  and  FIV Ple  E  Sangre  including  all  7 
predicted  disulphide  bonds  of  GL8  and  17  out  of  18  predicted  N linked 
glycosylation sites. The ES(E/D) motif present at the crown of the V3 loop is 
commonly found in field isolates of FIV Fca but is often lost during cell culture 
adaptation (Figure 3 4). The presence of the ES(E/D) motif correlates with use 
of  CD134  attachment  receptor  and  an  alteration  of  charge  at  one  of  the 
glutamate  residues  by  a  conversion  to  lysine  reduces  the  requirement  for 
CD134, allowing the virus to utilise CXCR4 directly for entry (Shimojima et al. 
1998;  Willett  et  al.  1997b;  Willett  et  al.  1997a;  Willett  et  al.  2007). 
Interestingly the FIV Ple E Sangre Env lacks the ES(E/D) motif but instead bears 
a TAT motif at this location.  
 Chapter 3. Receptor tropism of FIV in African lions 
94 
 
 
Figure 3-3 Env alignment of FIV-Ple E Sangre with FIV-Ple B 1027 and FIV-Fca 
GL8. Amino acid residues were aligned using ClustalW and reveal the N and C termini 
of the FIV-Ple strains are conserved (yellow bars), while the central section of FIV-Ple E Chapter 3. Receptor tropism of FIV in African lions
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Willett and Hosie 2008), was able to replicate in the absence or presence of 
CD134 (Figure 3 5). This provides evidence that the lion E subtype of FIV uses 
CD134 as an entry receptor, and confirms that CD134 is not required for the 
replication of the FIV Ple B subtype. 
 
Figure 3-5 Growth of FIV-Ple E Sangre is CD134-dependent in CLL cells. Cells 
were  infected  with  isolates  of  FIV-Fca  GL8,  Ple  E  and  Ple-  B  subtypes  and  culture 
supernatant aliquots were taken periodically and stored at -80
oC for subsequent analysis 
of reverse transcriptase activity. Whilst FIV-Ple B 458 was able to replicate in CLL cells 
devoid  of  CD134,  replication  of  FIV-Fca  GL8  and  FIV-Ple  E  Sangre  was  CD134-
dependent, providing evidence that FIV strains circulating in wild lion populations share 
CD134 as an entry receptor with FIV-Fca.  
3.2.4 Tropism of FIV Ple pseudotypes 
To further characterise the attachment receptors of FIV Ple, HIV 1 luciferase 
pseudotyped particles were generated and their receptor tropism was assessed 
on MCC cells transduced with human, feline or chimeric CD134. Human CD134 
is a non functional receptor for FIV but FIV Fca strains such as PPR and B2542 
need only to interact with cysteine rich domain 1 (CRD1) of feline CD134 and 
are therefore able to use chimeric feline human CD134 (fCRD1/hCD134) (de 
Parseval  et  al.  2005).  Other  strains  such  as  GL8  and  CPG41,  typical  ‘early’ 
isolates, require additional determinants in CRD2 and therefore cannot use the Chapter 3. Receptor tropism of FIV in African lions 
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chimeric receptor (Willett et al. 2006b). In domestic cat FIV strains that attain 
entry without feline CRD2 requirement (such as PPR and B2542), infection is 
readily  inhibited  by  soluble  trimeric  feline  CD134 ligand  (sFc TNC CD134L) 
perhaps suggesting a weaker interaction between Env and CD134 (Willett et al. 
2007; Willett et al. 2009). Like FIV Fca PPR, FIV Ple E Sangre infection was also 
found to be readily inhibited by low concentrations of CD134L (Figure 3 6; 46% 
reduction  in  infectivity  was  seen  at  2 g/ml  sfeCD134L  for  FIV Ple  E  Sangre 
compared to 21% for PPR and no decrease for GL8). Additionally,  FIV Ple E 
Sangre  entry  could  be  inhibited  by  AMD3100,  a  small  molecule  inhibitor  of 
CXCR4 dependent entry in FIV Fca, indicating that FIV Ple E shares both entry 
receptor  and  co receptor  with  FIV Fca.  Conversely  entry  of  FIV Ple  B  was 
unaffected, confirming its independence of CXCR4 and CD134.  
 
Figure 3-6 Like FIV-Fca, infection by FIV-Ple E can be inhibited with ligands of the 
receptor and co-receptor. Mya-1 cat T-cells were infected with HIV(luc) pseudotypes 
bearing envelopes of domestic cat FIV-Fca strains GL8 and PPR as well as FIV-Ple E Chapter 3. Receptor tropism of FIV in African lions 
98 
 
Sangre and B 458 in the presence of small molecule CXCR4 inhibitor AMD3100 (panels 
A and C) or soluble trimeric CD134L (sFc-TNC-CD134L; panels B and D) drawn as raw 
luciferase readings (A and B) or fold change in luciferase activity (C and D). In common 
with domestic cat strains of FIV such as PPR, FIV-Ple E Sangre was readily inhibited by 
CD134L and was also sensitive to AMD3100. In contrast, FIV-Ple B was insensitive to 
both these inhibitors. 
In domestic cat strains of FIV, a high degree of susceptibility to blocking by 
sCD134L  is  associated  with  a  reduced  requirement  for  the  CRD2  domain  of 
CD134  (Willett  et  al.  2006b).  In  order  to  test  whether  these  features  are 
associated in  FIV Ple infection,  the  virus was  titrated  onto a  panel  of  cells 
expressing  human,  feline  and  chimeric  fCRD1/hCD134.  The  co occurence  of 
high  susceptibility  to  sCD134L  with  reduced  requirement  for  CRD2  was  not 
found to be the case for FIV Ple E as entry was not supported by MCC cells 
bearing fCRD1/hCD134 (Figure 3 7). This finding suggests that FIV Ple E makes 
more complex interactions with its receptor, as has been postulated for ‘early’ 
domestic cat stains such as GL8. FIV Ple E Sangre is the first example of an Env 
displaying  these  properties  and  demonstrates  that  having  both  a  weak 
interaction with the receptor but a more complex CRD2 dependent interaction 
are  not  properties  that  are  mutually  exclusive  to  an  individual  envelope 
glycoprotein. Chapter 3. Receptor tropism of FIV in African lions 
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Figure 3-7 CD134 domain requirement for FIV-Ple E Sangre. As has been observed 
for certain strains of FIV-Fca such as GL8 (Willett et al. 2006b), FIV-Ple E is unable to 
use  chimeric  feline-human  CD134,  indicating  that  FIV-Ple  E  requires  CD134 
determinants in both CRD1 and CRD2. 
The CD134 variants from domestic cat and lion were sequenced and aligned to 
human CD134 (Figure 3 8). Lion CD134 was deposited in Genbank (accession 
EU915483).  Conservation  between  the  homologues  is  high,  with  variable 
residues largely confined to the cleaved leader sequence. The only mutations 
within  the  mature  peptide  are  within  CRD1,  namely  K42R  and  G59S. 
Interestingly,  residue  59  is  one  of  the  sites  responsible  for  the  differential 
permissivity between human and feline CD134, and forms part of the primary 
Env binding site (de Parseval et al. 2005), raising the possibility that one or 
both of these mutations could alter the Env binding site and have a profound 
effect on viral entry. Chapter 3. Receptor tropism of FIV in African lions 
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Figure 3-8 Alignment  of CD134 homologues.  Lion and  feline CD134 possess high 
levels  of  homology  throughout  the  protein  and  differences  between  the  homologues 
reside in the cleaved leader sequence (blue bar) and in cysteine rich domain 1 (CRD1). 
Residues  critical  for  the  FIV  Env-receptor  interaction  that  are  non-permissive  in  the 
human (hu) homologue are marked with a black line and overlap the G59S mutation 
between cat and lion. Residues that are identical between at least two of the homologues 
are shaded dark grey and conserved residues light grey.  
To further characterise the relative requirements of receptor and co receptor, 
plasmids encoding the lion and feline CD134 receptors were used to transduce 
CXCR4 negative  human  NP2  cells.  The  resulting  cells  were  then  further 
transduced with lion CXCR4. The presence of the mutations within lion CRD1 
could potentially affect the Env CD134 interaction. Entry for FIV Ple E Sangre 
was dependent on the presence of both CD134 and CXCR4 but, despite the 
differences  in  sequence,  without  preference  for  the  species specific  CD134 
variants ( 
Figure 3 9).  Chapter 3. Receptor tropism of FIV in African lions 
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Figure  3-9  CD134  and  CXCR4  are  obligatory  factors  for  FIV-Ple  E  entry. 
Expression of lion or feline CD134 or CXCR4 alone is insufficient for entry for both 
domestic cat GL8 and lion subtype E FIV variants. The viruses display no substantial 
preference for lion or feline CD134. 
To show that the FIV Ple Env is capable of mediating membrane fusion, AH927 
cells  stably  expressing  CXCR4  alone  or  CXCR4  and  feline  CD134  were 
transfected with plasmids bearing the env genes of FIV Fca GL8 or FIV Ple E 
Sangre. Transfection with either env resulted in the formation of large syncytia 
in  AH927 fCXCR4 fCD134  (Figure  3 10)  while  AH927 fCXCR4  cells  did  not 
significantly  differ  from  mock  transfected  cells,  indicating  that  FIV Ple  E 
Sangre is able to mediate membrane fusion in a CD134 dependent manner. Chapter 3. Receptor tropism of FIV in African lions
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Figure 3-11 FIV-Pco is able to replicate in CrFK independently of CD134. Human 
CD134 is a non-functional receptor for FIV infection (de Parseval et al. 2005). Here an 
FIV-Pco primary isolate was able to replicate in CrFKs in the presence of feline (fe) or 
human (hu) CD134, whilst FIV-Fca was only able to replicate in the presence of feline 
CD134, suggesting the puma virus uses an alternative receptor expressed in CrFKs.  
3.3 Discussion 
This study provides evidence that lion lentiviruses belonging to subtype E share 
usage  of  CD134  and  CXCR4  as  attachment  receptors  for  viral  entry  with 
domestic cat variants of FIV. Phylogenetic analysis of the lentiviruses reveals 
that FIV Ple is a monophyletic strain of FIV related to lentiviruses from puma 
(FIV Pco) and Pallas cat (FIV Oma) when analysis is performed over the gag 
open reading frame. However, using the env gene, it is shown that whilst FIV 
Ple  B  remains  clustered  with  FIV Oma  and  FIV Pco,  the  E  subtype  is  more 
closely  related  to  FIV Fca  (Pecon Slattery  et  al.  2008a).  The  results  are 
suggestive of a recombination event, but given the relatively high sequence 
divergence  between  FIV Ple  E  and  FIV Fca,  either  between  circulating  lion 
strains and an ancient ancestor of FIV Fca, or a more recent recombination 
event with an FIV strain that resembles FIV Fca circulating in lions or another 
species that is yet to be identified. Recombination in lentiviruses is not without Chapter 3. Receptor tropism of FIV in African lions 
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precedent:  an  increasing  number  of  HIV 1  variants  arising  from  presumed 
recombination events are being discovered, with 43  circulating recombinant 
forms  (CRFs)  listed  in  the  HIV  sequence  database  in  July  2009 
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). 
Recombination has also been shown to be widespread in the evolution of the 
primate lentiviruses, with the ancestors of both HIV 1 and HIV 2 themselves 
mosaics of the six major SIV lineages (Salemi et al. 2003). Evidence exists of 
recombination  in  FIV  env  and  gag-pol  in  Felis  catus  domestic  and  wild 
populations (Carpenter et al. 1998; Hayward and Rodrigo 2008). Recombination 
is  therefore  likely  to  be an important  mechanism  of  generating  diversity  in 
lentiviruses that otherwise replicate in a clonal manner, lacking the ability to 
exchange genetic material.  
3.3.1 Potential implications of receptor use on FIV Ple pathogenicity 
The  virus receptor  interaction  is  a  critical  determinant  of  the  host  cell 
population targeted and therefore a significant factor in the cytopathicity of 
retroviral infection. HIV 1 uses CD4 and chemokine receptors CXCR4 or CCR5 to 
preferentially infect diverse cell populations (Edinger et al. 1997; Dragic et al. 
1996; Feng et al. 1996). In a similar manner FIV Fca uses CD134 and CXCR4 to 
target  activated  T cells,  and  changes  in  receptor  tropism  correlate  with 
infection of other tissues and associated changes in pathogenicity (Willett et 
al. 2006b; Willett et al. 2006a; de Parseval et al. 2005). Studies of FIV Ple 
infection have found evidence of CD4+ T cell depletion in both wild (Roelke et 
al. 2009; Roelke et al. 2006) and captive lions (Bull et al. 2003). However the 
pathogenicity of FIV Ple in lions is uncertain, with several studies suggesting 
that  the  presumed  age  of  the  lentiviral  infection  in  lions  has  permitted 
adaptation to the host leading to attenuated pathogenicity, with findings of 
normal lifespans and fecundity in infected individuals and no association with Chapter 3. Receptor tropism of FIV in African lions 
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other disease correlates (Carpenter and O'Brien 1995; Hofmann Lehmann et al. 
1996). In the most complete analysis of FIV Ple pathology to date, Roelke et al. 
(2009)  suggested  that  Botswanan  and  Serengeti  lion  populations  suffer  the 
typical  manifestations  of  immunodeficiency  syndromes  including  increased 
levels  of  lymphadenopathy,  oral  papilloma  lesions  and  gingivitis  as  well  as 
chronic  inflammatory  responses  and  abnormal  red  blood  cell  parameters. 
However,  the  finding  that  circulating  subtypes  of  FIV Ple  use  diverse 
attachment receptors has direct implications for the cytopathology of FIV Ple, 
since the E subtype is presumably able to infect and deplete activated T cells 
in a manner reminiscent of domestic cat lentiviral infections. Future studies of 
FIV Ple  infection  in  wild  populations  should  attempt  to  correlate  receptor 
usage with pathological manifestations of the immunodeficiency syndrome, as 
the use of alternate entry receptors may go some way to accounting for the 
discrepancies in the findings of recent studies. As for the identity of the FIV 
Ple B subtype receptor, it is tempting to speculate that it is a more widely 
expressed cell surface molecule, given that high titres of replicating virus can 
be obtained in canine CLL cells, (Figure 3 5) and that infection is supported by 
3201  cells  (Smirnova  et  al.  2005).  Additionally,  a  strain  of  North  American 
puma  virus  FIV Pco,  which  is  proposed  to  be  a  distant  relative  of  FIV Ple 
(Pecon Slattery et al. 2008a), is able to replicate to high titres in CrFK cells 
that lacked feline CD134 (Figure 3 11). For FIV Fca, replication in CrFKs that 
lack  feline  CD134  requires  a  period  of  adaptation  which  corresponds  to 
mutations in env that allow CD134 independent entry (Siebelink et al. 1995; 
Verschoor et al. 1995). In contrast, FIV Pco replicates to high titres by day 2 
post infection, suggesting that FIV Pco is able to use an alternative receptor 
expressed on CrFK without a prior adaptation phase (Figure 3 11). Given the 
divergent  origins  of these  cell  lines  (CLL is  a  naive canine  CD3+  T cell  line 
(Willett et al. 2006a), 3201 is a feline lymphosarcoma cell line (Hardy, Jr. et 
al. 1980) and CrFK is a feline kidney derived epithelial cell line (Crandell et al. Chapter 3. Receptor tropism of FIV in African lions 
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1973)),  it  appears  likely  that  the  receptor  or  receptors  for  these  viruses  is 
widely expressed. The ability to replicate in these cells is therefore perhaps 
indicative of a group of FIV strains including FIV Ple B, FIV Pco and FIV Oma, 
which share usage of an alternative and perhaps broadly expressed receptor or 
receptors. Experimental infection of domestic cats with FIV Ple B 458 and FIV 
Pco 1697 showed that these viruses are able to replicate in T cells, causing 
acute  lymphopoenia  (VandeWoude  et  al.  2003;  VandeWoude  et  al.  1997a; 
Terwee  et  al.  2005)  but  can  be  confined  to  gut associated  lymphoid  tissue 
when inoculation is oronasal (Terwee et al. 2005). In the light of the findings 
presented here, a comparison of tissue tropism of FIV Ple E and B strains in 
domestic cats would be of substantial interest, as it may yield insights into the 
cellular targets and pathology induced by the alternative Env tropism.  
3.3.2 Comparison of FIV Ple E and FIV Fca receptor usage. 
Although FIV Ple E was found to share receptor tropism for CD134 and CXCR4 
with FIV Fca, it did not fall into the like typical ‘early’ or ‘late’ classifications 
of  FIV Fca.  Current  understanding  of  FIV Fca  tropism  suggests  that  viruses 
isolated from the early stages of infection such as GL8 and CPG41 require a 
more complex interaction with main receptor CD134 involving determinants in 
both CRD1 and CRD2 (de Parseval et al. 2005; Willett et al. 2006b). Studies of 
the mechanics of FIV entry, and comparisons with HIV 1 entry, suggest that an 
initial interaction between the SU V3 loop and CD134 result in a conformational 
change that exposes the relatively invariant CXCR4 interacting domain which 
promotes  co receptor  binding  followed  by  TM mediated  fusion with  the  cell 
membrane. The two step receptor, co receptor binding mechanism is thought 
to  sequester  the  invariant  CXCR4 interacting  domain  providing  cover  from 
humoral  immunity.  Although  the  host  will  typically  generate  antibodies 
directed to the variable loops, neutralisation is presumably quickly overcome Chapter 3. Receptor tropism of FIV in African lions 
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by expansion of escape mutations in these regions. Late stage viruses such as 
PPR and B2542, which are relieved of their CRD2 requirement, are possibly 
permitted  to  circulate  by  the  absence  of  full  levels  of  host  immunity,  and 
display  a  broader  cell  tropism  (Willett  and  Hosie  2008).  This  transition  is 
accompanied  by  an  increase  in  sensitivity  to  blocking  activity  of  CD134L 
(Willett et al. 2009; Willett et al. 2007). It is therefore of interest that FIV Ple 
E Sangre behaves like early FIV Fca strains in that it requires components of 
feline  CRD2  for  entry  but  like  late  FIV Fca  strains,  receptor  attachment  is 
readily blocked by low concentrations of CD134L. FIV Ple E Sangre therefore 
represents the first example of a viral Env simultaneously displaying both these 
properties. The relevance of these findings is unknown, but may be indicative 
of a different mechanism of viral entry or of a host specific adaptation. Also 
unknown is the stage of virus that FIV Ple E Sangre represents; although the 
host was healthy at the time of sampling, Sangre was 8 years old and from a 
population with high seroprevalence, making an early stage infection unlikely. 
Further research should establish whether the phenotype that FIV Ple E Sangre 
displays is typical amongst subtype E infected lions and if and how receptor 
usage and sensitivity to blocking changes during the course of infection.  
3.4  Conclusions 
All six member species of Panthera lineage bear species specific strains of FIV, 
whilst in contrast, the Felis lineage harbours only two seropositive species (F. 
catus and the Jungle cat, F. chaus) (Pecon Slattery et al. 2008b). The distinct 
pattern of infection in these taxa is evidence of an ancient infection in the 
Panthera, with evidence suggesting infection before the end of the Pliocene 
(2.53 mya) that has subsequently spread into other species. Consistent with the 
age of the infection, the diversity of FIV in free ranging lions is large [burk] 
and this study reveals that the diversity extends to use of alternate attachment Chapter 3. Receptor tropism of FIV in African lions 
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receptors. Learning the identity of the attachment receptor of other FIV Ple 
subtypes such as subtype B will provide an important insight into the evolution 
of the lentiviruses. Furthermore if the infection of alternative cell populations 
is  demonstrated  for  FIV Ple  B,  there  are  likely  to  be  diverse  pathogenic 
manifestations attributable to the use of distinct attachment receptors, with 
implications  for  the  management  of  free ranging  and  captive  breeding  lion 
populations.  
The domestic cat separated from its closest relatives about 10,000 years ago 
and the absence of FIV in the other Felis species suggests that the zoonosis of 
the virus into domestic cats took place after this divergence. Thus the two 
species  represent  an  interesting  comparison  between  an  ancient  and  a 
relatively  new  host  for  lentiviral  infection.  Models  of  pathogen  infection 
suggest that attenuation of viruses over time will occur to a limited extent 
given  certain  criteria  (May  and  Anderson  1979).  Consistent  with  a  certain 
degree of attenuation, seroprevalences in lions can approach 100% and it is 
apparent that lions are able to survive and breed given the continued existence 
of  these  populations.  Nevertheless,  evidence  exists  for  the  continued 
manifestations of immunodeficiency in lion lentiviral infections. Our knowledge 
of primate intrinsic immunity suggests that in past infections the host gained 
immunity that prevents retroviral infection, rather than viruses persisting as 
asymptomatic infections. Chapter 6 will probe the ability of lions to restrict 
lentiviral infection and show that lion T cells possess a broad anti retroviral 
post entry  restriction  mechanism.  Furthermore  the  nature  of  the  APOBEC3 
genes  in  this  species  is  examined  and  shown  to  provide  a  potent  block  to 
lentiviral  replication,  suggestive  of  an  ongoing  struggle  between  host  and 
parasite.  
Chapter 4.  An  investigation  of  antiretroviral 
factor TRIM5 in Feliformia 
4.1 Summary 
TRIM5α is an intracellular restriction factor that interferes with or ‘restricts’ 
incoming retrovirus particles in the cytoplasm and prevents efficient reverse 
transcription and integration (Stremlau et al. 2004). The gene was originally 
described in primates, where it is proposed to provide a block to cross species 
transmission  of  retroviruses.  The  protein  interacts  with  incoming  retroviral 
cores in the cytoplasm via an interaction between variable regions in the C 
terminal B30.2 domain and the capsid core (Stremlau et al. 2005). In a manner 
similar  to  the  restriction  provided  by  murine  factor  Fv1
b/b,  TRIM5α  variants 
from most species are able to restrict the N tropic strain of MLV but not the B 
tropic  strain,  and  the  viral  determinant  of  restriction  maps  to  the  exposed 
surface of capsid (Bishop et al. 2001; Cowan et al. 2002; Kozak and Chakraborti 
1996).  TRIM5α  variants  from  non primate species  such  as  cows  (Bos  taurus) 
(Ylinen et al. 2006; Si et al. 2006) and rabbit (Oryctolagus cuniculus) (Schaller 
et  al.  2007)  have  also  been  shown  to  posses  TRIM5α  with  antiretroviral 
properties,  suggestive  of  a  mammalian  TRIM5α  common  ancestor  with 
antiretroviral properties. In dogs, TRIM5 has been shown to be disrupted by the 
insertion of an unrelated gene PNRC1 and the genomic remnants of the gene Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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are redundantly pseudogenised (Sawyer et al. 2007). However, the nature of 
TRIM5 in cats is unknown, except that domestic cat cell line CrFK shows none 
of  the  characteristics  of  TRIM5α  restriction  suggestive  of  a  TRIM5α null 
genotype (Towers et al. 2000). For this reason CrFKs are commonly used for 
the exogenous expression and assay of other mammalian TRIM5α proteins. 
This  chapter  presents  a  study  of  domestic  cat  TRIM5  and  shows  that  while 
transcripts  can  be amplified,  the  encoded  protein is  truncated  early  in  the 
B30.2  domain.  Further  investigation  reveals  that  all  feliform  species  tested 
possess  the  truncating  mutation,  but  it  is  absent  from  caniform  sequences, 
giving an approximate date for the disruption event. Lacking a B30.2 domain is 
found to render the gene non functional as an anti retroviral agent and the 
truncated protein is able to act as a dominant negative against human TRIM5α 
suggesting that the feline TRIM5 retains sufficient homology in the coiled coil 
and  downstream  linker  regions  to  the  human  orthologue  in  order  to 
multimerise  and  disrupt  TRIM5α  activity.  This  finding  indicates  that  caution 
should  be  taken  when  expressing  exogenous  TRIM5  genes  in  cat  cells.  The 
results  explain  the  absence  of  post entry  restriction  in  the  felids  and  have 
implications for cross species transmission of lentiviruses and the development 
of animal models for HIV 1 infection.  
4.2 Results 
4.2.1 Domestic cat cells lack TRIM5α like restriction  
It has previously been reported that, unlike other mammals, cells derived from 
domestic  cats  lack  a  post entry  restriction  phenotype  typical  of  TRIM5α 
(Towers et al. 2000). To confirm these findings, the domestic cat cell line CrFK 
was challenged with N  or B  tropic MLV that had previously been titrated and 
normalised  on  MDTF  (Mus  dunni  tail  fibroblast)  cells,  which  lack  restriction Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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activity (Bock et al. 2000). Additionally, to confirm the ability of exogenously 
expressed  TRIM5α  to  mediate  restriction  in  cat  cells,  CrFK  cells  transduced 
with huTRIM5α were also assayed (Figure 4 1). As has previously been reported, 
cat cells lack the ability to restrict N tropic MLV, suggestive of an absence of 
functional TRIM5α. However, unlike canine D17 cells which support restriction 
by  exogenously  expressed  TRIM5α  genes  weakly  (Berube  et  al.  2007),  CrFK 
allows potent restriction of MLV N by the human variant, suggesting that the 
correct  cellular  environment  and  any  potential  cofactors  of  restriction  are 
present in domestic cats.  
 
Figure 4-1 Cat cells lack MLV-N-specific post-entry restriction. Domestic cat cells 
were infected with MDTF-normalised doses of VSV-G pseudotyped N- or B-tropic MLV 
bearing a GFP reporter gene. CrFK cells were equally susceptible to N- and B-tropic 
strains  indicating  a  lack  of  TRIM5α-like  post-entry  restriction.  However,  when 
transduced with huTRIM5α, a potent block to N-MLV is observed, indicating that cat 
cells are able to support the activity of the restriction factor.  
4.2.2 TRIM5 of domestic cats is truncated 
Using internal primers directed to huTRIM5α, an amplicon was identified from 
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and  O'Brien  2007)  for  homologous  sequences.  This  strategy  was  used  rather 
than performing a cross species BLAST search with non feline TRIM5 sequences 
because of the large number of TRIM family members, and the danger that in 
an incomplete genome project, an incorrect match may have been identified. 
Contigs  encoding  exons  2  and  8  were  found  in  the  database,  allowing  the 
design of primers to the full length open reading frame. The resulting TRIM5 
transcript from domestic cat T cells (Mya 1) was cloned and sequenced and 
deposited in Genbank (Accession number GQ183880). The cat TRIM5 was found 
to share substantial homology to hu and rabbit (rb) TRIM5α; however the 5’ 
end of exon 8 bears a stop mutation at residue 299. The resulting protein thus 
encodes only the RBCC domain and does not possess any of the B30.2 variable 
regions that are known to be responsible for capsid recognition (Figure 4 2). 
Sequence  downstream  of  the  stop  codon  at  position  299  bears  multiple 
frameshift and stop codons, suggesting that lack of protein level expression  
has permitted the accumulation of such errors. Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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Figure 4-2 Domestic cat TRIM5 is truncated but shows considerable conservation 
when  aligned  to  TRIM5α  orthologues.  The  amino  acid  sequence  of  feTRIM5  was 
aligned to human and rabbit TRIM5α, revealing substantial conservation in the RBCC 
domain (RBCC identical residues: fe-hu 59%; fe-rb 59%; hu-rb 60%). The feTRIM5 
transcript bears a stop codon at position 299, before the B30.2 domain variable region v1, 
and  encodes  a  truncated  protein.  Domain  architecture  is  indicated  with  yellow  bars; 
variable regions of B30.2 are labelled green; dark grey, conserved residue; light grey, 
conserved substitution. 
4.2.3 Cat TRIM5 is a true orthologue of primate TRIM5α. 
Confirmation  was  sought  that  the  gene  identified  is  a  true  orthologue  of 
primate  TRIM5  and  not  a  closely  related  TRIM  gene.  Firstly,  using  areas  of 
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was  established.  This  placed  TRIM5  amongst  its  closest  relatives:  TRIM6, 
TRIM22  and  TRIM34  (Figure  4 3A).  As  with  other  mammalian  species  the 
domestic cat TRIM gene cluster is flanked by olfactory genes. Haplotypes that 
are present in multiple species without karyotypic rearrangements are known 
as  regions  of  conserved  synteny.  In  this  case  synteny  has  been  conserved 
between  primates  (human  chr.  11,  rhesus  chr.  14)  and  carnivores  (cat 
chromosome  D1,  dog  chromosome  21).  The  presence  of  conserved  synteny 
suggests that the gene identified is a true TRIM5 orthologue. However, it is 
noteworthy that the cat, cow and dog TRIM5 genes are orientated oppositely 
with  respect  to  human  and  rhesus  macaque  TRIM5,  suggesting  an  inversion 
event has occurred. The timing and relevance of this event are unknown but 
may for example affect interactions with enhancer/suppressor elements and 
therefore expression levels. Secondly, a Neighbour Joining tree was drawn by 
aligning  full  length  TRIM  open  reading  frames  (Figure  4 3B).  This  reveals 
feTRIM5 to be monophyletic with TRIM5 variants from other mammalian species 
and the position of feTRIM5 reflects the established evolution of the mammals. 
Importantly, feTRIM5 clusters distantly from other closely related TRIM genes 
such as TRIM6, TRIM22 and TRIM34, thus confirming the transcript identified as 
a true orthologue of TRIM5.  Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia
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An investigation of antiretroviral factor TRIM5 in Feliformia
Conserved synteny and phylogenetic clustering indicate that cat TRIM5 
is a true TRIM5 orthologue. A) Paralogues TRIM6/34/5/22 are found in a cluster in 
human, dog and cat genomes. In all cases, the cluster is surrounded by olfactory genes. 
The human TRIM5 is in the opposite orientation to the dog and cat orthologues. Exons 2 
and 8 of the pseudogenised dog TRIM5 are shown. Other genes in cat, as well as dog 
TRIM6 are predicted genes or regions of homology only and may not be expressed or 
functional.  B)  A  neighbour-joining  phylogeny  was  constructed  using  amino  acid 
sequence  of  several  TRIM5  orthologues  as  well  as  the  closely  related  TRIM34  and 
TRIM22.  Domestic  cat  TRIM5  is  monophyletic  with  TRIM5  from  other  species
supported by high bootstrap values from 1,000 iterations. The tree was routed on outlier 
An investigation of antiretroviral factor TRIM5 in Feliformia 
115 
 
Conserved synteny and phylogenetic clustering indicate that cat TRIM5 
A) Paralogues TRIM6/34/5/22 are found in a cluster in 
omes. In all cases, the cluster is surrounded by olfactory genes. 
The human TRIM5 is in the opposite orientation to the dog and cat orthologues. Exons 2 
and 8 of the pseudogenised dog TRIM5 are shown. Other genes in cat, as well as dog 
genes or regions of homology only and may not be expressed or 
joining  phylogeny  was  constructed  using  amino  acid 
sequence  of  several  TRIM5  orthologues  as  well  as  the  closely  related  TRIM34  and 
yletic  with  TRIM5  from  other  species, 
. The tree was routed on outlier Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
116 
 
4.2.4 Exon structure of cat TRIM5 
Primate  and  non primate  TRIM5  orthologues  are  known  to  span  eight  exons 
(Nisole et al. 2005), with the largest being exons 2 (which includes the start 
codon ATG, the RING domain and the B Box2 domain) and 8 (which codes for 
almost the entire B30.2 domain). The cat TRIM5 gene was found to share seven 
of the eight exons present in huTRIM5α, skipping the 27 nucleotide exon 7 and 
thus moving directly (but remaining in frame) from exon 6 to exon 8. This is a 
transcript that has not been described in humans. However, two novel isoforms 
of TRIM5 were found in the macaque species Macaca nemestrina: TRIM5η (eta) 
bears  a  2bp  deletion  between  exons  6  and  7  resulting  in  a  frameshift  and 
truncation, resulting in a protein of 300 residues, comparable in size to cat 
TRIM5; TRIM5θ (theta) skips exon 7, like the cat TRIM5, but remains in frame 
for the entire exon 8, resulting in a protein of 486 residues (Brennan et al. 
2007). Interestingly a TRIM5α transcript was not identified in this species, and 
the  isoforms  identified  appeared  to  inhibit  viral  entry  poorly  and 
correspondingly, this species can be inoculated with lentiviruses including HIV 
1  (Agy  et  al.  1992)  and  HIV 2  (McClure  et  al.  2000).  The  role  of  these 
alternative isoforms is not clear, but the authors speculate that the deletion of 
exon 7 impacts on the stability of an α helix thought to stabilise the N terminal 
B30.2 domain, and thus reduces the antiretroviral activity of the protein. By 
analogy  with  the  TRIM21  crystal  structure  (Keeble  et  al.  2008),  the  exon  7 
region may compromise the PRY subdomain scaffold structure which supports 
the v1 domain critical for lentiviral restriction (Perez Caballero et al. 2005a; 
Stremlau et al. 2005; Yap et al. 2005).  Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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Figure 4-4 Exon structure of cat TRIM5. Transcripts encoding anti-retroviral human 
TRIM5α are comprised of eight genomic exons. Isoforms TRIM5γ and TRIM5δ encode 
variants that lack the C-terminal B30.2 domain, with TRIM5γ simply lacking the final 
exon 8, resulting in a stop mutation beyond the splice donor of exon 6 and TRIM5δ using 
an alternative splice acceptor in exon 8. Domestic cat TRIM5 is encoded by exons 2 to 8 
but skipping the 27 nucleotide exon 7. 
Although  this  study  found  transcripts  of  a  similar  size  in  diverse  Feliform 
species, it is of course possible that a transcript that encodes all eight exons is 
expressed in cat cells but was not detected in this study. TRIM5 isoforms such 
as huTRIM5δ use an alternative splice acceptor in exon 8, downstream of the 
B30.2 encoding region. To rule out this possibility in domestic cats, 3’ RACE 
was  performed,  which  allows  the  amplification  of  the  3’  terminus  in  an 
unbiased  fashion  (Frohman  et  al.  1988).  No  evidence  for  an  alternative 
transcript  was  found,  with  sequences  corresponding  only  to  the  transcript 
previously identified.  Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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4.2.5 Evaluating the antiviral activity of cat TRIM5  
Primate TRIM5 is able to interact with incoming retroviral cores through an 
interaction between its B30.2 domain and viral capsid protein (Mische et al. 
2005; Sebastian and Luban 2005; Stremlau et al. 2006b). Given that domestic 
cat TRIM5 lacks a B30.2 domain, it was predicted that the gene product would 
be unable to restrict retroviruses. To test the ability of feTRIM5 to restrict 
retroviral  infection,  a  murine  cell  line  MDTF  was  stably  transduced  with 
huTRIM5α or feTRIM5. The MDTF cell line was chosen since, like CrFK, it lacks a 
post entry restriction phenotype (Bock et al. 2000; Hatziioannou et al. 2004; 
Towers et al. 2000). Cells were challenged with dilution series of N or B tropic 
MLV, as well as HIV 1 and SIVmac VSV G pseudotyped particles, bearing a green 
fluorescent protein (GFP) marker gene and expression of GFP was monitored by 
flow  cytometry  (Figure  4 5).  Human  TRIM5α  restricted  MLV N  and  SIVmac, 
whilst cat TRIM5 restricted none of the virus particles tested. Thus, we can 
confirm feTRIM5 to be a non functional restriction factor and furthermore we 
can  ascribe  the  lack  of  post entry  restriction  in  domestic  cat  cells  to  the 
truncation of TRIM5.  Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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Figure 4-5 Domestic cat TRIM5 is a non-functional restriction factor. Permissive 
MDTF  cells  were  transduced  with  domestic  cat  TRIM5  or  human  TRIM5α.  Intact 
huTRIM5α specifically recognises and restricts N-tropic but not B-tropic MLV through 
an interaction of its B30.2 domain and the virus capsid. Domestic cat TRIM5, which 
lacks a B30.2 domain is unable to restrict MLV-N. 
4.2.6 Cat TRIM5 disrupts endogenous human TRIM5α activity 
In primates, alternative splice variants TRIM5γ and TRIM5δ lack a B30.2 domain 
and lose their ability to restrict retroviruses. Moreover, these isoforms have a 
dominant negative effect, disrupting TRIM5α restriction by forming multimers 
with full length TRIM5α (Mische et al. 2005; Perez Caballero et al. 2005a). To 
investigate whether the cat TRIM5 is able to perform this dominant negative 
activity, human TE671 cells which express endogenous levels of TRIM5α and 
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potently  restrict  MLV N  (Keckesova  et  al.  2004)  were  transduced  with  cat 
TRIM5 or a human TRIM5α mutated to bear a stop codon at the same location 
as the cat transcript, huTRIM5 P306STOP. Cells were then challenged with moi 
normalised N  or B tropic MLV.   
Both  cat  TRIM5  and  huTRIM5  P306STOP  were  found  to  have  a  dominant 
negative effect against endogenous TRIM5α as they were able to rescue titres 
of MLV N. This suggests that feTRIM5 localises to the cytoplasm where it is able 
to form dimers with huTRIM5α to prevent full levels of restriction. The domain 
responsible  for  TRIM5  self  interaction  is  the  coiled  coil  and  linker  2  region 
(Javanbakht  et  al.  2005;  Perez Caballero  et  al.  2005a).  This  suggests  that 
sufficient homology exists in these regions between human and feline variants 
of  TRIM5  to  allow  the  formation  of  higher  order  complexes.  The  data  also 
provide evidence that like human TRIM5, cat TRIM5 localises to the cytoplasm. 
Interestingly, feTRIM5 was able to provide higher levels of dominant negative 
activity  than  huTRIM5  P306STOP  despite  higher  levels  of  expression  of  the 
latter. However further attempts to characterise this discrepancy by transient 
expression of different ratios of the two genes in conjunction with full length 
TRIM5α proved unsuccessful (data not shown). Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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Figure 4-6 Dominant negative activity of feTRIM5. In a similar manner to human 
isoforms TRIM5γ and δ which also lack a B30.2 domain, feTRIM5 is able to act as a 
dominant negative against TRIM5α, suggesting that feTRIM5 localises to the cytoplasm 
and shares sufficient homology with the human variant to interact and form non-antiviral 
dimers.  
4.2.7 Knock down of endogenous TRIM5 in cat cells 
To  demonstrate  that  endogenous  TRIM5  in  cat  cells  does  not  contribute  an 
antiviral  phenotype,  TRIM5  knockdown  CrFK  cell  lines  were  made  by 
transducing cells with small hairpin RNA constructs directed to feline TRIM5. 
Cells were also transduced with feline CD134 to allow replication of primary 
FIV  isolates.  Confirmation  of  the  knockdown  was  sought  by  RT PCR  with 
feTRIM5 specific primers wam4 and wam13 with 2 fold serial dilutions of cDNA 
as template, which showed a four  to eight fold reduction in TRIM5 expression. 
No  difference  in  the  ability  to  replicate  in  the  cells  was  associated  with 
knockdown of TRIM5, suggesting that TRIM5 does not impact on FIV replication.  Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia
 
Figure 4-7 Knockdown of TRIM5 in cat cells.
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not be repeated due to time constraints and therefore remains inconclusive. 
4.2.8 Sensitivity of FIV to TRIM5α restriction
In  order  to  test  whether  TRIM5α  from  other  mammalian  species  is  able  to 
restrict  the  growth  of  replication
expressing various mammalian TRIM genes were challenged with FIV mo
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Knockdown of TRIM5 in cat cells. Small-hairpin RNAs directed to cat 
TRIM5 (feT5sh1 and 2) or negative control gene luciferase (shLuc) were transduced into 
expressing feline CD134. The resulting cells were infected with FIV GL8 and 
aliquots taken periodically and stored at -80 °C for subsequent p24 ELISA
plotted as the mean of three individual wells +/- range. No substantial 
of feT5sh1 or 2 was observed on the replication of FIV. Levels of TRIM5 RNA were 
measured by serial dilution RT-PCR (B) and appear to show a reduction in 
levels.  However  subsequent  real-time  RT-PCR  analysis  suggested  that  the  transcript 
levels were not reduced significantly, making the findings questionable.
Further confirmation of effective knockdown was sought using 
, in contradiction to Figure 4 7B, showed that TRIM5 levels were not 
reduced  substantially  in  either  the  feT5sh1  or  sh2  transduced  cells,  using 
either the same or fresh RNA samples (data not shown). The experiment could 
not be repeated due to time constraints and therefore remains inconclusive. 
Sensitivity of FIV to TRIM5α restriction 
In  order  to  test  whether  TRIM5α  from  other  mammalian  species  is  able  to 
restrict  the  growth  of  replication competent  FIV  in  vitro, 
expressing various mammalian TRIM genes were challenged with FIV mo
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hairpin RNAs directed to cat 
hLuc) were transduced into 
. The resulting cells were infected with FIV GL8 and 
for subsequent p24 ELISA (A). Data are 
substantial effect of presence 
Levels of TRIM5 RNA were 
PCR (B) and appear to show a reduction in expression 
PCR  analysis  suggested  that  the  transcript 
antly, making the findings questionable. 
Further confirmation of effective knockdown was sought using real time RT 
showed that TRIM5 levels were not 
ither  the  feT5sh1  or  sh2  transduced  cells,  using 
either the same or fresh RNA samples (data not shown). The experiment could 
not be repeated due to time constraints and therefore remains inconclusive.  
In  order  to  test  whether  TRIM5α  from  other  mammalian  species  is  able  to 
in  vitro,  CrFK  CD134  cells 
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clone CPG41. Cell free aliquots were stored at  80 °C and examined for p24 
levels  by  ELISA  (Figure  4 8).  The  results  imply  that  conserved  lentiviral 
structures  are  present  in  FIV  CA  that  permit  recognition  and  restriction  by 
diverse TRIM5 and TRIMCyp homologues. 
 
Figure  4-8  FIV  replication  can  be  inhibited  by  diverse  TRIM5  and  TRIMCyp 
orthologues. CrFK CD134 cells expressing various TRIM5α variants were tested for 
their ability to support FIV replication. All TRIM5α variants prevented replication to 
some degree but owl monkey TRIMCyp (omk), cow and rhesus macaque (rh) TRIM5α 
prevented  significant  levels  of  replication.  NC,  uninfected  negative  control;  CrFK, 
untransduced control. 
4.2.9 Evolutionary analysis of TRIM5 in the Feliformia 
In  order  to  invade  a  new  species,  retroviruses  must  be  able  to  evade 
destruction by host immune responses. The lack of antiretroviral TRIM5 in cats 
would  therefore  have  implications  for  cross species  transmission  if  the 
disabling mutation was found to be conserved between species. An analysis of 
TRIM5  from  various  Feliform  species  was  therefore  conducted  in  order  to 
determine  the  prevalence  of  the  mutation.  First,  we  compared  TRIM5 Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia
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Next,  genomic  DNA  was  prepar
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obtained from two
yield  PCR  products,  possibly  due  to  degradation  of  bra
extraction, but may be indicative of mutations in these species that do not 
permit amplification with the degenerate primers.
Common 
name 
Latin name
Domestic cat  Felis catus 
domesticus
Snow leopard  Uncia uncia
African lion  Panthera leo
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expression and identity between members of the Carnivora. 
spanning all coding exons was performed using template cDNA from domestic 
and PBMCs from diverse felids (Figure 4 9). In all cases a product 
of about 901bp indicates that expression of the transcript is maintai
felid species tested. 
TRIM5 expression is maintained in Felids. RT-PCR reveals that a TRIM5 
transcript of the same size is expressed in PBMCs from diverse felids and transcripts are 
present in commonly used domestic cat cell lines CrFK and Mya-1. 
enomic  DNA  was  prepared  from  several  species 
section  of  exon  8  was  amplified  with  degenerate  primers  (gex8T5  5’  and 
gex8T5  3’)  designed to  amplify  from  both  dog  and  cat  DNA
two species (white tailed mongoose and Africa
yield  PCR  products,  possibly  due  to  degradation  of  bra
extraction, but may be indicative of mutations in these species that do not 
permit amplification with the degenerate primers. 
Latin name  Family  Tissue 
Felis catus 
domesticus 
Felidae   
Domestic cat 
lineage 
Mya 1 T cell 
line 
Uncia uncia  Felidae – 
Panthera 
Culture PBMC
Panthera leo  Felidae   
Panthera 
Culture PBMC
(Angola 1) 
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PCR reveals that a TRIM5 
transcript of the same size is expressed in PBMCs from diverse felids and transcripts are 
1.  
ed  from  several  species  (Table  4.A)  and  a 
section  of  exon  8  was  amplified  with  degenerate  primers  (gex8T5  5’  and 
gex8T5  3’)  designed to  amplify  from  both  dog  and  cat  DNA.  Template  DNA 
species (white tailed mongoose and African civet) did not 
yield  PCR  products,  possibly  due  to  degradation  of  brain  samples  prior  to 
extraction, but may be indicative of mutations in these species that do not 
PCR product 
cell  Y 
Culture PBMC  Y 
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Cheetah  Acinonyx 
jubatus 
Felidae   
Puma lineage 
Culture PBMC  Y 
Hyena  Crocuta 
crocuta 
Hyenidae  PBMC  pellet  Y 
European 
wildcat 
Felis 
sylevstris 
Felidae – 
Domestic cat 
lineage 
Culture PBMC  Y 
White tailed 
mongoose 
Ichneumia 
albicauda 
Herpestidae  Brain  N 
African civet  Civettictis 
civetta 
Viverridae  Brain 
(hippocampu
s) 
N 
Madagascan 
fossa 
Cryptoprotca 
ferox 
Eupleridae  Whole blood  Y 
 
Mink  Mustela 
lutreola 
Mustelidae  Mv1 Lu CCL64 
cell line 
Y 
Domestic dog  Canis lupus 
familiaris 
Canidae  CLL cell line  Y 
Table 4.A Carnivoran samples for genomic DNA extraction. Exon 8 of TRIM5 was 
analysed by degenerate primer PCR using template genomic DNA extracted from the 
above tissues and cell cultures. Expected product sizes were 525bp for dog and 536bp for 
cat and amplicons were sequenced directly from gel purified PCR product. 
Sequencing  of  successfully  amplified  exon  8  fragments  revealed  that 
remarkably, all Feliform species bear the same stop codon as was found in 
domestic cat (Figure 4 10A). However, the stop codon was absent from the 
caniform species mink and dog. A phylogenetic tree of the exon 8 fragments 
(Figure  4 10B)  is  consistent  with  established  carnivore  phylogeny  (Figure 
4 10C), confirming the origin of the genomic DNA and obviating the possibility 
of PCR contamination. The sequences derived from the analysis can be found in 
Appendix 3. Chapter 4. An investigation of antiretroviral fac
 
Figure 4-10 TRIM5 truncation is conserved in all feliform species analysed.
5’ end of TRIM5 exon 8 was sequenced from genomic DNA. The location of the stop 
codon (bold) in felids means that the B30.2 is truncated before any of the co
structural motifs or variable regions. Spaces reflect codon usage except for the dog exon 
8 pseudogene sequence where it is preserved for clarity. B) A Neighbour
a 100bp region of TRIM5 exon 8 is consistent with established carnivor
confirming  the  identity  of  amplicons.
Numbers  reflect  bootstrap  values  after  1000  iterations  and  distance  is  given  as  base 
substitutions per site. C) Established phylogenetic tree of the carnivores 
2006; Gaubert and Cordeiro
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is proposed to have take
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TRIM5 truncation is conserved in all feliform species analysed.
5’ end of TRIM5 exon 8 was sequenced from genomic DNA. The location of the stop 
codon (bold) in felids means that the B30.2 is truncated before any of the co
structural motifs or variable regions. Spaces reflect codon usage except for the dog exon 
8 pseudogene sequence where it is preserved for clarity. B) A Neighbour
a 100bp region of TRIM5 exon 8 is consistent with established carnivor
confirming  the  identity  of  amplicons.  Sequences  used  are  presented  in  Appendix  3.
Numbers  reflect  bootstrap  values  after  1000  iterations  and  distance  is  given  as  base 
substitutions per site. C) Established phylogenetic tree of the carnivores 
2006; Gaubert and Cordeiro-Estrela 2006) indicates that truncation of TR
before the split of the Felidae and Hyenidae lineages. An independent TRIM5 disruption 
is proposed to have taken place on the canid lineage after the felid
The presence of the truncation in all Feliform species, but it
dog TRIM5 pseudogene, dictates that the disruption event must have occurred 
 Caniform split, estimated at 53.8 mya 
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TRIM5 truncation is conserved in all feliform species analysed. A) The 
5’ end of TRIM5 exon 8 was sequenced from genomic DNA. The location of the stop 
codon (bold) in felids means that the B30.2 is truncated before any of the conserved 
structural motifs or variable regions. Spaces reflect codon usage except for the dog exon 
8 pseudogene sequence where it is preserved for clarity. B) A Neighbour-Joining tree of 
a 100bp region of TRIM5 exon 8 is consistent with established carnivoran evolution, 
Sequences  used  are  presented  in  Appendix  3. 
Numbers  reflect  bootstrap  values  after  1000  iterations  and  distance  is  given  as  base 
substitutions per site. C) Established phylogenetic tree of the carnivores (Johnson et al. 
indicates that truncation of TRIM5 took place 
before the split of the Felidae and Hyenidae lineages. An independent TRIM5 disruption 
place on the canid lineage after the felid-canid split 53.8 myr.  
The presence of the truncation in all Feliform species, but its absence in the 
dictates that the disruption event must have occurred 
mya (Bininda Emonds et 
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disrupted gene in fossa and hyena implies that the event took place before the 
Felidae diverged from the Hyaenidae and Eupleridae 47 mya (Bininda Emonds 
et al. 1999). Thus, two independent mutations which disable TRIM5 restriction 
have  occurred  during  carnivoran  natural  history.  Although  the truncation  of 
TRIM5 is compatible with observations that cat cells lack restriction activity, 
other possibilities such as read through transcripts or the splicing of another 
gene to the 3’ end of TRIM5 cannot be ruled out. Given the recent findings that 
fusions between TRIM5 and CypA have arisen at least twice in the primates 
(Sayah et al. 2004; Virgen et al. 2008; Wilson et al. 2008; Newman et al. 2008; 
Liao et al. 2007), 3’ primers directed to feline CypA were used in conjunction 
with  various  5’  TRIM5  primers  in  RT PCR  reactions,  but  no  product  was 
detected.  All  published  sequence  downstream of  feTRIM5  was examined  for 
cyclophilin  exons  using  BLAST,  with  no  positive  matches.  Additionally,  3’ 
primers directed to TRIM22 were used in conjunction with TRIM5 5’ primers to 
detect  for  potential  read through  transcripts,  with  no  products  detected. 
Finally rapid amplification of cDNA ends (3’ and 5’ RACE) was performed to 
sequence the transcript ends without bias. No transcript other than the one 
already described was found.  
4.3 Discussion 
There is evidence of strong positive selection in primate TRIM5α B30.2 domain, 
driven by a genetic conflict or ‘arms race’ between restriction factor and virus 
within the past 33 myr (Sawyer et al. 2005; Liu et  al. 2005). The resulting 
orthologues are highly divergent in the variable domains of B30.2 and each 
have specific repertoires of restricted virus (Ohkura et al. 2006; Stremlau et al. 
2005; Nakayama et al. 2005). Non primate species also possess antiretroviral 
TRIM5α  orthologues  including  cows  (Ylinen  et  al.  2006;  Si  et  al.  2006)  and 
rabbits (Schaller et al. 2007) which also show evidence of positive selection (Si Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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et al. 2006). Thus it is likely that ancestral mammalian TRIM5α, as well as the 
ancestral carnivoran TRIM5α, possessed antiviral activity and positive selection 
of TRIM5α driven by host virus interactions may be a feature common amongst 
mammals. Therefore the findings that the Feliformia and at least one taxon in 
the  Caniformia  have  maintained  seemingly  deleterious  TRIM5  alleles  are 
surprising and in direct contrast to non carnivoran mammals, where TRIM5α 
evolution is characterised by strong positive selection and gene duplications. 
4.3.1 Implications  of  TRIM5  truncation  for  viral  transmission  and 
replication 
It  is  thought  that  escaping  TRIM5α  restriction  may  be  a  widespread 
requirement  for  retroviral  zoonosis  and  population  invasion  in  diverse 
mammalian species. Thus the loss of antiretroviral TRIM5 in carnivorans has 
implications for the evolution and cross species transmission of retroviruses. 
Dogs are currently thought to be free of exogenous retroviral infection but high 
titres of replicating FIV can be obtained in canine cells which express the FIV 
receptor  feline  CD134  (Willett  et  al.  2006a),  suggestive  of  a  lack  of 
intracellular  defence  (and  potential  vulnerability)  to  this  pathogen.  In  the 
primates, molecular phylogenies of SIV from divergent species broadly reflect 
phylogenies of the host, suggesting that cross species transmission is relatively 
rare and predominantly occurs between closely related species (VandeWoude 
and Apetrei 2006). In the felids, cross species transmission of FIV also appears 
to be relatively rare given the high levels of viral sequence divergence within 
infected species (VandeWoude and Apetrei 2006; Pecon Slattery et al. 2008a). 
However when cross species transmission events do take place they frequently 
occur  between  distantly  related  species  (Troyer  et  al.  2005).  Accordingly, 
lentiviral  evolution  in  the  felids  appears  to  more  closely  reflect  current  or 
historical geographical overlaps of species’ ranges rather than the phylogeny of Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
129 
 
the  host,  most  notably  evidenced  by  a  partition  of  phylogeny  between  old 
world and new world FIV strains which is not recapitulated in phylogenies of 
the host (Pecon Slattery et al. 2008a; Pecon Slattery et al. 2008b; Troyer et al. 
2005). For example, cross species transmission of FIV is hypothesised to have 
taken place between the distantly related lion and Asian Pallas cat (Otocolubus 
manul) sometime during the Pleistocene, when the range of lions extended to 
Asia  (Pecon Slattery  et  al.  2008a).  Additionally,  the  FIV  strains  infecting 
cheetahs and leopards are closely related, despite the host species belonging 
to divergent lineages of the felids: cheetahs belong to the Felis lineage, whilst 
leopards belong to the Panthera lineage (Johnson et al. 2006; Troyer et al. 
2005). In addition to these ancient cross genus transmissions, recent zoonoses 
of FIV have also been documented: from captive snow leopard to tiger (Troyer 
et al. 2005); from domestic cat to puma (Carpenter et al. 1996) and Japanese 
Tsushima leopard cat (Nishimura et al. 1999); and multiple transmissions of FIV 
between free ranging pumas, Florida panthers and bobcats have been reported 
(Franklin et al. 2007; Miller et al. 2006). Furthermore, experiments have shown 
that  domestic  cats  can  be  infected  with  FIV  strains  from  highly  divergent 
species including lions and pumas (VandeWoude et al. 1997a; Terwee et al. 
2005;  VandeWoude  et  al.  2003).  The  last  common  ancestor  of  these  three 
species was at the late Miocene ~10 mya during the radiation of the modern 
felid  genera.  The  ability  of  viruses  to  jump  between  relatively  unrelated 
species and the number of recent transmissions point to a lack of host defence 
to  FIV  and  is  in  contrast  to  the  primates,  where  it  has  proven  difficult  to 
develop a non human model for HIV 1 infection in all species but our closest 
relative, the chimpanzee. Thus the relative rarity of cross species transmission 
in  the  felids  appears  to  owe  more  to  lack  of  inter species  contact  than  to 
robust defences.  Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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The  absence  of  antiretroviral  TRIM5α  in  the  felids  may  have  effects  on 
lentiviral  evolution  in  this  taxon.  It  is  noteworthy  that  FIV  is  particularly 
sensitive  to  TRIM5α  and  rhTRIMCyp  and  omkTRIMCyp,  with  several  studies 
reporting high levels of FIV restriction (Schaller et al. 2007; Saenz et al. 2005; 
Virgen  et  al.  2008).  Thus  the  absence  of  TRIM5α  or  TRIMCyp  may  have 
permitted the evolution of FIV towards structural optima that would otherwise 
be strongly restricted. This hypothesis is consistent with studies of emergence 
of resistance to antiretroviral drugs, where mutants that escape the effects of 
the  drug  are  usually  less  fit  than  susceptible  strains,  when  replication  is 
compared in the absence of the drug (for a review of fitness effects of drug 
resistance  see  Martinez Picado  and  Martinez  2008).  Although  compensatory 
mutations allowing greater fitness eventually do usually occur, viruses often 
revert to wildtype once the drug treatment is ceased (Svedhem et al. 2002; 
Olivares et al. 2004). This comparison is an interesting one and future work 
detailing  the  fitness  costs  associated  with  escape  from  restriction  factors 
would  be  informative.  Conversely,  experiments  detailing  the  nature  of 
lentiviral mutants that arise in long term culture where restriction is relieved 
may also help illuminate this aspect of the host virus relationship. 
4.3.2 Possible causes of TRIM5 truncation 
Mammalian  TRIM5  has  been  shown  to  be  highly  variable  in  both  molecular 
sequence  and  in  copy  number,  with  as  many  as  eight  copies  in  the  cow 
genome. However, the evolution of non antiviral TRIM5 alleles has now been 
documented  in  several  cases  such  as:  dogs,  where  it  is  disrupted  by  the 
insertion  of  PNRC1,  preventing  expression  at  the  RNA  level  (Sawyer  et  al. 
2007);  humans,  where  a  rare,  dominant  negative  allele  encoding  a  TRIM5α 
transcript truncated at the B30.2 v1 variable loop is present in West African 
populations (Torimiro et al. 2009); Macaca nemestrina where atypical isoforms Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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have replaced TRIM5α (Brennan et al. 2007); and the Feliformia where RNA 
expression is maintained but a stop mutation prevents antiretroviral activity. 
However, the selective pressure that has caused the maintenance of inactive 
TRIM5 alleles such as these is unclear.  
One possibility is the acquisition of a novel function of a truncated TRIM5 in 
cats. In this study, transcripts of the gene were detected in cDNA derived from 
domestic cat, wildcat, lion and cheetah, indicating maintenance of TRIM5 gene 
expression. Thus felid TRIM5 may have an alternative role that does not involve 
the  B30.2  domain.  This  is  plausible  since  many  TRIM  genes  are  expressed 
without an additional C terminal domain, either through alternative splicing 
such  as  TRIM5δ  and  γ,  or  the  absence  of  a  B30.2  domain  from  the  gene 
structure,  such  as  TRIM19/PML,  and  have  diverse  or  unknown  functions 
(Sardiello et al. 2008). Indeed, the evolution of novel B30.2 lacking isoforms 
appears to be ongoing in the primates, with the discovery of TRIM5η and θ 
which appear to be unique to Macaca nemestrina (Brennan et al. 2007) and 
TRIM5 R332X in humans (Torimiro et al. 2009). Knowledge of the function of 
these truncated variants may go some way towards explaining the cause of 
multiple  independent  short  TRIM5  isoforms  in  mammals.  A  second  possible 
explanation for loss of active full length TRIM5α is an unknown cost associated 
with  its  expression.  Although  no  evidence  for  this  exists,  a  parallel  can  be 
drawn to human APOBEC3H, where destabilising mutations have arisen at least 
twice,  potentially  to  limit  exposure  of  cellular  nucleic  acids  to  a 
hypermutation inducing  enzyme  (OhAinle  et  al.  2008).  A  potential  cost 
associated  with  TRIM5α  expression  is  the  non specific  targeting  of  cellular 
proteins, although this remains speculation. Finally, it is presumed that the 
evolution  of  restriction  factors  is  sculpted  by  previous  encounters  with 
retroviruses,  thus  an  alternative  explanation  for  the  absence  of  TRIM5α 
restriction is that carnivorans were relatively unaffected by retroviruses. It is Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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noteworthy therefore that carnivorans appear to have suffered relatively little 
endogenous  retrovirus  activity  compared  to  primates:  there  are  13,000 
LTR/ERV lineage specific sequences in the dog genome compared to 133,000 in 
the human and 470,000 in the mouse genomes (Lindblad Toh et al. 2005) (the 
annotated  cat  genome  sequence  awaits  publication).  Thus  a  period  of  low 
retroviral activity early in Carnivoran evolution may have reduced the pressure 
to maintain anti retroviral TRIM5α and allowed the fixation of non reversible 
disrupting  alleles.  Although  there  are  now  several  cases  of  loss  of  antiviral 
activity, the nature of the evolutionary forces responsible may be different in 
each case, and are difficult to ascertain without knowledge of the pathogens 
that have historically affected each taxon or the function of the novel gene 
products.  
Canine cells support only low levels of restriction by exogenously expressed 
TRIM5α  (Berube  et  al.  2007),  suggesting  that either  a  required  co factor  of 
TRIM5α restriction is absent or that an endogenous dog protein is exerting a 
dominant negative effect. Since canine TRIM5 is known to be disrupted and not 
transcribed (Sawyer et al. 2007), the former explanation seems more likely. In 
contrast, feline cells, in which truncated TRIM5 is expressed and capable of 
dominant  negative  activity,  readily  support  TRIM5α  restriction  (Saenz  et  al. 
2005).  Presumably,  the  high  levels  of  expression  associated  with  eukaryotic 
expression  vectors  saturate  the  endogenous  levels  of  truncated  TRIM5, 
obscuring any dominant negative effect. The ability to host exogenous TRIM5α 
suggests that cats have maintained the as yet unidentified co factors necessary 
for restriction, whilst dogs have not. Thus it remains possible that other post 
entry restriction factors are operating in cat cells that use the same pathways. 
Interestingly,  TRIM22,  a  gene  known  to  be  upregulated  upon  interferon 
stimulation  (Rajsbaum  et  al.  2008),  is  under  adaptive  selection  in  the Chapter 4. An investigation of antiretroviral factor TRIM5 in Feliformia 
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Carnivorae  (Sawyer  et  al.  2007),  suggestive  of  a  possible  role  in  antiviral 
activity.  
4.4 Conclusions 
The lack of TRIM5α mediated post entry restriction in the carnivorans contrasts 
strongly  to  the  primates  where  TRIM5α  can  reduce  retroviral  infectivity  by 
several orders of magnitude in non permissive cells. This is thought to provide 
a barrier to transmission that must be overcome for successful invasion. Since 
primates and carnivorans are currently affected by closely related lentiviruses 
that infect and deplete similar cell populations, insight may be gained from 
direct comparisons between these taxa into the comparative role of TRIM5α 
and other restriction factors in the evolution and cross species transmission of 
lentiviruses. This will be particularly powerful upon the completion of the cat 
genome project as the nature and extent of endogenised retroviruses in the 
felids as well as the host defences may be more fully analysed. Of particular 
interest  is  the  APOBEC3  gene  family  which  has  recently  been  shown  to  be 
expanded and active in felids (Munk et al. 2008), and tetherin which appears 
increasingly to be a potent block to a broad range of enveloped viruses that 
must be overcome for successful replication (Neil et al. 2008; Jouvenet et al. 
2009). Thus the nature of these restriction factors and the extent to which 
they may compensate for TRIM5α are worthy of future study.  
Chapter 5.  The  role  of  Cyclophilin  A  in  the 
replication of feline immunodeficiency virus 
5.1 Summary 
Full levels of infectivity for HIV 1 are dependent on the host factor cyclophilin 
A (CypA), a peptidyl proline isomerase that interacts with an exposed proline 
rich loop in capsid (CA) and catalyses cis-trans isomerisation of the G89 P90 
bond. Previous studies have shown that CypA is also bound by FIV (Lin and 
Emerman 2006), but does not interact with HIV 2, SIVmac or EIAV (Yoo et al. 
1997; Braaten et al. 1996), suggesting that the interaction is widely conserved 
but not absolutely required. The role of the CA CypA interaction is not fully 
defined but may promote the viral stage known as uncoating – a post entry 
restructuring  of  viral  components  that  promotes  reverse  transcription  and 
entry  to  the  nucleus.  For  primate  lentiviruses,  the  affinity  of  the  CA CypA 
interaction appears to be maintained within a narrow window, even in mutants 
that are able to replicate under conditions of CypA inhibition (Yoo et al. 1997; 
Ylinen et al. 2009). To investigate the effects of CA CypA inhibition for FIV, 
replicating virus and pseudotyped FIV particles are used to demonstrate that 
like HIV 1, inhibition of CypA prevents full levels of infectivity and that CypA is 
required during post entry stages of the lifecycle. We next ask whether the 
affinity of the CA CypA interaction is conserved between primate and feline Chapter 5. The role of CypA in the replication of FIV 
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lentiviruses, and find that for a domestic cat strain of FIV, binding affinity to 
its cognate CypA is almost identical to that reported for HIV 1. Examination of 
a non domestic strain of FIV isolated from lions (FIV Ple, also known as LLV) 
possesses a higher affinity for CypA.  
CypA can also play a part in post entry restriction: rhesus macaque TRIM5α 
restricts HIV 1 more readily when CypA is present, suggesting that structural 
changes  induced  by  the  isomerase  activity  are  better  recognised  by  the 
restriction factor (Keckesova et al. 2006; Berthoux et al. 2005; Stremlau et al. 
2006a). To assess the sensitivity of FIV to promotion of TRIM5α restriction by 
CypA,  FIV  pseudotypes  were  used  to  demonstrate  a  cell  type dependent 
decrease  in  infectivity  associated  with  CypA  inhibition  in  human  cells. 
However, TRIM5α restriction of FIV is only weakly enhanced by CypA inhibition 
and TRIM5 is non functional in cat cells, indicating that FIV does not use the 
CA CypA interaction to protect from TRIM5α, and suggesting, more generally, 
that lentiviral CA CypA interaction is maintained even in the absence of TRIM5. 
TRIM5 CypA fusion proteins in rhesus macaques (rh) and owl monkeys (omk) are 
able to strongly restrict lentiviral replication (Wilson et al. 2008; Sayah et al. 
2004; Newman et al. 2008; Virgen et al. 2008). Mutations in the rhTRIMCyp 
cyclophilin domain D66N and R69H remodel the interacting surface by causing a 
change from ‘open palm’ to ‘closed fist’ conformation, resulting in a change in 
specificity from viruses that interact with CypA (e.g. HIV 1) to viruses that do 
not (e.g. HIV 2; Price et al. 2009). Uniquely, FIV is restricted strongly by both 
rh  and  omk  variants,  suggesting  an  alternative  binding  mechanism  for  this 
virus. ITC was performed to confirm that FIV capsid N terminal domain (CA
N) is 
able to bind the mutant rhTRIMCyp cyclophilin domain. To investigate how FIV 
is able to interact with both Cyp variants, crystal structures of FIV CA
N were 
solved and showed that FIV has a shortened proline rich loop that is displaced Chapter 5. The role of CypA in the replication of FIV 
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relative to the HIV 1 loop by ~15Å and hence is unaffected by the change from 
‘closed fist’ to ‘open palm’ conformation. We next asked how FIV is able to 
interact with CypA at a similar affinity to HIV 1, given that its proline rich loop 
is substantially shorter and its binding surface is therefore reduced. Structure 
guided  models  were  used  to  predict  that  FIV  CA  R89  makes  stabilising 
hydrophobic and cation π interactions with the CypA hydrophobic pocket. In 
support of this model, mutagenesis of this residue negatively impacts binding 
affinity.  In contrast, mutation  of  P90  was  found  to completely  ablate  CypA 
binding  in  findings  reminiscent  of  HIV 1.  However,  unlike  its  primate 
counterpart, the P90A mutant is found to be non functional in tissue culture 
assays,  suggesting  critical  structural  significance.  Finally,  an  alternative 
potential binding partner, Ranbp2, located at the nuclear pore is identified 
that bears a cyclophilin domain. FIV CA is found to interact with this protein in 
immunoblotting  assays,  and  the  potential  for  future  work  on  this  binding 
partner is discussed.  
The  study  finds  that  diverse  lentiviruses  have  a  conserved  interaction  with 
CypA that is beneficial to both HIV and FIV in cells of their respective hosts. 
The affinity of the interaction is maintained within a narrow range despite the 
highly divergent structure of the proline rich loops. FIV is proposed to bind 
cyclophilin in a manner that allows promiscuous binding to both rhTRIMCyp and 
cytosolic free CypA. This mechanism is supported by structural and biophysical 
data.  
5.2 Results 
5.2.1 Identification of feline CypA  
An  analysis  of  the  nascent  cat  genome  project  (Pontius  and  O'Brien  2007) 
revealed the presence of two regions with high CypA homology, present in BAC Chapter 5. The role of CypA in the replication of FIV 
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clones/contigs AC235013 and AANG01610851. To establish whether the genes 
are expressed in cat cells, total RNA was extracted from Mya 1 cells and RT 
PCR using primers specific to each CypA was performed. Products were cloned 
into  prokaryotic  expression  vector  pOPTH  and  sequencing  confirmed  100% 
identity to published genomic sequences. Interestingly, the AC235013 sequence 
bears an arginine to cysteine substitution at position 69; this position is known 
to  switch  the  specificity  of  rhesus  TRIMCyp  restriction  from  HIV 1  to  HIV 2 
(Wilson et al. 2008; Virgen et al. 2008). However, when RNA preps were DNase 
treated  before  reverse  transcription,  amplification  of  the  gene  encoded  by 
AC235013 was no longer successful, suggesting that previous amplification was 
from contaminating genomic DNA. In contrast, amplification of AANG01610851 
CypA (bearing R69) was DNase resistant, indicating that the latter is expressed 
in cat cells, confirming it as the biologically relevant version.  
An  alignment  of  feline  and  human  (NM_021130)  CypA  reveals  97%  identity 
between the homologues (Figure 5 1), suggestive of highly conserved structure 
and function. In contrast, FIV and HIV 1 CA share only partial homology with 
29% identical residues, reducing to 23% in the N terminal domain (CA
N) (Figure 
5 2A). The sequence of the proline rich loop is highly divergent, with the FIV 
loop shorter by four residues. Given this high level of sequence divergence, the 
finding that both capsids bind the relatively invariant CypA (Lin and Emerman 
2006)  is  therefore  interesting  as  it  suggests  that  either  the  capsids  share 
conservation  of  structure  despite  divergent  primary  sequences,  or  that  the 
capsids use alternative mechanisms to interact with CypA. Amongst strains of 
FIV, homology of CA
N is substantially higher at 53% identical and 70% conserved 
residues  (Figure  5 2B).  Conservation  is  almost  total  within  the  proposed 
proline rich  loop,  suggesting  a  biologically  important  and  conserved 
interaction.  Chapter 5. The role of CypA in the replication of FIV 
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Figure 5-1 Human and feline CypA share 97% identical residues. Beta strands are 
denoted by arrows and helices are denoted by cylinders. Residues F60, M61, F113 and 
L122 which create the substrate-binding hydrophobic pocket are marked by black bars. 
Large functional differences between the CypA homologues are unlikely given the high 
levels of identity. Identical residues in grey. 
 
 
Figure  5-2  Alignment  of  lentiviral  capsid  sequences.  A)  FIV  and  HIV-1  CA  N-
terminal domains show substantial variation (23% identical residues, 43% conserved). 
Secondary structures are shown for HIV-1 CA, with arrows representing beta strands and 
cylinders  representing  alpha-helices  (numbered  for  HIV-1).  The  proline-rich  loop 
between helices 4 and 5 is present in both sequences (single bar) but is highly divergent 
in both its length and primary sequence. The nature of the isomeric peptidyl-proline bond 
(double bar) is also divergent, with FIV possessing RP compared to HIV-1’s GP. B) 
Capsid sequences from FIV strains isolated from diverse host species show substantial Chapter 5. The role of CypA in the replication of FIV 
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conservation throughout CA and show high levels of conservation in the proline-rich 
loop.  P90,  shown  to  be  crucial  for  CypA  interaction  and  proposed  site  for  cis-trans 
isomerisation (Lin and Emerman 2006) is indicated with a double bar. 
5.2.2 Biological effects of FIV CA CypA interaction 
The  inhibitor  of  the  CA CypA  interaction,  cyclosporine  A  (CsA),  is  an 
immunosuppressant  that  interferes  with  the  intracellular  T cell  activation 
pathway.  CsA  analogues  NIM811  and  Debio 025  were  designed  as  non 
immunosuppressive CsA analogues that do not provide the calcineurin binding 
surface when complexed with CypA. The drugs were assayed for their toxic 
effect on activated feline T cells Mya 1 (Miyazawa et al. 1989) and on naive 
CD3+ T cell line CLL (Willett et al. 2006a) (Figure 5 3). Mya 1 cell viability was 
found  to  be  substantially  reduced  after  5  days  incubation  with  2μM  CsA, 
whereas NIM811 and Debio 025 showed a reduced toxic effect. CLL cells were 
largely unaffected by the presence of the drugs, as is expected given their lack 
of mitogen stimulation and activation.  
 
Figure 5-3 Relative toxicity of CypA-binding drugs. Cell viability was measured after 
5 days incubation in 2μM drug or solvent only (ethanol). For stimulated T-cell line Mya-
1, CsA was found to exert a 67% reduction on the percentage of viable cells, compared to 
a  27%  reduction  by  non-immunosuppressive  Debio-025.  In  contrast,  CLL  cells Chapter 5. The role of CypA in the replication of FIV 
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transduced  with  feline  CD134  were  found  to  be  unaffected  by  any  of  the  drugs, 
indicative of their naive state.  
The ability of FIV to replicate in the presence of CsA and its analogues was 
assayed by challenging CLL CD134 and Mya 1 with FIV Fca GL8 (Figure 5 4). In 
both CLL and Mya 1, a reduction in FIV replication was seen upon the addition 
of  inhibitors,  suggesting  that  the  CA CypA  interaction  is  important  for 
replication of FIV. Inhibition of replication was more pronounced in Mya 1, in 
particular with CsA, an effect presumably due to the toxicity effects of the 
inhibitors on Mya 1 cell viability.  
 
Figure  5-4  Inhibitors  of  the  CA-CypA  interaction  impair  FIV  replication.  CLL 
CD134 and Mya-1 cells were challenged with FIV-Fca GL8 and incubated with CsA and 
its  analogues  NIM811  and  Debio-025  at  2 M.  Supernatant  aliquots  were  frozen  and 
subsequently  analysed  for  reverse  transcriptase  activity.  A  repeatable  decrease  in  RT 
activity was observed in the presence of the inhibitors, suggesting that the CA-CypA 
interaction is important for replication of FIV.  
 For HIV 1, the effects of the CA CypA interaction are manifest during the early 
post entry  stage  of  replication  (Towers  et  al.  2003).  To  establish  at  which Chapter 5. The role of CypA in the replication of FIV 
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stage of replication the CA CypA interaction is important in the FIV lifecycle, 
the drugs were added to cells transfected with FIV GFP(VSV) encoding plasmids 
(virus  production)  or  to  target  cells  (virus  entry).  When  added  during  virus 
production,  supernatant  was  subsequently  pelleted  through  a  20%  sucrose 
cushion to remove traces of the inhibitor (Figure 5 5). A small non significant 
increase  in  titre  (two tailed  t-test;  p  =  0.094  for  control  vs  2μM  CsA)  was 
observed when inhibitors were added during virus production. A similar effect 
is seen in HIV 1 production in human cells, with a ~10% increase in viral titre 
reported  by  Towers  et  al.  (2003).  However,  during  viral  entry,  a  13 27% 
decrease in titre was observed at 0.5μM inhibitor that was significant (two 
tailed t-test; CsA p = 0.012; NIM811 p = 0.018; Debio 025 p = 0.0008 for control 
vs 0.5μM inhibitor). Although small in magnitude, repeated over several cycles 
of  infection,  this  decrease  in  titre  could  substantially  reduce  the  titre  of 
replicating virus and is likely to be the cause of the reduced replication of FIV 
in Figure 5 4. We can therefore conclude that CypA acts as a cofactor for viral 
replication in cells of its host and that CypA exerts its effect post entry, early 
in the lifecycle. The findings are reminiscent of HIV 1, but of a much lower 
magnitude: HIV 1 pseudotype infectivity is reduced approximately three fold 
during early replication stages of infection in human Jurkat and TE671 cells 
(Towers  et  al.  2003;  Hatziioannou  et  al.  2005).  However,  for  HIV 1,  CsA 
treatment is proposed to increase susceptibility to an unidentified restriction 
factor in human cells (Keckesova et al. 2006; Sokolskaja et al. 2006) so much 
of the decrease in infectivity may be attributed to this factor. Chapter 5. The role of CypA in the replication of FIV 
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Figure 5-5 Effect of CypA inhibitors on FIV pseudotype production and entry. A) 
293T cells, transfected with FP93, GinSin and VSV-G expressor MDG were incubated 
with CypA inhibitors. Viral supernatant was pelleted over a sucrose cushion to remove 
inhibitors and titrated onto CrFKs at an moi of ~0.1. A small but non-significant increase 
in titre was observed for both CsA and NIM811. B) FIV-GFP(VSV) pseudotypes were 
titrated onto CrFKs pre-incubated with CypA inhibitors at an moi of ~0.1. A significant 
decrease in titre was seen for 0.5μM of all the drugs, an effect that seemed to diminish as 
concentrations increased further. A toxic effect of NIM811 on CrFK cells was observed 
at 4 μM and no data was recorded for these samples. n = 3. 
Restriction of HIV 1 by rhesus macaque TRIM5α is enhanced by the presence of 
CypA, suggesting that CypA perfoms a catalytic role that promotes the TRIM5α 
CA interaction (Keckesova et al. 2006; Berthoux et al. 2005; Stremlau et al. 
2006a).  In  contrast,  in  humans  cells  it  is  probable  that  CypA  both  aids  in 
uncoating and protects HIV 1 from an unidentified post entry restriction factor 
(Keckesova et al. 2006; Sokolskaja et al. 2006). To assess whether CsA affects 
huTRIM5α mediated or other restrictions of FIV in human cells, FIV GFP(VSV) 
pseudotypes were titrated onto human TE671 and HeLa cells in the presence of 
CsA or solvent only (Figure 5 6). In TE671 cells, no change in FIV infectivity was 
observed, suggesting that in these cells FIV is not targeted by the unidentified 
human factor, nor does the CypA CA interaction alter the huTRIM5α mediated Chapter 5. The role of CypA in the replication of FIV 
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restriction of FIV. However, in HeLa cells, which are known to express much 
higher  levels  of  CypA,  a  much  lower  level  of  infection  is  achieved,  which 
reduces further on the addition of CsA. Although the causes of these cell type 
specific responses are unknown, by analogy with HIV they suggest a role for 
CypA in either uncoating or protection from restriction factors. 
 
Figure 5-6  Differing effects of CsA treatment on FIV infectivity in human cells. 
TE671 and HeLa cells, which express low and high levels of CypA respectively, were 
infected with FIV (VSV)-pseudotyped particles in the presence or absence of CsA. The 
results  suggest  that  in  HeLa  cells,  CypA  aids  in  FIV  infectivity,  possibly  by  aiding 
uncoating or protecting from a restriction factor such as TRIM5α.  
To investigate whether restriction of FIV by TRIM5α can be modulated by the 
CA CypA  interaction,  CrFK  cells  transduced  with  huTRIM5α  were  challenged 
with FIV luc(VSV) pseudotypes (Figure 5 7). An approximately 10 fold reduction 
in  titre  is  observed  in  cells  expressing  huTRIM5α,  and  a  reduction  in  titre 
associated with addition of CsA is more pronounced in the presence of TRIM5α. 
However the magnitude of the change is small, and given that TRIM5 is non 
functional as a restriction factor in cat cells (Chapter 4; McEwan et al. 2009), 
the FIV CA CypA interaction is unlikely to have evolved for this purpose.  Chapter 5. The role of CypA in the replication of FIV 
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Figure 5-7 Effect of CsA and TRIM5α on FIV infectivity. CrFK cells transduced with 
human TRIM5α were challenged with FIV-luc(VSV) pseudotypes. TRIM5α reduces FIV 
infectivity by an order of magnitude. CsA has a greater effect on the infectivity in the 
presence  of  TRIM5α,  suggesting  that  isomerase  activity  of  CypA  may  protect  FIV 
slightly from TRIM5α-mediated restriction. However, FIV has evolved in the absence of 
functional  TRIM5α  (Chapter  4;  McEwan  et  al.  2009),  making  deliberate  evasion  of 
restriction by this mechanism an unlikely biological scenario. 
5.2.3 ITC reveals lentiviral CA CypA affinity to be conserved 
To investigate the binding properties of FIV capsid for CypA, the CA
N of FIV Fca 
and FIV Ple E Sangre as well as domestic cat and lion CypA genes were cloned 
into prokaryotic expression vector pOPTH and recombinant His tagged proteins 
were purified by Ni affinity chromatography. Further purification of proteins 
was  performed  by  ion  exchange  chromatography  and,  for  CA
N  constructs, 
subsequent  gel  filtration  (see  Materials  and  Methods).  The  proteins  were 
prepared for isothermal titration calorimetry assays that measure the change 
in enthalpy associated with intermolecular interactions when CypA is titrated 
into CA
N (Figure 5 8 and Table 5.A). The analysis reveals that FIV Fca CA
N binds 
its cognate CypA partner with a stoichiometry of 1:1 and a Kd of 6.2 μM, a Chapter 5. The role of CypA in the replication of FIV 
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figure that compares closely to HIV 1 CA CypA interaction of 5.3 μM. FIV Ple 
CA
N  was  found to  bind  lion  CypA  with  a  slightly  higher  affinity,  at  2.2  μM. 
Changing the species of the CypA had little effect on the Kd, suggesting that as 
predicted,  the  species specific  differences  between  feline  and  human  CypA 
have little effect on the interaction. 
 
Figure 5-8 Isothermal titration calorimetry reveals FIV to bind CypA. Example trace 
of ITC shows heat associated with multiple injections of CA
N into cell bearing cat CypA. 
The  reaction  has  a  stoichiometry  (N)  of  approximately  1:1,  Kd  of  6.2μM  and  is 
exothermic, ΔH = -8579 cal/mol. 
  Cat CypA  Lion CypA  Human CypA 
FIV-Fca  6.2  7.8  7.2 
FIV-Ple  1.9  2.2  3.0 
HIV-1  n.d.  n.d.  5.3 
Table 5.A Binding constants for capsid and CypA variants. Various CA
N domains 
were assessed for their ability to bind CypA. Shown are Kd values in  M. FIV-Ple is 
found to have the highest binding affinity at 2.2μM for its cognate CypA, whilst FIV-Fca Chapter 5. The role of CypA in the replication of FIV
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affinity of the interaction, and all interactions were within a narrow range of 2
5.2.4 Structural analysis of feline cyclophilin A
The  similarity  of  binding  constants  between  human  and  feline  CypA  are  in 
accordance with the high levels of 
structure  of  feCypA  was  solved  and  reveals  almost  total  conservation  of 
structure  around  the  hydrophobic  pocket  (
substitutions between t
Figure 5-9 Superimposed structure
structure of feline CypA (light blue) was solved and superimposed on published hu
CypA (white) structure bound to HIV
in green; PDB: 1AK4). Around the hydrophobic pocket, which interacts with HIV
structural conservation is high. A rotated view (right) shows feline mutations I5, D23, 
D84 and M131 (sticks) to be on the posterior and lateral surfaces, making substantial 
differences in biological activities of human and feline CypA unlikely.
5.2.5 FIV interacts with both CypA and rhesus TRIMCyp
The cyclophilin domain of rhesus macaque TRIMCyp b
relative to wildtype CypA that alter its specificity from HIV
. The role of CypA in the replication of FIV 
1 Kd values are very similar. Changing the CypA variant had littl
affinity of the interaction, and all interactions were within a narrow range of 2
Structural analysis of feline cyclophilin A 
The  similarity  of  binding  constants  between  human  and  feline  CypA  are  in 
accordance with the high levels of similarity between these proteins. A crystal 
structure  of  feCypA  was  solved  and  reveals  almost  total  conservation  of 
structure  around  the  hydrophobic  pocket  (Figure  5 9).  The  four  amino  acid 
substitutions between the species are found on the distal surfaces.
Superimposed structures of human and feline cyclophilin A.
structure of feline CypA (light blue) was solved and superimposed on published hu
CypA (white) structure bound to HIV-1 capsid (proline-rich loop AGPIAP motif shown 
PDB: 1AK4). Around the hydrophobic pocket, which interacts with HIV
structural conservation is high. A rotated view (right) shows feline mutations I5, D23, 
D84 and M131 (sticks) to be on the posterior and lateral surfaces, making substantial 
differences in biological activities of human and feline CypA unlikely.
FIV interacts with both CypA and rhesus TRIMCyp
The cyclophilin domain of rhesus macaque TRIMCyp bears two point mutants 
relative to wildtype CypA that alter its specificity from HIV
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affinity of the interaction, and all interactions were within a narrow range of 2-8  M. 
The  similarity  of  binding  constants  between  human  and  feline  CypA  are  in 
similarity between these proteins. A crystal 
structure  of  feCypA  was  solved  and  reveals  almost  total  conservation  of 
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of human and feline cyclophilin A. A crystal 
structure of feline CypA (light blue) was solved and superimposed on published human 
rich loop AGPIAP motif shown 
PDB: 1AK4). Around the hydrophobic pocket, which interacts with HIV-1, 
structural conservation is high. A rotated view (right) shows feline mutations I5, D23, 
D84 and M131 (sticks) to be on the posterior and lateral surfaces, making substantial 
differences in biological activities of human and feline CypA unlikely. 
FIV interacts with both CypA and rhesus TRIMCyp 
ears two point mutants 
relative to wildtype CypA that alter its specificity from HIV 1 CA binding to Chapter 5. The role of CypA in the replication of FIV 
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HIV 2 binding (Price et al. 2009). Substitutions D66N and R69H result in a 15Å 
remodelling  of  a  10 residue  lobe  to  give  the  closed  fist  conformation  and 
precluding HIV 1 CA binding. FIV is unique in that it can be restricted by both 
owl  monkey  TRIMCyp,  whose  CypA  domain  resembles  wildtype  CypA,  and 
rhTRIMCyp.  To  formally  demonstrate  FIV  CA rhTRIMCyp  binding,  ITC  was 
performed using CA
N and the Cyp domain of rhTRIMCyp and, as predicted an 
interaction was observed. However, suggestions that FIV’s high sensitivity to 
rhTRIMCyp restriction may be due to high binding affinities were unfounded as 
the Kd was found to be lower than for feCypA (Table 5.B), suggesting that the 
sensitivity is achieved through other means. 
  Cat CypA  rhTCyp 
FIV-Fca  6.2  10.9 
FIV-Ple  1.9  7.3 
Table  5.B.  Binding  constants  for  FIV  CA
N-rhesus  TRIMCyp.  FIV  is  particularly 
sensitive  to  restriction  by  rhesus  macaque  TRIMCyp  (Virgen  et  al.  2008),  but  the 
sensitivity is not conferred by a higher affinity interaction between CA and rhTRIMCyp 
compared to CypA. 
5.2.6 Crystal structure of FIV capsid  
Despite being highly divergent at the protein level, HIV 1 and FIV both interact 
with CypA at affinities within a small range of Kd values. Especially interesting 
is the conformation of the highly divergent predicted proline rich loop raising 
interesting questions about the comparative structures. Do FIV and HIV 1 share 
a similar structure in order to interact with CypA or is binding by FIV achieved 
via a different mechanism? And what is the basis of FIV’s dual specificity for 
CypA and rhTCypA? In order to address these questions, a crystal structure of 
FIV CA
N was sought and solved to a resolution of 2.3Å.  Chapter 5. The role of CypA in the replication of FIV 
148 
 
The  structure  of  FIV  CA
N  is  the  first  published  to  date.  Comparison  of  the 
structure with HIV 1 capsid (1AK4; Gamble et al. 1996) reveals a remarkably 
conserved  wedge shaped  structure,  with  the  proline rich  loop  extending 
outwards  between  helices  4  and  5  (Figure  5 10).  The  α helices  display  a 
strikingly  similar  orientation  in  most  regions  of  the  protein,  representing 
conserved exposed regions of capsid core meta structure. One particular region 
of dissimilarity is in the FIV region corresponding to HIV 1 helices 5 and 6 which 
appear  to  be  fused  creating  a  longer  kinked  C terminal  helix.  The  α 6  α 7 
linker region in HIV 1 bears a proline proline dipeptide that re orientates the 
strand the downwards into the α 6 helix. This linker region, including the PP 
dipeptide, is missing in FIV, resulting in the enlarged fusion helix.  Chapter 5. The role of CypA in the replication of FIV
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Figure 5-10 Superimposed structure of FIV and HIV-1 capsid N-terminal domains. 
Despite only 23% identical residues, FIV (dark red) and HIV-1 (1AK4) (grey) capsids 
share  remarkable  structural  conservation,  characterised  by  a  wedge-shaped  structure 
comprising the major helices 1, 2, 3, 4 and 7 (HIV-1 numbering) with a proline-rich loop 
extending outwards between helices 4 and 5. The side chains in the crest of the proline-
rich loops are shown as sticks (FIV: 87GPRPL91 , HIV-1: 89GPIAP93, isomerised bond 
underlined) and reveal FIV to have a divergent loop that is displaced by ~13Å. A side 
view (below) clearly shows the fusion of helices 6 and 7 that creates the larger FIV N-
terminal α-helix. 
5.2.7 Proline rich loop mutants identify important residues in the CA 
CypA interaction 
As is evident from the primary sequence alignment, the proline rich loop for 
FIV is considerably shorter than in HIV 1, raising interesting questions about 
how the shorter FIV loop is still able to bind CypA. To address this issue, two 
alternative methods were employed. Firstly, it was  attempted to crystallise 
CA
N CypA complexes. CA
N and huCypA as well as CA
N and rhTCypA were mixed 
at  1:1  molar  ratio  and  run  on  a  gel  filtration  column  to  purify  the  larger, 
complexed species. However, crystallisation of the complex was unsuccessful 
with  only  uncomplexed  CA
N  or  CypA  crystals  forming.  Secondly,  it  was 
attempted to use 4 mer or 5 mer oligopeptides corresponding to the proline 
rich loop of FIV CA with feCypA to grow complexed crystals. However, initial 
ITC experiments to confirm binding of the peptides were unable to show an 
interaction. A crystal screen was performed nonetheless and yielded crystals 
for the 4 mer peptide. Subsequent X ray diffraction revealed that the peptide 
had not bound, with the symmetric unit comprising only feCypA.  
A model of the FIV CA CypA interaction was therefore made by superimposing 
the CA structure on HIV 1 CypA structure. The model suggests that the short 
FIV proline rich loop has a reduced region of contact with CypA, not extending Chapter 5. The role of CypA in the replication of FIV
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CypA interaction, and provides some insight as to why FIV and HIV 1 diverge at 
this residue. In contrast, mutating the P90 residue to alanine was found to 
prevent detectable interaction with CypA, indicating the structural importance 
of this residue. A P90A mutant of replication competent FIV molecular clone, 
as  well  as  pseudotyped  mutant  was  also  generated  but  unlike  HIV 1  where 
mutating P90 prevents the CypA interaction but allows infection, the FIV P90A 
mutants were found to be non functional. This finding has been repeated by 
others (G. Towers, personal communication) but is in contradiction to Lin and 
Emerman (2007) who were able to produce viable pseudotype with the P90A 
mutation. The discrepancy is potentially explained by the use of alternative 
strains of FIV (Lin and Emerman used 34TF10, whereas this study used GL8) but 
suggests that in the GL8 background, P90 is structurally integral to capsid’s 
function.  
 
 
Table 5.C Binding affinity for FIV CA mutants with cat CypA. CA
N mutants R89G, 
which is hypothesised to contribute to the binding of the CypA catalytic domain through 
cation-π interactions, and P90A, which is proposed to be the site of cis-trans isomerase 
activity,  were  assayed  for  their  ability  to  bind  cat  CypA  by  ITC.  As  predicted,  R89 
contributes to the strength of interaction with Cyp as mutation to the corresponding HIV-
1  residue  glycine  reduces  binding  affinity  substantially.  Mutation  of  P90  prevents 
detectable interaction. 
Structure guided models were used to assess how FIV is able to interact with 
both wildtype CypA and rhTRIMCyp. The model suggests that that the shorter 
FIV proline rich loop is deflected away from the 66 73 loop by a kink generated 
by  proline  85,  so  that  when  bound  to  rhTRIMCyp  with  its  ‘closed  fist’ 
conformation, the 66 73 loop does not interfere with binding (Figure 5 12). 
  Kd (μM) 
FIV-Fca WT  5 
FIV-Fca R89G  21 
FIV-Fca P90A  None detected Chapter 5. The role of CypA in the replication of FIV
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This  study  shows  that  whilst  FIV’s  proline rich  loop  is  highly  conserved, 
disruption of the interaction only impacts marginally on infect
However, mutation of P90 ablates binding and appears to prevent replication. 
This effect is probably best explained by structural abnormalities in the mutant 
protein that prevent proper function, rather than by functional differences of
CypA binding. Curiously, an alignment of diverse lentiviruses capsids reveals 
rich  loop is  present not  only  in those  viruses  with confirmed 
CypA binding but also those confirmed as non binding. It is also noteworthy 
that naturally occurring HIV 1 isolates are found which are insensitive to CsA, 
again  suggesting  that  the  interaction  is  dispensable  (Chatterji  et  al.  2005; 
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Figure 5-13 The presence of a proline-rich loop is not a feature unique to viruses 
which bind CypA. Alignment of amino acid sequences to HIV-1 shows that a proline-
rich region is present in HIV-2 which does not bind CypA and is even present in EIAV. 
Y or N indicates studies demonstrating CypA  binding or its absence;  HIV-1 domain 
architecture is shown.  
These  observations  support  the  hypothesis  that  the  primary  function  of  the 
proline rich  loop  is  to  interact  with  an  alternative  protein  that  resembles 
CypA, as this would explain the close resemblance to the CypA binding loop in 
viruses  such  as  HIV 2.  A  search  was  therefore  carried  out  for  genes  which 
contain a CypA domain, and that might be important for post entry stages of 
the  lifecycle.  Most  notably,  a  protein  was  identified  in  a  BLAST  search  of 
human RefSeq protein sequences that bears a domain closely related to CypA, 
named Ranbp2 or Nup358. Ranbp2 is a large (358 kDa) protein located at the 
nuclear  membrane  that  is  involved  in  conversion  of  RanGTP  to  RanGDP,  a 
process  important  for  translocation  of  cellular  proteins  across  the  nuclear 
membrane.  Consistent  with  a  possible  role  in  the  lentiviral  lifecycle,  the 
protein has been identified in three out of four whole genome siRNA screens as 
a  necessary  cofactor for  HIV  replication  (Bushman et  al.  2009;  Konig  et al. 
2008; Brass et al. 2008; Ranbp2 was not identified in Zhou et al. 2008). An 
obvious potential role of Ranpb2 is interaction with capsid present in the RT 
complex to facilitate entry to the nucleus, a requirement for replication in 
non dividing  cells.  However,  being  a  major  component  of  the  nuclear  pore 
complex, it is unclear whether knockdown of Ranbp2 specifically prevents HIV 
1 nuclear import or simply structurally compromises the nuclear pore.  Chapter 5. The role of CypA in the replication of FIV
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Figure 5-14 Far-western blot using full length FIV capsid.
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A method known as far western blot (or overlay assay) was optimised based on 
an  established  protocol  (Einarson  et  al.  2007)  that  allows  identification  of 
cellular binding partners for specific proteins. In this case the technique uses 
recombinant CA protein to probe renatured SDS PAGE proteins displayed on a 
nitrocellulose  membrane  and  subsequent  immunoblotting  for  CA
tagged  FIV  capsid  (entire  protein)  to  probe  membranes 
bearing HeLa and CrFK nuclear and cytoplasmic fractions, a series of bands 
could be detected that are likely to represent cellular binding
14). Several of these bands are conserved in size between cat 
and human cells, most notably the bands at ~55 and ~65 kDa, whilst others 
appear to be species  and subcellular location specific. In cat cells these were 
specific bands at ~350 kDa and ~170 kDa and CrFK nucleus and 
cytoplasmic band at ~110 kDa. In human cells, these were 
band at ~100 kDa, and predominantly cytoplasm specific band at ~13
 
western blot using full length FIV capsid. Probing fractionated cell 
lysates with FIV capsid demonstrates that the far-western technique can identify potential 
protein binding partners in CrFK (cat) and HeLa (human) cells. Some proteins identified 
have conserved size between the species, for example the bands present at ~55 and 65 
kDa,  whilst  others  appear  species-specific  but  may  represent  species
variations or isoforms of same protein.  
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The  N terminal  domain  of  CA  bears  the  proline rich  loop  responsible  for 
interacting with CypA. It was therefore decided to use CA
N, in order to identify 
bands which only interact with this domain (Figure 5 15). Human cell lysate 
was found to interact with FIV CA
N at ~130 kDa and a doublet at ~65 kDa. The 
bands at 55 and 110 kDa were no longer present, perhaps indicative of a CA C 
terminal specific interaction. The human cell lysate was also probed with α 
Ranbp2 polyclonal antibody and found to identify the same bands at ~130 kDa 
and a doublet at 65 kDa. The data therefore represent strong evidence that FIV 
CA can interact with Ranbp2. However, bands at the expected Ranbp2 size of 
358 kDa were faint or not identified. This suggests that the protein is perhaps 
poorly transferred to the membrane in its full size and the bands indentified 
are likely to be either Ranbp2 isoforms or products of proteolysis. The P90A 
mutant, previously shown to be non functional for replication and unable to 
bind CypA, was found to identify the same bands. The result is surprising given 
the hypothesised lack of interaction for this protein. One possible explanation 
for this binding is the large excess of CA used to probe the membrane and the 
non stringent binding conditions may have allowed complete saturation of the 
sites  available  for  binding  on  the  membrane.  Further  optimisation  of  this 
technique may allow detection of bands of differential intensity that better 
reflect the binding affinity. Chapter 5. The role of CypA in the replication of FIV
 
Figure 5-15 FIV capsid and 
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FIV capsid and α-Ranbp2 antibodies interact with proteins of the same 
Western blot (WB) on 293T cell lysate with α-human Ranbp2 identifies a band at 
~130 kDa and a doublet at ~65 kDa, when probed with an α-rabbit IgG secondary Ab. 
exactly the same size as those identified by FIV CA
blot  (FW)  with  detection  by  mouse  α-CA  and  α-mouse  IgG  secondary.  Contrary  to 
expectation, the FIV CA mutant P90A was also found to interact with proteins of the 
Discussion 
s study demonstrates that FIV, like the primate lentiviruses
and is modulated by host factor cyclophilin A. Like HIV 
host,  disruption  of  the  interaction  with  CsA  or  its  non
analogues prevents full levels of infectivity in both replicating viruses and in 
entry  stages  of  pseudotype  infection.  FIV  also  displays  a  cell
dependent  CypA  dependence  in  human  cells.  The  precise  nature  of  this 
relationship is unclear but suggests that FIV is sensitive t
CypA given that HeLa cells have been shown to express high levels of CypA 
(Ylinen  et  al.  2009).  Possible  mechanisms  of  CypA’s  positive  role  in  FIV 
replication include aiding uncoating, as has been hypothesised for HIV
preventing restriction by other cellular factors. Sensitivity of FIV to huTRIM5α 
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is modestly increased by treatment with CsA, suggesting that in this system 
CypA  can  protect  against  restriction.  In  contrast  restriction  of  HIV 1  by 
rhTRIM5α is promoted by CypA (Keckesova et al. 2006; Berthoux et al. 2005; 
Stremlau  et  al.  2006a).  The  best  current  model  of  the  effects  of  CypA  on 
lentiviral infectivity suggests that CypA performs a catalytic isomerisation that 
alters  capsid  conformation  which  subsequently  alters  the  ability  of  other 
cellular restriction factors to recognise and destroy incoming capsid (Towers 
2007; Luban 2007). This suggests that in the context of TRIM5α, where binding 
is mediated by variable domains in the B30.2 domain, its ability to bind and 
restrict can be modulated by CypA (potentially increasing rhTRIM5α’s affinity 
for  HIV 1;  decreasing  huTRIM5α’s  affinity  for  FIV).  Although  CypA  has  been 
shown to perform such a catalytic role on CA in vitro, the in vivo relevance of 
isomerisation has yet to be formally demonstrated. Other hypotheses, such as 
generation  of  a  novel  CA CypA  complexed  surface  that  is  subsequently 
recognised by restriction factors, or CypA dependent recruitment of cellular 
machinery cannot be ruled out. Study in this field is impeded by the absence of 
CypA  mutants  that  bind  CA  but  do  not  perform  the  catalytic  function,  and 
similarly, functional CA mutants that bind CypA but cannot be isomerised. Thus 
like some of the primate lentiviruses, infectivity of FIV is influenced by the CA 
CypA interaction but its precise role remains unclear. 
Unlike the surfaces of restriction factors that interact with pathogens, CypA is 
remarkably conserved. Its ubiquitous expression and relative invariance suggest 
a critical house keeping role, although its function is elusive. Yeast mutants 
lacking all twelve cyclophilin genes remain viable, although display retarded 
growth  (Dolinski  et  al.  1997).  Moreover,  the  contribution  of  each  knockout 
gene  is  additive,  suggesting  that  the  cyclophilins  do  not  complement  each 
other’s function and that each cyclophilin has a specific role, rather than each 
contributing to a protein folding phenotype. Roles for individual proteins have Chapter 5. The role of CypA in the replication of FIV 
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been ascribed to several cyclophilins such as signal transduction (Duina et al. 
1996) and rhodopsin folding (review Gothel and Marahiel 1999; Stamnes et al. 
1991) but CypA has no precise role defined to date. Nevertheless, it is likely 
that CypA is constrained by cellular tasks and is unable to undergo the high 
levels  of  positive  selection  that  interaction  with  pathogens  usually  entails. 
However, the TRIMCyp fusion protein is presumably relieved of its cellular role 
and,  in  rhesus  macaques,  has  acquired  mutations  that  remodel  the  binding 
surface and promote HIV 2 restriction (Wilson et al. 2008; Virgen et al. 2008; 
Price et al. 2009). The ability of FIV to bind both Cyp variants demonstrates 
that binding to CypA and rhTRIMCyp are not properties mutually exclusive to an 
individual virus.  
It  is  becoming  clear  that  lentiviruses  maintain  the  affinity  of  the  CA CypA 
interaction within a narrow range. It would be expected that HIV 1 growing in 
the absence of CypA (e.g. under CsA inhibition) would acquire mutations to 
increase the affinity in order to maintain a given level of CA Cyp interactions. 
However,  the  mutants  arising  possess  Kd  values  within  the  same  low 
micromolar range but may be more sensitive to the activity of CypA, perhaps 
by  being  more  liable  to  uncoating  by  low  levels  of  peptidyl proline 
isomerisation. The finding that FIV binds CypA with almost identical affinity as 
HIV 1  is  surprising  given  the  evolutionary  distances  and  scarce  amino  acid 
identity between the viruses and implies that binding to CypA is very tightly 
regulated on the part of the virus. Moreover it appears that viruses can employ 
a CypA dependent or –independent strategy with no more than a few point 
mutations.  HIV 2 can  switch  to  CypA binding  with a  single  mutation at  A88 
(Price et al. 2009) and HIV 1 CsA independent strains are circulating in humans 
at 4 7% of strains in the Los Alamos database (Chatterji et al. 2005). These 
findings  were  the  rationale  for  investigating  other  proteins  with  cyclophilin 
domains which raises the potential lentiviral co factor Ranbp2. Future work Chapter 5. The role of CypA in the replication of FIV 
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will attempt to demonstrate a functional association between capsid and this 
protein. It is of note that Ranbp2 interacts with microtubules in the cytoplasm 
and since lentiviral particles are known to use the microtubules for transport 
towards the nucleus (Arhel et al. 2006; McDonald et al. 2002), this suggests a 
potential  role  of  the  Ranbp2  Cyp  domain  in  permitting  docking  of  the  RT 
complex at the nuclear pore before transport across the nuclear membrane. If 
nuclear  entry  is  found  to  be  dependent  on  Ranbp2,  there  are  likely  to  be 
implications  for  strategies  to  disrupt  the  HIV  lifecycle  through  cyclophilin 
inhibitors.  For  example,  it  has  been  proposed  to  make  artificial  restriction 
factors  involving  CypA,  such  as  Fv1Cyp  and  huTRIM5 CypA  fusion  protein. 
However, given the ease with which lentiviruses are able to dispense with the 
CypA interaction the restriction factors are unlikely to be robust against escape 
mutants. The cyclophilin domain of Ranbp2 is fairly divergent from cytosolic 
CypA,  with  the  human  versions  sharing  66%  identity,  potentially  making  it 
possible to maintain Ranbp2 binding whist switching on or off CypA binding. 
Thus, if the CA Ranbp2 interaction is proven to be required for infection of 
non dividing  cells,  inhibition  of  this  interaction  or  restriction  factors  that 
mimic the Ranbp2 Cyp domain are more likely to be successful.   
Chapter 6.  Characterisation  of  intrinsic 
immunity to lentiviruses in African lion cells. 
6.1 Summary 
The  feline  immunodeficiency  virus  infects  numerous  Feliform  species  as 
species specific  viral  strains.  In  each  host,  the  virus  has  undergone 
considerable selection to allow successful replication and population invasion. 
In  contrast,  hosts  will  attempt  to  limit  infection,  and  genetic  variants  that 
confer  resistance  to  viral  replication  will  be  selected,  creating  a  molecular 
arms race between host and pathogen. In order to assess the impact of such 
antagonistic  relationships  in  the  felids,  a  comparison  was  made  between  a 
relatively recent host of the virus, the domestic cat (<10,000 years infected) 
and a more ancient host, the African lion which is likely to have been infected 
with lentiviruses since the early Pleistocene (Antunes et al. 2008). Lion cells 
support very low levels of replication of both domestic cat and lion variants of 
FIV. In contrast, domestic cat cells support high titre replication of all viruses 
assayed. The results are interpreted as evidence of the existence of a block to 
lentiviral replication in lion cells relative to the novel host, the domestic cat. 
This block is termed lion cell non permissivity (LNP) and is further explored in 
this study. LNP is found to be a dominant post entry block to replication that 
targets both feline and primate lentiviruses. TRIM5α is truncated in lion cells, Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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eliminating this protein as a candidate for LNP. Moreover, treatment of lion 
cells with proteasome inhibitor MG312 does not affect the level of restriction, 
nor does treatment with As2O3, a drug that disrupts sub cellular localisation 
and antiviral activity of TRIM proteins (Zhu et al. 1997; Anderson et al. 2006). 
Furthermore, unlike TRIM5α  restriction,  LNP  does  not  target the  N terminal 
domain of capsid. The identity of the cause of LNP is unknown but does not act 
in  a  manner  similar  to  previous  well  characterised  post entry  restriction 
factors.  
Subsequently, a comparative analysis of the APOBEC3 (A3) family of restriction 
factors is performed between lions and domestic cats. In domestic cats, read 
through fusion protein A3CH is a potent restriction factor whilst single domain 
proteins A3C and A3H are inactive against FIV (Munk et al. 2008). In lions, A3CH 
retains this antiviral activity but surprisingly, FIV replication is also blocked by 
single  domain  protein,  lion  A3H.  This  result  is  of  interest  as  for  most  A3 
proteins,  two  domains  are  required  for  antiviral  activity  with  one  domain 
specialising  in  RNA  binding  and  the  other  in  single stranded  (ss)  DNA 
deamination. A homology model is used to predict the residues in lion A3 that 
potentially permit RNA binding and dimerisation. The study shows that lions 
possess  a  strong  intrinsic  immune  protection  from  lentiviruses  and  provide 
evidence of evolution of host restriction in the felids in response to ongoing 
infections.  
6.2 Results 
6.2.1 Lion T cells poorly support the replication of FIV Fca 
To  investigate  the  ability  of  host  cells  to  support  the  replication  of  FIV, 
concanavalin A stimulated, IL 2 dependent T cells were challenged with four 
viral strains, two lion derived strains (FIV Ple E Sangre and Ple B 458) as well as Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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two molecular clones of domestic cat FIV (FIV Fca GL8 and Petaluma). The lion 
cells  used  in  this  experiment  are  derived  from  an  uninfected  Angolan  lion, 
whilst Mya 1 T cells (Miyazawa et al. 1989) were used for domestic cat. Puma 
T cells  were  derived  from  a  specific pathogen  free  North  American  puma 
(Puma  concolor).  Frozen  viral  supernatant  was  examined  for  reverse 
transcriptase activity as a marker of retroviral replication. Cells from domestic 
cat supported replication of all viruses tested, whist Angolan lion and Puma 
cells  supported  only  very  low  titres  of  FIV Fca  but  did  permit  FIV Ple  B 
replication (Figure 6 1). Interestingly, the lion cells used in this experiment 
were unable to support the growth of FIV Ple E, a strain circulating in southern 
African  lions  (Pecon Slattery  et  al.  2008a).  The  findings  are  reminiscent  of 
VandeWoude  et  al.  (1997)  who  found  that  lion  cells  poorly  supported  the 
replication of FIV Fca. However, these findings go further as they suggest that 
even  host adapted  strains  FIV Ple  B  458  and  FIV Ple  E  Sangre  are  poorly 
infectious in lion cells.  
 
Figure 6-1 Host permissivity to FIV replication. FIV is able to replicate to high titres 
in cells of the domestic cat, whereas Angolan lion and Puma cells poorly support growth 
of domestic cat strains of FIV (GL8 and Petaluma) and only support growth of lion-
derived FIV in a strain-dependent manner. Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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The data imply that either the viruses are unable to make use of the lion/puma 
cell host machinery or there exists a dominant block to replication in these 
cells.  Given  that  lions  are  the  natural  host  of  FIV Ple,  the  former  case  is 
unlikely since considerable host adaptation will have taken place in the time 
since lentiviruses entered the species, estimated between 169,000 and 3.6 mya 
(Antunes et al. 2008; Pecon Slattery et al. 2008b). Furthermore FIV Ple strains 
are able to replicate to high titres in domestic cat cells, a non native host, 
implying that the ability to replicate to high titre is a factor that is host  but 
not virus dependent. The only strain that produced a positive RT result  in lion 
cells at seven days post infection was FIV Ple B, a strain that uses non CD134, 
non CXCR4 entry receptors (Chapter 3; McEwan et al. 2008). This raised the 
possibility that mutations in either of these receptors are responsible for the 
non permissive phenotype in lion cells. 
6.2.2 Contribution of receptor variation to LNP 
To test the hypothesis that LNP is due to lion mutations in CD134 or CXCR4, 
variants of the receptor and co receptor from cats and lions were cloned and 
sequenced. Analysis of the sequences reveals that lion and feline CD134 share 
97% amino acid identity with a cluster of amino acid mutations in the predicted 
signal peptide region and a G59S point mutation in the predicted Env binding 
site, cysteine rich domain 1 (CRD1), which could potentially alter Env binding 
and entry. An alignment of feline and lion CD134 has been presented previously 
in Figure 3 8. A comparison of the lion and feline CXCR4 seven transmembrane 
domain protein shows 99% amino acid identity with only a single amino acid 
change,  a  serine  to  asparagine  substitution  in  extracellular  loop  2  (ECL2), 
creating  a  potential  N glycosylation  site  in  lion  CXCR4  at  position  N193. 
Whether this site is in reality glycosylated in lion CXCR4 has not been studied 
but any of these interspecific polymorphisms could potentially alter the Env Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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receptor  interaction  and  be  responsible  for  LNP.  CD134  and  CXCR4  of  each 
species were therefore stably expressed in all four combinations on NP2 cells 
and  challenged  with  HIV luc  particles  pseudotyped  with  a  panel  of  FIV  Env 
glycoproteins (Figure 6 2). Permissivity of the cell lines was not substantially 
altered by changing the combinations of receptor and co receptor, suggesting 
that domestic cat and lion CD134 and CXCR4 support infection of FIV at similar 
levels.  These  data  indicate  that  LNP  cannot  be  explained  by  differences  in 
entry receptors as lion CD134 and CXCR4 support levels of infection directly 
comparable to those of the domestic cat for a range of FIV envelopes.  
 
Figure 6-2  FIV usage of lion CD134 and CXCR4. Cat and lion FIV entry receptor 
CD134 and co-receptor CXCR4 from domestic cats and lions were expressed in all four 
combinations  on  NP2  cells  and  challenged  with  panel  of  HIV-luc(FIV)  pseudotypes 
using various Env isolates from domestic cats. Levels of entry were similar regardless of 
receptor combination indicating that lion cell non-permissivity is not due to differences 
in efficiency of the entry receptors between cats and lion. 
6.2.3 LNP operates post entry against primate lentiviruses. 
The finding that species specific polymorphisms in receptor and co receptor do 
not account for the differing levels of infectivity suggests that receptor binding Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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and entry are not the stages responsible for LNP. However, it remains possible 
that  receptor  expression  levels  differ  between  the  species  or  access  to 
receptors  is  somehow  impeded  in  lion  cells.  To  obviate  this  problem,  pan 
tropic VSV G pseudotyped particles were used in preference to FIV Env for the 
remainder of this study. In order to assess the breadth of LNP lentiviral targets, 
lion  cells  and  domestic  cat  cells  were  challenged  with  primate  lentivirus 
pseudotypes. Lion T cells were found to permit much lower levels of infection 
compared to domestic cat cells. Furthermore a differential level of restriction 
was found between the viruses used: HIV 1 was restricted at a low level, whilst 
SIV from rhesus macaques (SIVmac) was restricted at much higher levels, a 
difference that was found to be repeatable and statistically significant (Figure 
6 3).  
 
Figure  6-3  Lion  cells  differentially  restrict  primate  lentiviruses.  A)  GFP-bearing 
VSV-G-pseudotyped  particles  of  primate  lentiviruses  display  a  reduced  titre  on  lion Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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compared to domestic cat T-cells. B) Expressed as fold restriction, HIV-1 is restricted 
about 20-fold whilst SIVmac is restricted about 80-fold and HIV-2 is restricted at an 
intermediate level. There is a significant difference between levels of restriction between 
HIV-1 and SIVmac (unpaired two-tailed t-test, n=3). 
To  assess  the  relative  ability  of  T cells  to  support  lentiviral  infection, 
pseudotypes were titrated onto permissive CrFK as well as Mya 1 and Angola 1 
cells (Figure 6 4). Mya 1 and Angola 1 cells supported levels of infection far 
below CrFKs. For FIV, the levels of infection achieved in lion cells were too low 
for  meaningful  interpretation.  Optimisation  of  the  pseudotype  production 
protocol by altering the ratio of plasmids transfected, use of phenol red free 
medium and transfection reagent all allowed marginal increases in titre, but 
titres were always in the region of 10
5 infectious units per ml. Titres of HIV 1 
were much higher, possibly due to the fact that pseudotypes were produced in 
human cells.  
 
Figure  6-4  Titration  of  HIV  and  FIV  pseudotypes.  10-fold  serial  dilutions  of 
pseudotype were titrated onto CrFK, Mya-1 and Angola-1 lions T-cells and GFP positive 
cells were enumerated. Multiplicities of infection (number of infectious units per cell) 
were calculated for undiluted supernatant and show that CrFKs are ~1,000 times more Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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susceptible to HIV infection than Mya-1. Lion cells display a further ~25-fold restriction 
to HIV compared to Mya-1 cells. 
The results imply that LNP operates post entry and has a broad specificity of 
infection. The difference in restriction levels between SIVmac and HIV 1 allows 
further dissection of the LNP phenotype.  
6.2.4 Mapping the viral determinants of LNP  
Given that post entry restriction factors such as Fv1 and TRIM5α are known to 
target incoming viral capsids, it was proposed that LNP might also employ this 
strategy. Although it is known that lions lack a functional TRIM5α (McEwan et 
al.  2009;  Chapter  4)  and  Fv1  is  specific  to  mice  (Best  et  al.  1996),  it  was 
hypothesised that LNP may share its target in common with these post entry 
restriction  mechanisms.  In  order  to  test  this  hypothesis,  a  chimeric  HIV 1 
SIVmac construct was used, HIV S/H CA (Owens et al. 2003). HIV S/H CA is an 
HIV 1 gag pol expressor with the N terminal 146 amino acids of capsid replaced 
with that of SIVmac. It was found that using this construct gave no significant 
increase in levels of restriction relative to HIV 1, indicating that LNP does not 
target  the  N terminal  domain  of  capsid.  As  a  control,  the  chimeric  and 
wildtype viruses were assayed against puma cells but found to lack the LNP 
phenotype, providing evidence that LNP is specific to the Panthera lineage. Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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Figure 6-5 Chimeric lentiviral capsid is not targeted by LNP. HIV-1 and chimeric 
S/H capsids were restricted only mildly, whilst SIV capsid was restricted strongly. Puma 
cells were used as a comparison and show no restriction of pseudotypes when compared 
to domestic cats. 
6.2.5 Sensitivity of LNP to proteasome inhibitor and arsenic compounds 
MG132 is a protease inhibitor that relieves the block to reverse transcription 
imposed by TRIM5α on restricted lentiviruses (Anderson et al. 2006; Wu et al. 
2006). Another drug, As2O3, has been shown to rescue restriction of HIV 1 by 
TRIM5α (Berthoux et al. 2003; Saenz et al. 2005). The activity of As2O3 is poorly 
defined  but  may  exert  its  effects  by  disrupting  the  formation  of  cytosolic 
protein concentrations known as cytoplasmic bodies, which contain TRIM family 
proteins such as TRIM5α (Campbell et al. 2007) and PML (also known as TRIM19) 
(Reymond et al. 2001; Zhu et al. 1997). Furthermore, the drug has been shown 
to  disrupt  an  unidentified  restriction  phenotype  against  HIV 1  in  human 
dendritic cells (Pion et al. 2007). However, no effect was observed when lion 
and cat  cells  were  treated  with the  drugs  (Figure  6 6),  suggesting  that  the 
restriction  is  not  caused  by  proteasome dependent  pathways  or  arsenic 
sensitive proteins. Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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Figure 6-6 Protease inhibitor and arsenic trioxide do not relieve LNP. Cat and lion 
T-cells were incubated with MG132 (1  g/ml) or As2O3 (2  M) prior to infection. No 
substantial change was observed in the restriction of HIV-1. For As2O3 experiment, n =3. 
6.2.6 Analysis of feline APOBEC3 genes 
It  has  previously  been  reported  that  the  domestic  cat  genome  bears  an 
expanded  cluster  of  APOBEC3  genes  (Munk  et  al.  2008).  In  order  to  test 
whether  extended  periods  of  endemic  lentiviral  infection  have  altered  the 
restrictive ability of lion APOBECs, A3C, A3H and A3CH were amplified from 
lion  and  domestic  cat  cDNA  and  cloned  into  eukaryotic  expression  vector 
VR1012. The cloned genes were sequenced and found to bear 100% identity to 
published sequences, except lion A3CH, as this is the first published sequence 
for this gene. The lion A3C transcript cloned was found to encode A3C1 variant 
as described previously (Munk et al. 2008). Homology between feline A3H and 
the  huA3G  catalytically  active  CD2  is  low  but  the  Zn coordinating  motif  is 
present in both (Figure 6 7). Restriction by human A3G is contingent on both 
RNA binding  and  catalytic  functions,  and  accordingly  it  has  previously  been 
reported that domestic cat A3C and A3H are inactive against FIV, whilst two 
domain read through protein A3CH is highly active.  Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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Figure 6-7 Alignment of feline A3H and human A3G C-terminal catalytic domain. 
The domains share only 33% sequence identity, but share the Zn-coordinating H/C-X-E-
X23-28-P-C-X2-C  motif.  The  three  arginine  residues  of  huA3G  predicted  to  form  the 
charged single-stranded DNA binding groove (Chen et al. 2008) are marked with double 
black bars and are conserved in the feline variant. 
To assess the impact of the felid A3 genes on the infectivity of FIV, VR1012 A3 
plasmids were co transfected with FIV Vif GFP(VSV) encoding plasmids FP93, 
GinSin and MDG. The viral titre was then assayed by plating supernatant onto 
fresh target 293T cells (Figure 6 8). 0.25 g of plasmids encoding read through 
transcript A3CH from both lions and cats was sufficient to completely abolish 
the production of infectious FIV virions. The feline single domain A3C and A3H 
were unable to restrict virus, suggesting that in domestic cats fusion of the two 
domains is necessary to produce a functional restriction factor. In contrast, the 
lion  A3H  protein  was  able  to  restrict  the  production  of  infectious  virions, 
despite  being  a  single  domain  protein,  raising  questions  concerning  the 
mechanism of restriction for the single domain restriction factor.  Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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Figure 6-8 Titrations of feline and lion APOBECs. 293T cells were transfected with 
plasmids encoding FIV-GFP(VSV) pseudotype and VR1012-A3, normalised with empty 
VR1012  vector.  Pseudotype  was  harvested,  plated  onto  fresh  293T  cells  and  GFP 
expression examined. Read-through transcripts from both species prevented production 
of infectious virus above 0.25 g plasmid. A strong restriction was also provided by lion, 
but not feline, single domain protein A3H.  
For  both  HIV 1  and  FIV,  the  APOBEC  restriction  is  largely  overcome  by  the 
expression of accessory protein Vif (Munk et al. 2008; Sheehy et al. 2002). To 
assess the ability of Vifs to counteract the restriction phenotype, genes were 
cloned  from  FIV Ple  strains  B  and  E  and  were  co transfected  into  viral 
producing cells. Given the ability of FIV Ple B to replicate in lion cells, it was 
expected  that  this  Vif  variant  may  provide  the  strongest  rescue  of  titre. 
However, very little Vif dependent rescue was observed against any of the A3s, 
with  the  exception  of  liA3C1  (Figure  6 9).  It  is  possible  that  this  poor  Vif 
activity is due to poor or mis located expression (see 6.3 Discussion), making it 
difficult to draw robust conclusions from these data. Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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Figure 6-9 Lentiviral restriction imparted by feline and lion APOBEC3 genes. A 
strong restriction phenotype is associated with the lion A3s as well as feline A3CH. With 
the  potential  exception  of  liA3C1,  Vifs  were  unable  to  overcome  the  restriction. 
However, this may owe more to problems with expression than biological activity. 
6.2.7 Structural comparisons of feline APOBEC3H 
In human cells, the antiviral APOBEC3s are two domain proteins with both RNA 
binding ability (associated with CD1) and ssDNA deaminase activity (associated 
with CD2). It was therefore surprising to find antiviral activity associated with 
the  lion  single  domain  proteins.  Structural  studies  of  human  A3G  CD2  have 
revealed the presence of a positively charged groove that permits interaction 
with the negatively charged nucleic acid backbone (Holden et al. 2008; Chen et 
al.  2008).  In  the  absence  of  a  DNA A3G  complex  structure,  the  precise 
orientation  of  the  nucleic  acid  across  the  groove  is  not  clear  and  remains 
controversial (Bransteitter et al. 2009) but is thought to bring the catalysed 
base into the proximity of the catalytically active Zn
2+ ion (Furukawa et al. 
2009; Chen et al. 2008; Holden et al. 2008).  
Domestic  cat  A3H  only  poorly  restricts  FIV,  whilst  the  lion  variant  potently 
prevents the production of infectious virions. Recent work in our lab suggests 
that the puma A3H variant also possesses antiviral activity. The ability of these Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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non domestic cat variants to restrict is unusual, given that the proteins are 
single  domain  cytidine  deaminases.  To  investigate  possible  mechanisms  of 
action, an alignment of feline and lion A3H variants was made (Figure 6 10). 
Residues shared by lion and puma variants but absent in the feline A3H were 
identified (V7D, H43D, E51K, A65S, G140S, P106R/H (R in lion; H in puma), 
A179P,  cat  numbering).  Four  of  the  seven  substitutions  replace  neutral 
residues with charged ones or switch the charge, suggesting a possible role in 
alteration of protein protein or protein nucleic acid interactions. 
 
Figure 6-10 Alignment of cat and lion A3H. Whilst feline A3H is unable to restrict 
FIV, the lion version restricts almost as well as the two-domain A3CH. Possible causes 
of the large change in phenotype are the two substitutions in the catalytic domain as well 
as four charge switch substitutions. 
Next  a  homology  model  of  feline  A3H  was  created  using  the  two  APOBEC 
crystal  structures  solved  to  date,  huAPOBEC2  and  huAPOBEC3G  CD2  domain 
(PDB: 2NYT and 3E1U respectively) (Prochnow et al. 2007; Holden et al. 2008). 
The  model  predicts  the  conservation of  the  prototypic  APOBEC  structure: a 
central  β sheet  surrounded  by  six  α helices  (Figure  6 11).  APOBEC3G  CD2 
structurally differs from A2 primarily in its longer loops that protrude from the 
structure  between  conserved  β strands  and  α helices  (Holden  et  al.  2008). 
Superimposed structures of feline A3H on human A3G CD2 suggest that again 
the main structural difference is the length and orientation of the loops, with Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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the feline variant possessing shorter loop 3 and a deflected loop 1. Moreover, 
the model suggests that charge switch mutations V7D, E51K and P160R/H are 
located on the surface of the protein predicted to interact with viral single 
stranded  DNA  (Furukawa  et  al.  2009;  Chen  et  al.  2008;  Bransteitter  et  al. 
2009). Of particular interest is the P160R/H mutation that varies between all 
three species. The residue is neutral in cats but positively charged in both lions 
and pumas. Analogy with recent human A3G ssDNA binding models (Chen et al. 
2008; Furukawa et al. 2009), suggests that this residue has the potential to 
make  electrostatic  interactions  with  the  negatively  charged  nucleic  acid 
backbone,  potentially  increasing the  affinity  of  binding  in  the non domestic 
species.  Chapter 6. Characterisation of intri
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homologues is present within the loop domains. Loop-3, known to make contact with 
nucleic acid bases (Bransteitter et al. 2009), is considerably shorter in the feline version 
but loop-7, involved in dimerisation in CD1 (Huthoff et al. 2009), is conserved.  
Recently, a homology model of a human single domain protein A3C, that is 
active against SIVmac but not HIV 1, has been presented (Stauch et al. 2009). 
Activity for this protein is dependent on RNA binding which is mediated by a 
novel  substrate  binding  pocket  and  subsequent  dimerisation  performed  by 
exposed aromatic residues that permit packaging into SIV Vif particles. The 
catalytic  site  is  therefore  unoccupied  by  RNA  and  free  to  bind  ssDNA  once 
reverse transcription is under way in the target cell. Human A3G also forms 
RNA dependent dimers: CD1 domain residues R24 and R30 interact with RNA 
(Huthoff et al. 2009) which subsequently promotes intermolecular interactions 
via  aromatic  residues  Y124,  F126  and  W127  present  in  CD1  loop 7  region 
(Huthoff  et  al.  2009;  Gooch  and  Cullen  2008).  However  unlike  the  single 
domain A3C, dimerisation is not necessary for huA3G antiviral function (Opi et 
al. 2006).  
The  mode  of  activity  observed  for  liA3H  suggests  that  virion  incorporation 
takes  place,  given  that  the  restriction  observed  is  post entry,  making  RNA 
dependent dimerisation a likely mechanism for this protein. A comparison with 
A3C also shows that of the four residues known to comprise the novel RNA 
binding pocket (K22, T92, R122 and N177), two are identical (R122 and T92), 
one is conserved (K22R), making it possible that RNA binding for liA3H takes 
place  at  this  alternative  location.  Inspection  of  the  feline  sequence  also 
reveals  a  patch  of  aromatic  residues  in  loop 7  including  Y122  and  W115, 
leading to the hypothesis that feline A3H exists as a dimer through interactions 
at this surface. A homology model (Figure 6 12) also predicts adjacent W117 at 
the crest of α helix 4 to be exposed and may also contribute to intermolecular 
interactions.  This  loop  is  absolutely  conserved  between  feline  and  lion Chapter 6. Characterisation of intri
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interesting case as it is predicted to combine these functions in a single domain 
protein.  Future  work  should  evaluate  how  A3H  impacts  on  viral  infectivity 
alone  and  in  concert  with  A3C  –  both  as  the  fusion  protein  and  individual 
proteins. 
6.3 Discussion 
Studies of host retrovirus interactions in primates have suggested that genes 
which  provide  resistance  to  circulating  or  endogenous  pathogens  will  be 
selected for, and, given time, will confer host resistance to the pathogen. It is 
likely  that  APOBEC  proteins  have  had  a  part  to  play  in  this  process.  For 
example  the  human  endogenous  retrovirus,  HERV K,  is  present  in  multiple 
copies  in  the  human  genome  as  the  relic  of  an  infection.  Some  of  these 
insertions  have  occurred  comparatively  recently,  since  the  divergence  with 
chimpanzees (Belshaw et al. 2005). The sequences show large numbers of G to 
A base substitutions, evidence of APOBEC mediated antiviral activity (Lee et 
al. 2008; Perez Caballero et al. 2008). Furthermore, a reconstructed consensus 
HERV K is strongly restricted by huA3F, suggesting a causal role of APOBECs in 
the demise of this parasite (Lee and Bieniasz 2007). It is therefore of interest 
that lions, which are thought to have harboured lentiviruses for many hundreds 
of thousands of years, display a very different permissiveness compared to a 
fairly recent host, the domestic cat.  
It has previously been suggested that a certain amount of host adaptation has 
taken  place  in  lion  FIV  strains  that  reduces  pathogenicity  and  therefore 
prolongs  the  lifetime  of  infection[burk]  (Carpenter  and  O'Brien  1995). 
However, the findings presented in this study show that both FIV Fca and FIV 
Ple, which replicates to a high titre in domestic cat cells, are poorly infectious 
in lion cells but conversely, these strains are replication competent in feline 
cells.  The  simplest  explanation  for  the  findings  is  that  lion  cells  actively Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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prevent  FIV  replication,  rather  that  the  virus  attenuating  to  preserve  the 
health of its host. Indeed a lentiviral post entry restriction (LNP) was described 
that  prevents  post entry  stages  of  human,  feline  and  simian  lentiviral 
infections.  The  factor  or  factors  responsible  for  LNP  remain  unidentified. 
Experiments to test whether lion A3 proteins could block replication at a post 
entry stage were performed, but no evidence of a post entry APOBEC mediated 
block was found (data not shown). However, a post entry APOBEC block cannot 
be  ruled  out  until  the  ability  of  lion  APOBECs  to  perform  RNA directed 
mutagenesis has been studied. Another potential candidate for LNP is TRIM22, 
a  protein  known  to  be  under  positive  selection  in  the  Carnivorae,  possibly 
complementing the absence of TRIM5α (Sawyer et al. 2007). Despite repeated 
attempts to clone the TRIM22 gene from cat and lion cDNA, this study was 
unable to examine the role of this gene. However, the finding that LNP does 
not  target  the  N terminal  domain  of  capsid  makes  TRIM22  an  unlikely 
candidate,  since  TRIM5α  is  known  to  interact  with  this  viral  domain. 
Furthermore,  no  effect  on  LNP  was  observed  by  treating  cells  with  arsenic 
trioxide, a compound that is known to disrupt TRIM protein activity (Zhu et al. 
1997; Campbell et al. 2007; Saenz et al. 2005). An unidentified block to HIV 1 
post entry stages has been described in Mya 1 domestic cat T cells (Munk et al. 
2007). It is possible that the restriction described is performed by the same 
factor as LNP, given that both act at the same stage in the lifecycle. This study 
used Mya 1 as a permissive cell line relative to lion cells, but in reality both 
species  may  be  restrictive  with  more  active  variants  present  in  lion  cells. 
Interestingly, the FIV Ple B strain was able to replicate in lion cells (albeit at a 
lower level than in cat cells), suggesting that FIV Ple B is able to neutralise or 
escape LNP. Given that FIV Ple B and E share considerable levels of identity 
across the genome with the exception of env (Pecon Slattery et al. 2008a), it is 
possible that resistance is somehow provided by this same gene product, for 
example  by  employing  divergent  entry  pathways  or  actively  overcoming Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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restriction.  This  is  not  without  precedence,  since  HIV 2  uses  its  Env 
glycoprotein to fulfil the role of HIV 1 Vpu in overcoming tetherin restriction 
(Bour  et  al.  1996;  Jia  et  al.  2009).  Like  the  discovery  of  alternate  entry 
receptors, the differential permissivity of lion cells to the B and E clade viruses 
has  implications  for  the  pathology  and  management  of  FIV  in  free ranging 
lions. However, further questions need to be answered before the implications 
become clear: for instance, does the differential in vitro permissivity correlate 
with  in  vivo  viral  titre?  And  is  the  differential  permissivity  specific  to  the 
Angolan  lions  from  which  the  T cells  in  this  study  were  derived  or  is  it 
widespread  amongst  lion  populations?  Furthermore,  despite  evidence  of  T 
lymphocyte depletion (Roelke et al. 2009), the tissue tropism of FIV Ple has not 
formally been demonstrated and replication may be more efficient in other 
cell populations. 
It has been reported that lion populations in the west of southern Africa do not 
harbour  FIV  (Antunes  et  al.  2008).  This  is  in  stark  contrast  to  eastern 
populations where seropositivity can approach 100% in adult lions (Ramsauer et 
al. 2007; Roelke et al. 2009; Brown et al. 1994). The absence of FIV in western 
areas  has  been  explained  by  the  lower  population  density  (Antunes  et  al. 
2008). However, several felid species that exist at low population densities are 
known to bear FIV, such as Pallas cats (Barr et al. 1995) and pumas (reviewed 
in Poss et al. 2008). With the source of the lion cells used in this study, Angola, 
being on the west coast of southern Africa, it is possible that LNP is present in 
the localised lion population and has contributed to the absence of FIV west of 
the Kalahari. If confirmed, the lion would provide the first extant example of a 
host  acquiring  resistance  to  its  own  lentivirus  and  would  be  of  substantial 
interest in the study of host parasite ecology. On a molecular level, isolating 
the  factor  responsible  for  LNP  is  of  substantial  interest  given  the  broad 
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screen:  expressing  lion  cDNA  clones  in  permissive  cells  and  screening  for 
antiviral activity. The technique is limited as it would not identify the cause if 
LNP were a function of two or more proteins or a recessive property, but with 
previous restriction phenotypes (rhesus macaque Lv1 and non permissivity of 
CEM cells) the technique has proved successful and  lead to the isolation of 
TRIM5α and huA3G (Stremlau et al. 2004; Sheehy et al. 2002). 
A single domain APOBEC presents problems for the host: RNA binding and RNA 
directed catalytic activity allows virion packaging but risks targeting self RNA 
whilst  ssDNA binding  and   deamination  prevents  virion  incorporation.  Two 
strategies to overcome this problem have been described for APOBEC proteins 
so  far:  the possession  of an  additional  RNA binding  pseudocatalytic domain, 
such as huA3G CD1 (Huthoff and Malim 2007), or the presence of an additional 
RNA binding pocket for single domain proteins, such as huA3C (Stauch et al. 
2009).  These  strategies  permit  both  encapsidation  and  deaminase  activities 
without high levels of host mRNA mutation. A previous study of domestic cat 
APOBECs found little or no anti lentiviral activity associated with the single 
domain proteins (Munk et al. 2008). Like human A3 proteins, two covalently 
joined domains in the form of read through protein A3CH, were found to be 
required, presumably with each domain specialising separately in RNA binding 
and ssDNA deamination (Munk et al. 2008). Whilst we repeated the finding that 
feline  single  domain  A3  proteins  are  poorly  active  against  FIV,  this  study 
presents the single domain lion APOBEC3H protein capable of potent antiviral 
activity.  The  lion  A3H  protein  is  therefore  of  considerable  interest  as  it 
prompts questions as to the mechanism of action for a single domain cytidine 
deaminase. Here, we have proposed a model for the activity of A3H which 
shares conserved residues with the A3C RNA binding  pocket and a potential 
dimerisation  domain.  Future  work  should  use  such  structural  information  to 
define which mutations are responsible for rendering the lion and puma A3H Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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variants more potent against FIV compared to the domestic cat variant and the 
mechanism of antiviral activity should be addressed. Although RNA binding and 
dimerisation  are  the  most  attractive  hypotheses  for  liA3H  activity,  other 
mechanisms  such  as  the  formation  of  A3C/A3H  heterodimers  to  allow  RNA 
binding  and  deaminase  activity  are  also  potential  in  vivo  methods  of 
overcoming the problems associated with single domain proteins. Also possible 
is the presence of deaminase independent activity as has been described for 
A3G (Newman et al. 2005; Bishop et al. 2008). This issue could be resolved by 
introducing mutations into the catalytic domain of liA3H in order to determine 
the  relative  contributions  of  deamination  and  deaminase independent 
restriction. 
Human APOBEC3 activity is overcome by HIV 1 Vif protein (Sheehy et al. 2002). 
Whilst this study was able to demonstrate some Vif dependent rescue of viral 
infectivity  in  the  context  of  lion  A3C1  restriction,  no  rescue  was  observed 
against other A3 proteins. It is likely that this inability of Vifs to counteract 
APOBECs is due to poor expression or mis localisation of Vif. The problems are 
overcome by codon optimisation to alter the third base in each codon to better 
reflect mammalian codon usage. Doing so has been shown to improve mRNA 
nuclear  export  (Nguyen  et  al.  2004)  and  restore  FIV  Vif  localisation  to  the 
cytoplasm (Paul et al. 2007). Time constraints prevented the construction of 
such codon optimised Vifs but future work will better assess the ability of FIV 
strains to overcome APOBEC mediated restriction.  
Although APOBECs are unlikely to be the cause of post entry LNP in lion cells, 
it  remains  possible  that  the  block  to  replicating  FIV  is  partially  due  to  A3 
proteins.  This  issue  could  be  addressed  by  recovering  viral  sequences  from 
infected  cells  in  order  to  quantify  the  extent  of  G  to  A  substitutions. 
Additionally,  it  remains  possible  that  the felid  APOBECs  have alternative  or Chapter 6. Characterisation of intrinsic immunity in African lion cells 
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additional viral targets: potent restriction of FFV and partial restriction of FeLV 
by feline APOBECs has been observed (Munk et al. 2008; Lochelt et al. 2005). 
However, FIV is likely to be the principal driver of positive selection in the 
lions given the pathogenicity and prevalence of FIV in wild lion populations and 
the apparent absence of FeLV, RD114 and FFV in this species (Antunes et al. 
2008; Roelke et al. 2009). Furthermore, the very fact that lion APOBECs have 
evolved to potently restrict FIV is in itself further evidence that FIV is a major 
target of restriction, making lions an ideal species for the study of ongoing 
arms race between host and lentivirus and potentially giving a glimpse of the 
future for lentiviral infections in other species.   
Chapter 7.  Concluding Remarks 
‘A slow sort of country,’ said the Queen. ‘Now here, you see, it 
takes all the running you can do, to keep in the same place. If you 
want to get somewhere else, you must run at least twice as fast as 
that!’ 
-   Alice in Wonderland, Lewis Carroll 
 
The words of the Red Queen have been used to describe situations in biology 
involving  a  continuous  arms  race  between  conflicting  species,  where  an 
advantage for one species is quickly counteracted by a reactionary change in 
the other (Van Valen 1973). During retroviral infection, natural selection in the 
parasite  acts  to  increase  transmission  whilst  selection  in  the  host  acts  to 
suppress  replication.  An  antagonistic  relationship  therefore  develops  that 
drives innovation and selection of measures that promote the cause of each 
genetic  entity.  Accordingly,  positive  selection  is  apparent  in  host  gene 
products that provide resistance to infection providing evidence of ongoing and 
historical  conflicts.  In  contrast,  the  high  mutation  rate  on  the  part  of  the 
retroviruses obscures the effects of historical conflicts but provides an efficient 
means  of  isolating  important  functions  by  examining  variable  and  constant 
regions as well as monitoring escape mutants. Despite the ability to rapidly Chapter 7. Concluding remarks 
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evolve  resistance  to  host  defences,  the  vast  majority  of  retroviruses  are 
extinct, as evidenced by the large number of endogenous retroviral sequences 
present in mammalian genomes (8% of human genomic DNA), suggesting that 
the host usually wins out in these battles when played out over evolutionary 
time.  
The lentivirus is a comparatively new type of retrovirus, the oldest mammalian 
encounter dated to 7 12 mya (Katzourakis et al. 2007; Gilbert et al. 2009), and 
is still spreading through the taxa, arriving in humans within the past 150 years 
(Worobey et al. 2008). Few endogenous lentiviruses have been found, which 
has lead some commentators to suggest that their tropism precludes entry to 
the germline (Stoye 2006). While this may be a contributing factor, it seems 
likely  that  simply  not  enough  time  has  elapsed  for  substantial  levels  of 
endogenisation. Our scope for investigation is also limited to the species for 
which bioinformatic datasets are available. Two endogenisation events have 
been described which occurred in the Leporidae (rabbits and hares) and the 
prosimian species grey mouse lemur (Gifford et al.  2008; Katzourakis et al. 
2007).  However,  no  replication competent  lentivirus  has  been  isolated  from 
the entire Lagomorpha order or from any prosimian species, suggesting that 
the  viruses  that  gave  rise  to  these  endogenous  sequences,  and  their  close 
relatives, are likely to be extinct. We therefore have an idea of the timescale 
required  for  a  species  to  clear  a  lentiviral  infection:  less  than  12 7  my  in 
rabbits and less than 4.3 my in lemurs (Katzourakis et al. 2007; Gifford et al. 
2008; Gilbert et al. 2009; van der Loo et al. 2009). The means by which these 
hosts cleared there infections is unknown but is likely to have involved multiple 
factors acting at diverse stages in the lentiviral lifecycle. The discovery of an 
active TRIM5α in rabbits (Schaller et al. 2007) points to the involvement of this 
protein but restriction of the endogenous RELIK lentivirus has not to date been 
demonstrated.  Chapter 7. Concluding remarks 
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In this study we have identified felid species, the domestic cat and African 
lion, which represent recent and anciently infected hosts. The presumed age of 
infection in the lions, greater than 324,000 years since the genetic coalescence 
of modern lions (Antunes et al. 2008) and up to the earliest time of global 
dissemination of the virus, 3.6 mya (Troyer et al. 2008; Pecon Slattery et al. 
2008b),  puts  it  within  an  order  of  magnitude  of  the  lifetime  of  previous, 
extinct  lentiviral  infections,  making  an  ideal  host  in  which  to  examine  the 
changes in the host brought about by long term lentiviral infection. The post 
entry restriction factor TRIM5α was found to be truncated and non functional 
in all  felids  examined,  indicative of  a  disrupting  mutation early  in  Feliform 
evolution.  Nonetheless,  we  found  that  lion  cells  potently  hindered  the 
replication of FIV and primate lentiviruses. This is in direct contrast to the 
domestic cat, whose cells support FIV replication to a high titre. We found 
evidence that the APOBEC3 class of restriction factors is active in the felids, 
and in lions potently restricts FIV and found evidence of a post entry block to a 
broad range of viruses.   
Lentiviruses, almost by definition, should replicate in the cells of their natural 
host,  meaning  that  restriction  factors  must  largely  be  overcome.  What 
therefore  is  the  role  of  restriction  factors?  It  has  been  proposed  that  their 
primary  role  is  to  prevent  cross species  transmission  by  restricting  viruses 
before  they  can  establish  themselves  in  a  novel  host  (Cullen  2006).  Whilst 
restriction  of  viruses  undergoing  zoonosis  undoubtedly  takes  place,  it  is 
probable that host restriction factors are under selective pressure to target 
endemic  pathogens,  even  if  they  contribute  only  minimally  to  control  of 
infection. Recent evidence implies that even a small decrease in viral titre can 
make large differences to pathology. For example, the murine APOBEC3 locus 
exerts a minor effect on Friend Virus 3 (FV3) replication in vitro yet appears to 
contribute to its clearance by a neutralising antibody response (reviewed in Chapter 7. Concluding remarks 
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Ross 2009; Santiago et al. 2008). As has been noted above, the neutralisation 
of human APOBEC3G is not complete, with low levels of packaged restriction 
factor and induced mutation observable in clinical HIV 1 isolates (Nowarski et 
al. 2008; Zhang et al. 2003), suggesting that even this low level of activity 
could aid in the antiviral response. Also in humans, TRIM5α restricts HIV 1 at a 
low level (30% reduction; this study, Figure 4 5). Eight non synonymous TRIM5α 
polymorphisms  have  been  identified  (Javanbakht  et  al.  2006b)  and  one  of 
these, R136Q, effects a very modest increase in HIV 1 restriction in vitro, yet 
contributes  strongly  to  survival  in  AIDS  patients  after  X4  switching,  raising 
percent survival at 3 years post switch from 19% to 45% for RQ heterozygotes 
and 70% for QQ homozygotes (van Manen et al. 2008). Conversely, mutation 
H43Y, which impairs TRIM5α E3 ligase activity (Sawyer et al. 2006) accelerates 
disease progression in humans, with 100% progression to AIDS observed in YY 
homozygotes  within  seven  years  of  seroconversion  compared  to  55%  for  HH 
homozygotes (van Manen et al. 2008). Thus it seems probable that even the 
modest restriction provided by TRIM5α against HIV 1 contributes substantially 
to limiting the pathology of infection. Furthermore, many of these restriction 
factors can be up regulated by interferon, which contributes further to levels 
of  restriction  (Rajsbaum  et  al.  2008;  Carthagena  et  al.  2008;  Vetter  et  al. 
2009). Thus those restriction factor alleles conferring even minor increases in 
restriction are likely to be preferentially inherited and the cumulative effect of 
many such restrictions may eventually lead to a non permissive phenotype. A 
by product of this process is the potent restriction of retroviruses from other 
species that share structural features or similar replication strategies, but have 
not been in locked step coevolution, leading to a powerful barrier to cross 
species  transmission.  These  data  imply  that  the  many  log  restrictions  that 
researchers in the field are accustomed to are probably not the phenotypes on 
which  natural  selection  routinely  works  but  effects  of  using  viruses  and Chapter 7. Concluding remarks 
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restriction factors that have not been involved in coevolutionary host parasite 
relationships.  
The forces that drove the disruption of TRIM5α in both the  Caniformia and 
Feliformia are unclear. Red Queen situations are characterised by Darwinian 
struggles  between  competing  biological  entities  but  an  alternative  view  of 
evolution, termed the ‘Court Jester model,’ recognises that abiotic factors also 
influence evolution, speciation and extinction (Benton 2009). Such factors have 
no  doubt  impinged  on  felid  and  lentiviral  evolution,  for  example  in  the 
oceanographic  events  that  permitted  felid  and  FIV  migration  into  North 
America leading to their subsequent isolation and diversification. Furthermore, 
certain attributes of modern felids, such as the low genetic diversity in modern 
cheetah populations (Menotti Raymond and O'Brien 1993) that has led to high 
levels of susceptibility to viral infection (e.g. to Feline infectious peritonitis 
virus; Heeney et al. 1990) cannot be ascribed to the Red Queen hypothesis 
alone. In this instance, it is likely that a combination of climatic changes and 
hunting  by  humans  lead  to  the  expunging  of  genetic  diversity  during  the 
extinction  of  the  Pleistocene  megafauna  ~12,000  years  before  present 
(Menotti Raymond and O'Brien 1993; Barnosky et al.  2004). Thus changes in 
abiotic factors may have had a role to play, for example by genetic isolation of 
ancestral feliform and caniform species, in sculpting the genetic constitution 
of  modern  species.  From  a  Red  Queen  point  of  view,  however,  a  potential 
biotic change that may have lead to the truncation of TRIM5α is a temporary 
dearth  in  retroviral  infection.  Assessing  the  validity  of  such  hypotheses  is 
impossible but is supported by low levels of taxon specific ERV sequences and 
by a paucity of retroviruses in other carnivoran species such as the dog. The 
loss  of  functional  TRIM5α  appears  to  have  rendered  domestic  cat  cells 
exceptionally permissive to infection, with diverse retroviral pseudotypes able 
to infect cell lines and replication competent retroviruses RD114, FIV, FeLV Chapter 7. Concluding remarks 
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and FFV all circulating in this species. This permissiveness is not present in 
lions however, and the lack of TRIM5α restriction appears to be compensated 
for by an alternative potent post entry restriction. Along with puma cells, they 
can prevent the replication of FIV and display potent APOBEC3 activity. These 
findings are in support of the Red Queen hypothesis and suggest that resistance 
to infection is developing in these species via a combination of post entry and 
APOBEC3 mediated restriction. Although it is probable that FIV Ple overcomes 
such  restrictions  to  a  sufficient  degree  in  order  to  replicate  and  be 
transmitted, as  with murine  FV3  and human  HIV 1 infection, the  restrictive 
phenotype  is  likely  to  play  a  considerable  part  in  controlling  the  course  of 
infection and pathology. It may be no coincidence, therefore, that conflicting 
conclusions  about  the  pathology  of  FIV infection  of  African  lions  have  been 
drawn over the past fifteen years (Carpenter and O'Brien 1995; Roelke et al. 
2009;  Roelke  et  al.  2006;  Hofmann Lehmann  et  al.  1996).  The  alternative 
receptor tropisms present in lion FIV isolates may also have confounded these 
studies as the subtypes are likely to alter in tissue tropism and presumably 
cytopathology. Future research should further elucidate the prevalence, causes 
and in vivo effects of restriction in lions. Comparisons with other species that 
display evidence of historic lentiviral infection such as rabbits and Madagascan 
lemurs  may  expose  the  processes  involved  in  species level  clearance  of 
lentiviral infection. 
  
Appendix 1: Primers  
 
Name  Sequence (5' to 3') 
feT5fwd  TGTGTGCCGAATCAGGTACT 
feT5rev  TCTTCTGCAGCATGTCCATC 
gex8 feT5 f  ATCCCTYTYACAGKGTCACA 
gex8 feT5 r  MATGAARAGAAYKTATAGATGAGAAACC 
  WHERE  M=A/C, K=G/T R=G/A AND Y=C/T 
huT5stopF  GTTGATGTGACAGTGGCTTGAAACAACATTTCATG 
huT5stopR  CATGAAATGTTGTTTCAAGCCACTGTCACATCAAC 
Ts12  CCCAGTAATGTTTCCCTGA 
Ts16  CATAGTCTAGGAAAACTCCAACACG 
Ts2  TGTGGCCACAGCTTCTGCCAAG 
Ts3  CATGTGGCCAACATAGTGGAG 
wam13c  TCATATTTTCGAATCAGTGTGGAATCACGTGAGC 
wam4e2  CAGGGAATTCGCCACCATGGGATTTGTCCTGTCA 
feCXCR4 F  GCGAATTCACCATGGACGGGTTTCGTATATAC 
feCXCR4 R  CGGTGGATCCGAGGAGTGAAAACTTGAAGA 
feCD134 F  CGATCTAGAATGAGGGTGGTTGTGGGGGCT 
feCD134 R  ATGGGATCCCGCTGGGGACCCCTGGGGGGCTC 
LLV E 5' Not  ACTGGTCGACACCATGGCAGAAGGAGGAAGAGT 
LLV E 3' Sal  ACAGCGGCCGCTTAGGTATTAGACTCATCAT 
LLV B 5' Sal  ACTGGTCGACACCATGGCGGAAGGAGGAAG 
LLV B 3' Not  ACAGCGGCCGCTCAGACTACTCCTAGAAACT 
LLV E Vif F  ACTGGTCGACACCATGAGTGGTGAAGATATAAGTCAGG 
LLV E Vif R  ACAGCGGCCGCCTAGCCACCTTTCCCTATTAAATATAG 
LLV B Vif R  ACAGCGGCCGCCTACCACATGCTTTCATAGCTAATCTT 
LiA3C1 F  ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAAACCCAATGC 
LiA3C1 R  ACAGCGGCCGCTCACCTAAGGATTTCTTGAAGCTCTGCAGCC 
LiA3C2 F  ACTGGTCGACACCATGGAGCCCTGGCGCCCCAGCCCAAGAAACCCAATGG 
LiA3C2 R  AS LIA3C1 R 
LiA3H F  ACTGGTCGACACCATGAATCCACTACAAGAAGACATATTC 
LiA3H R  ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAAATCATTC 
FeA3Ca F  AS LIA3C2 F 
FeA3Ca R  AS LIA3C1 R 
FeA3H F  ACTGGTCGACACCATGAATCCACTACAGGAAGTCATATTC 
FeA3H R  ACAGCGGCCGCTCATTCAAGTTTCAAATTTCTGAAGTCATTC 
feCypC69 5' 
BamHI 
CACGGGATCCCGCACTATGTTCTTTGACA 
feCypR69 5' 
BamHI 
CTCCGGATCCTTAACCATGGTCAACCCCAT  
192 
 
feCypC/R 3' SalI  GCTAGTCGAGTTAGATTTGTTCACAGTC 
feCypA R69 5' 
Nde 
AACATATGGTCAACCCCATCGTG 
feCypA C69 5' 
Nde 
AACATATGTTCTTTGACATTACCAT 
feCypA R/C 3' 
Mlu 
AAACGCGTTTAGATTTGTCCACAGTCA 
GL8 gag F  GCCACCAGGGTGCGCTGCA 
GL8 gag R  GCCCATGGATTATTTGGATCT 
GL8 G87A  GGTAATGGTCTAGGTGCATCA     
GL8 P90A  GGTAATGCTCTAGGACCATCA     
LLVE CA 5' 
nde#2 
AACCATATGCCTATACAAGTGGTAAATGGAGTACC 
LLVE CA 3' 
mlu#2 
TGCACGCGTGCTTTTTGCTTTTACCTTCATCAAA 
feT5TaqMan 5'  GCTGTTGACCGACCTCATCT 
feT5TaqMan 3'  AAGACCCTGCTCCTTTCCAT 
feT5 Probe   FAM CAACGATGGACATGCTGCAGGA TAMRA  
wam13  TCAGTGTGGAATCACGTGAGC 
wam4  CTGCTATGGCTTCTGAACTCCTG 
G8 CAN5’ Nde  ACCATATGCCTATTCAAACAGTAAATGGA 
G8 CANe’ Mlu  TGACGCGTCTAGCTTTTTGCTTTTACCTTC 
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Appendix 2: Buffers and solutions 
Beads wash buffer: 50 mM Tris, 300 mM NaCl, 1 mM DTT, pH 8.0 
CHAPS lysis buffer: 30 mM Tris Cl, 150 mM NaCl, 1% CHAPS w/v, pH 7.5 
EB: 10 mM Tris Cl, pH 8.5 
FW
 basic buffer: 20 mM HEPES, 50 mM KCl, 10 mM MgCl2, 1 mM DTT, 0.1% 
Triton X 100, pH 7.5 
FW blocking buffer: 5% nonfat dry milk in far Western basic
 buffer 
FW wash buffer 1: 0.2% Triton X 100, PBS 
FW wash buffer 2: 0.2% Triton X 100, 100 mM KCl, PBS 
LB: 10% Bacto Tryptone w/v, 5% yeast extract w/v, 85 mM NaCl, pH 7.5  
PBS: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM KH2PO4 
SDB: 10 mM HEPES, 4 mM MnCl2, 50  g/ml dextran sulphate, 1% Triton X 100 
v/v, pH 7.6 
SDS PAGE loading buffer: 0.25 M Tris HCl, 2.5% SDS w/v, 10% glycerol v/v, 1% 
β mercaptoethanol v/v, 0.02% bromophenol blue, pH 6.8 
TBE (10x): Tris base 890 mM, Boric acid 890 mM, EDTA 2 mM 
TE: 10 mM Tris HCl, 0.1 mM EDTA, pH 7.6 
TY broth: 5% Tryptone peptone w/v, 3% yeast extract w/v, 10 mM CaCl2  
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Appendix  3:  Carnivoran  TRIM5  exon  8 
sequences 
The 5’ end of TRIM5 exon 8 was PCR amplified from genomic DNA isolated from 
tissue samples described in Table 4.A using primers gex8 feT5 f and gex8 feT5 r. 
The first 100 bp of exon 8 are given and the truncating stop codon, where present, is 
in bold. 
Mya 1 cells, domestic cat, Felis catus domesticus 
CTCACGTGATTCCACACTGACCCCAAAATACGACATATTTTGGCATTTCTACGGGATGA
AGACCAGTGAGATATATGTGCTGGTGGAAATCAAATAATGC 
Hyena, Crocuta crocuta 
CTCACGTGATTTCATACTGACCCCCGGATACAACATATTTTGGCAGTTCTACAGAATGA
AGACAAGTGAGATATGTATGCTGTTGGAAGTCAAATAATGC 
Cheetah, Acinonyx jubatus 
CTCACGTGATTCCACACTGACCCCAAAATACGACATATTTTGGCATTTCTACGGGACGA
AGACCAGTGAGATATATGTGCTGGTGGAAATCAAATAATG 
European wildcat, Felis catus sylvestris 
CTCACGTGATTCCACACTGACCCCAAAATACGACATATTTTGGCATTTCTACGGGACGA
AGACCAGTGAGATATATGTGCTGGTGGAAATCAAATAATG 
Lion, Panthera leo 
CTCACGTGATTCCACACTGACCCCAAAATACGACGTATTTTGGCATTTCTACGGGACGA
AGACCAATGAGAGATATGTGCTGTTGGAAATCATATAATG 
Mink Mv1 Lu CCL64 cell line, Mustela lutreola  
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CTCACATGACTCCAAATCATCTCCAAAATACAACATATACTCCCCGTTTCTACAGATAAA
AGAGAAATGAGATGTATGCGCTGTTGGAAACCGAATAATG 
Fossa, Cryptoprocta ferox 
CTCACGTGATTTCATGCTGACCCCCAAATACAACATATTTTGGCAATTCTACAGAATGA
AGACAAGTGTGATATGTATGCTGTTGGAAGTCAAATAATGC 
Dog, Canis lupus domesticus 
CTCATATGACTCCAGATAATGCCAAAAATAACAACATATGCTATTTCTACAGATCAAAGA
CAAATGAGATATGTGTTTCATTGGAAACTAGATAATGCAT 
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Appendix 4: Phylogeny of the Carnivora 
 
 
Schematic Carnivora phylogeny, based on (Johnson et al. 2006) and (Bininda-Emonds et 
al. 1999). Progenitor miacids diverged into Caniformia and Feliformia in the Eocene. 
The  late  Miocene  radiation  has  given  rise  to  the  modern  Felidae  genera,  including 
Panthera and Felis.    
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